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ABSTRACT
Charcot-Marie-Tooth (CMT) disease is one of the most common inherited
neurological diseases with a prevalence of 1 in 2500. It is clinically and genetically
heterogeneous with at least 22 loci and 11 genes now described with mutations
resulting in the disease.
L-periaxin is a protein expressed in myelinating Schwann cells. It relocates from the
adaxonal membrane in newly myelinating Schwann cells to the abaxonal membrane
when myelination is complete. Periaxin-null mice develop a late-onset demyelinating
peripheral neuropathy, suggesting that periaxin is important in maintaining compact
myelin in a healthy Schwann cell.
We show that mutations in the human PERIAXIN gene are associated with a subtype
of autosomal recessive CMT disease (Type 4F)/Dejerine-Sottas disease. Eight
different mutations are now described in seven different families. We carried out
immunohistochemistry on sural nerve biopsies from three of these patients, showing
evidence of a stable truncated L-periaxin protein, missing its C-terminal domain in
two patients (C715X and R1070X). This expands our knowledge of the function of
L-periaxin. The PDZ domain at the N-terminus of L-periaxin allows
homodimerisation of the protein, and the basic domain binds dystrophin-related
protein 2 (DRP2), underpinning the DRP2-dystroglycan complex at the apical
surface of the Schwann cell, and presumably forming a mechanical and functional
link to the basement membrane. Even though the truncated proteins contain these
domains the attendant demyelination suggests that they are not sufficient for L-
periaxin's function.
The C-terminus of L-periaxin binds to the F-box protein Fbl6 which is shown to be
in the Schwann cell cytoplasm. Fbl6 targets molecules for ubiquitination and
degradation by the proteasome. The truncated forms of L-periaxin found in human
patients found so far have lost this Fbl6 binding site.
The periaxin-null mouse is a mouse model of the human disease CMT4F.
Morphological studies of peripheral nerve in these mice show that myelination and
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axon number are normal in early life. One of the putative roles of L-periaxin is in
myelin repair, and nerves in the periaxin-null mice can undergo remyelination, but
with an abnormal control on the limit on myelin thickness. The periaxin-null mouse
nerve fibres have thicker myelin sheaths than the wild-type controls, and this may be
the forerunner of demyelination.
These studies suggest that studies of the cell biology of periaxin in the mouse and in
human patients are likely to be synergistic in expanding our knowledge of Schwann
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1. INTRODUCTION
To conduct impulses rapidly, nerves must either have a large diameter, or be
insulated with a myelin sheath. Vertebrates use the latter option and for them myelin
is an essential part of the central and peripheral nervous system. Acquired and
inherited diseases affecting the myelination of the nervous system emphasise this
importance.
In the peripheral nervous system (PNS) the Schwann cell forms the compact myelin
sheath, whereas the oligodendrocyte performs this role in the central nervous system
(CNS). The Schwann cell forms a one to one relationship with the axon, unlike the
oligodendrocyte which can myelinate many different axons. Between each axo-glial
segment lies the node of Ranvier where sodium channels are clustered. The action
potential 'jumps' from one node to the next in a fast and efficient manner by saltatory
conduction (saltare - to jump) (Figure 1).
1.1. THE DEVELOPMENT OF THE SCHWANN CELL
The Schwann cell is named after the German anatomist Theodor Schwann (1810-
1882). Schwann cells develop from the neural crest and migrate along growing
neurites (Le Douarin et al., 1991). In mature peripheral nerve they form two
subtypes: nonmyelinating and myelinating Schwann cells, which are present in
comparable numbers. There are two intermediates; the Schwann cell precursor,
present at mouse embryonic day 12 and 13 and the immature Schwann cell, present
from mouse embryonic day 15 until birth. At birth, Schwann cells start to
differentiate into myelinating and nonmyelinating Schwann cells (Reviewed by
lessen and Mirsky (Jessen and Mirsky, 1999) (Figure 2)). Myelinating Schwann cells
generate myelin sheaths that wrap large diameter axons, and nonmyelinating cells
accommodate small diameter axons in shallow troughs along their surface.
Myelinating Schwann cells undergo extensive changes in gene expression and
protein synthesis to allow them to synthesise large amounts of membrane and myelin
specific proteins. This is made possible by the combined action of a set of
transcription factors that are preferentially expressed in Schwann cells.
1
1.1.1. Transcription factors in Schwann cell differentiation
There are several families of transcription factors that are expressed in myelinating
Schwann cells: homeodomain proteins, zinc finger proteins and HMG-domain
proteins.
Pax3 is a paired homeodomain protein which is expressed during early development
in the spinal cord and neural crest cells. There is a transient rise in Pax3 expression
around the time of birth, it is then down-regulated in myelinating Schwann cells, but
continues to be expressed in nonmyelinating Schwann cells. Pax3 may determine the
choice between a myelinating and nonmyelinating Schwann cell phenotype (Wegner,
2000).
SC1P (also called Tst-1 or Oct 6) is another homeodomain protein expressed in
Schwann cells. SCIP expression is dependent on an increase in intracellular cAMP
levels, hence the name 'suppressed c-AMP-inducible POU protein.' This increase is
conferred by axonal contact and occurs at the promyelinating stage. The protein is
then down-regulated in most myelinating Schwann cells. Inactivation of both SCIP
alleles in mice leads to transient arrest of Schwann cell development at this
promyelinating stage, but when the cells have overcome this block, differentiation
proceeds normally (Bermingham et al., 1996).
The Krox/Egr transcription factors are zinc finger proteins. The onset of Krox-
20/Egr2 expression in the peripheral nervous system correlates with the appearance
of embryonic Schwann cells (Topilko et al., 1994). Expression of Krox-20/Egr2
requires continual neuronal signalling from axonal contact, reaching maximal levels
just before onset of myelination and remains unaltered in myelinating Schwann cells
throughout life. In contrast, nonmyelinating Schwann cells express Krox-24/Egrl
(Topilko et al., 1997). Krox-20 upregulates the expression of many myelin proteins
including myelin protein zero (P0), myelin basic protein (MBP), myelin associated
glycoprotein (MAG), peripheral myelin protein 22 (PMP22) and periaxin (PRX)
(Nagarajan et al., 2001). Other proteins, such as glial fibrillary acidic protein (GFAP)
and neural cell-adhesion molecule (NCAM), normally present in immature Schwann
cells and nonmyelinating cells, are down-regulated.
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The Sox proteins contain a high-mobility-group (HMG) domain as their DNA-
binding domain, similar to the one in male sex-determining factor SRY. Sox 10 is
expressed early in the neural crest and is then preferentially expressed in the late
embryonic glial cell lineage and in mature Schwann cells and oligodendrocytes. Sox
proteins are weak transcription factors on their own, but efficiently cooperate with
co-expressed transcription factors. SoxlO strongly potentiates the activity of Pax3
and SCIP in transfection experiments (Kuhlbrodt et al., 1998). Thus, SoxlO may be
involved not only in the commitment of cells to the myelinating glial lineage but also
in maintenance of glial-specific gene expression.
1.1.2. The process of myelination
For successful myelination, Schwann cells must establish a 1:1 relationship with an
axon, extend longitudinally until limited by a node of Ranvier, and form a myelin
sheath by the spiralisation of the plasma membrane. Before birth, Schwann cells send
cytoplasmic processes into bundles of axons, and progressively sort individual axons
so that this 1:1 relationship is established, in a process called radial sorting (Webster,
1984). Axons destined to remain unmyelinated are ensheathed in groups by
nonmyelinating Schwann cells. The transition of the Schwann cell, from a bipolar
cell to a precisely ordered cylinder containing a compact myelin sheath, represents a
complex architectural problem which has been solved in part by exploiting
polarisation. Schwann cells deposit and organise a basal lamina at their basal surface
away from the axon. The apical surface envelopes an adjacent axon with a layer of
cytoplasm bounded by an extension of the plasma membrane. Then, these cells wrap
concentric extensions of their membrane around the axon whilst remaining fixed to
the basal lamina. After several rounds of spiralisation, cytoplasm is extruded by the
apposition of the cytoplasmic surfaces of the membrane to allow compaction of the
mature multi-lamellar sheath (Figure 3a). This compaction may be generated in part
by interactions between the membrane proteins. The extracellular domain of P0
forms a tetrameric array that interlocks with similar arrangements in the opposing
membranes, and the intracellular domain interacts in a homophilic manner. P0 may
also be involved in a heterophilic interaction with PMP22 via the L2/HNK-1
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epitopes of their glycosidic links (Bell and Haites, 1998). These arrangements allow
closer juxtaposition of the membranes.
1.1.3. The role of extracellular matrix in myelination of peripheral nerve
The extracellular matrix (ECM) is critical for myelination of peripheral nerve. The
basal lamina of the Schwann cell is formed during embryonic development and
contains type IV collagens, laminin 2, fibronectin, N-syndecan, entactin and heparan
sulphate proteoglycan (Bunge, 1993). ECM formation and myelination are tightly
linked (Bunge, 1993). Immature Schwann cells do not have a basal lamina (Giannini
and Dyck, 1990) and it is thought that contact with an axon regulates Schwann cell
expression of laminin chain genes and directs synthesis of a basal lamina
surrounding each Schwann cell-axon unit (Doyu et ah, 1993).
In the absence of the assembly of ECM, myelination cannot proceed. Collagen
synthesis is inhibited by exclusion of ascorbic acid and this prevents myelination in
culture (Eldridge et al., 1989). Laminin is an essential component of the basal lamina
as blocking pi-integrin, one of its receptors on the Schwann cell basal membrane,
inhibits myelination (Fernandez-Valle et al., 1994). The dy/dy mouse, with low levels
of expression of the laminin a2-chain gene (Lama2), has a discontinuous basal
lamina around Schwann cells, a reduced number of myelinated axons and abnormal
myelination. In dy/dy nerves, regenerating axons are found lying on the external
surface of the Schwann cell in direct contact with the basal lamina (Uziyel et al.,
2000). This suggests that, in the absence of the competent basal lamina, Schwann
cells are not polarised and that polarised Schwann cells are required for normal
myelination.
The ECM provides the structural and mechanical integrity to the PNS. In the central
nervous system, there is no extracellular collagen and oligodendrocytes are not
ensheathed in basal lamina. This allows much denser packing of nerve fibres, but at
the cost of poor mechanical strength. Peripheral nerves are continually subjected to
stretching and direct trauma, both in development and adulthood, and require higher
tensile and mechanical strength (Podratz et al., 2001).
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1.1.4. Schwann cell cytoplasm
Even in mature compact myelin, Schwann cell cytoplasm persists in channels called
Schmidt-Lanterman incisures and in the adaxonal or periaxonal rim of the mature
sheath (Bunge et al., 1989). These channels may serve as supply lines for the
delivery of nutrients, or they may provide the submembrane scaffold for locating and
orientating proteins within discreet areas of the myelin sheath (Figure 3b). The
periaxonal rim of cytoplasm is contained in the paranodal loops, which are important
in the formation of the node of Ranvier.
1.1.5. Formation of the Node of Ranvier
In myelinated fibres, sodium channels concentrate in the axonal membrane at nodes
of Ranvier that are delimited by axoglial adhesion zones between each Schwann cell-
axon unit. The tight wraps of Schwann cell myelin expand at their extremities to
form cytoplasm-filled paranodal loops which adhere to the axonal membrane with
septate-like junctions. These junctions contain contactin-associated protein (caspr)
(alternatively known as paranodin) (Einheber et al., 1997; Menegoz et al., 1997), and
contactin forming a cis complex in the paranodal axon membrane (Boyle et al.,
2001). Caspr/paranodin interacts with the alternatively spliced isoform of the
neuronal cell adhesion molecule neurofascin (NF155) in the Schwann cell membrane
(Tait et al., 2000). The establishment of these tight contacts during development may
help to cluster the sodium channels at the node of Ranvier (Rasband et al., 1999)
(Figure 4). However, mouse mutants that are unable to synthesise myelin
galactolipids and that display disrupted paranodal axoglial interactions still maintain
nodal sodium channels (Dupree et al., 1999). Mice deficient in contactin also have
disrupted junctions yet maintain sodium channel clustering (Boyle et al., 2001).
Nevertheless, all of these mutants have severe neurological phenotypes, linked to
substantially reduced conduction velocities.
Myelinated axons also have potassium channels which are sequested in the
juxtaparanodal region. These Shaker or Kv potassium channels are believed to
accelerate the rate of repolarisation of the axolemma. The myelin deficient rat (md),
and mice deficient in caspr/paranodin, contactin or galactocerebrosidase have
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aberrant localisation of potassium channels, with displacement of the Kv channels
into the paranodal region nearer to and sometimes overlapping with the sodium
channels (Bhat et al., 2001; Boyle et ah, 2001; Dupree et al., 1999). Thus the
segregation of sodium and potassium channels is disrupted in these mutants that
show demyelination. Disruption of the interaction between Schwann cells and the
axon is one of the earliest correlates of axonal dysfunction in the demyelinating
disease Guillain-Barre syndrome (Griffin et al., 1996). Lack of channel segregation
may contribute to conduction block and spontaneous impulses seen in demyelinating
diseases. Spontaneous impulse generation has been implicated in neuropathic pain in
some demyelinating conditions (Gillespie et al., 2000).
Although much progress has been made in understanding the process of myelination
and the interactions between Schwann cells and axons, we still lack knowledge of
how myelin proteins interact to form, maintain and repair myelin. This is of critical
importance in the understanding and development of future therapies for human
demyelinating diseases both in the peripheral nervous system and ultimately the
central nervous system.
1.2. PERIPHERAL NEUROPATHY
Peripheral neuropathy is a clinical syndrome where there is a disorder of function of
the peripheral nerves. A typical patient has a progressive weakness and numbness of
the hands and feet starting distally and progressing proximally. The pathology of the
disorder of the peripheral nerves can be primarily demyelinating or axonal. The
syndrome can be due to acquired or inherited causes, and if acquired may be
reversible, especially if the pathology shows a picture of demyelination. The
commonest cause of peripheral neuropathy in the developed world is secondary to
diabetes mellitus, and the commonest cause of inherited peripheral neuropathy is
Charcot-Marie-Tooth disease.
1.2.1. Inherited Human Peripheral Neuropathy
There has been extensive study of both axonal and demyelinating inherited forms of
human peripheral neuropathy, over the last 10 years. In 1991, the molecular basis of
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the first subtype was determined (Lupski et al., 1991), but this has now expanded to
include many more molecular mutations. Clinical phenotype/genotype correlations in
these patients and examination of the cell biology of the molecules involved are
complementary to the understanding of myelination and demyelination. Many
inherited human neuropathies come under the umbrella of Charcot-Marie-Tooth
(CMT) disease, or hereditary motor and sensory neuropathy (HMSN). The naming of
these diseases is controversial, with the clinical world keen to avoid using
eponymous names for diseases, but scientists still use the historical names. The name
of each type of neuropathy depends on the conviction of the groups that first describe
them, and the list is becoming daily more complicated. I will name the diseases CMT
diseases unless they are called a different name in most of the literature.
1.2.2. Charcot-Marie-Tooth Disease
In 1886, Drs Charcot, Marie and Tooth described patients with an inherited form of
peroneal muscle atrophy - a disorder now known as Charcot-Marie-Tooth disease
(CMT), or, more commonly by clinicians, hereditary motor and sensory neuropathy
(HMSN).
CMT disease is common, with a prevalence of 1 in 2500 in the UK (Skre, 1974). The
first symptoms usually begin in the first or second decade of life consisting of a
progressive distal sensory and motor loss. Symptoms usually first occur in the legs,
and progress to the hands leaving the patient with a sensory loss in a 'glove and
stocking' distribution and an ascending motor weakness of the limbs. The distal
muscle weakness may be obvious from an early age with an abnormal gait or
clumsiness in running. Other typical features include weakness at the ankle, steppage
gait, and the characteristic pes cavus deformity of the foot (Figure 5). Patients are
moderately to severely disabled by these symptoms, although the disease is not
usually life-threatening. Confirmation of the clinical diagnosis relies primarily on
electrophysiology, and less on histopathology after sural nerve biopsy in this country,
due to the permanent and sometimes painful sensory loss associated with this
procedure.
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In 1968, Dyck and Lambert (Dyck and Lambert, 1968) divided CMT disease into
two types based on pathological and neurophysiological differences. They defined
patients with slow nerve conduction velocities of normal amplitude indicating a
primary demyelinating neuropathy as CMT disease type 1. Those with a primary
axonal loss, with normal nerve conduction velocity but low amplitude were
described as CMT type 2 patients. These differences indicated different aetiologies
for the two classes of neuropathies, with myelin being initially affected in CMT1 and
the axon directly affected in CMT2. However, some patients did not fit into this
convenient classification, and they were said to have 'intermediate' forms of the
disease.
However, since the advent of the molecular genetic revolution, CMT disease has
been divided further according to the mutations in the genes involved. It has also
challenged the initial subdivision, as families have been found who fulfil the CMT2
criteria, and yet have mutations in connexin-32, the gene defect leading to a subtype
of CMT1 (Timmerman et al., 1996b). The clinical homogeneity, yet genetic
heterogeneity of these subtypes suggests that they share a common physiological
pathway to their phenotype, which is likely to be damage to the axon. This probably
explains why patients with CMT can be asymptomatic for years, even with very
reduced nerve conduction velocities; only when axons are damaged do symptoms
appear (Krajewski et ah, 2000; Sahenk, 1999).
Initially most research was into demyelinating forms of the disease and the
autosomal dominant subtypes, through ease of classification. However, the number
of autosomal recessive subtypes that have been identified is expanding. The first
gene identified with mutations causing CMT2 was identified in 2000 - NF-L
(Mersiyanova et al., 2000). To date, in traditional CMT diseases, mutations have
been described in eleven genes, and CMT families have been linked to more loci,
dividing up CMT disease into at least twenty-two subclasses. There is continuing
controversy on how to subdivide the disease (Vance, 2000); however an attempt is
made in Table 1. There is a view that efforts should be made to simplify the
terminology for these inherited neuropathies by concentrating on the molecular
diagnosis. One of the objections to continuing to call these diseases CMT diseases is
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in defining the size of umbrella of CMT disease - when does an inherited peripheral
neuropathy become a CMT disease? If CMT disease defines all inherited
neuropathies then diseases such as the pure sensory and motor neuropathies (HSN
and HMN) also are CMT diseases. Certainly, the natural home of these diseases is
linked to the traditional CMT diseases, but they are often separated artificially in the
literature.
The proteins encoded by these genes are involved in a variety of cellular functions,
including cytoskeletal scaffolding (NF-L), the transport of small molecules within
and across the myelin sheath (Cx32), signal transduction (MTMR2), cell
arrest/proliferation and differentiation (PMP22, NDRG1, EGR2), myelin
maintenance and formation (PO and PRX) and axonal transport (KIF1B(3), as
discussed later.
The prevalence of all types of CMT disease is 20-40:100 000 with CMT2 accounting
for about 20% of this (Ionasescu, 1995).
The commonest mutation associated with CMT disease is duplication of the gene
PMP22 which accounts for about 70% of demyelinating CMT disease (Nelis et al.,
1996) and about 52% of unselected patients with hereditary neuropathies (Boerkoel
et al., 2002). In this unselected subset of 153 patients, 7% had Cx32 mutations, 3%
myelin protein zero (MPZ) mutations, 3% PMP22 mutations and about 1% had
EGR2, PRX and NF-L mutations respectively. MTMR2 mutations were not seen. Of
note, 33% of these patients still did not have their CMT disease molecularly
diagnosed, suggesting that there are more genes involved yet to be discovered. Also,
one third of the point mutations seen represented de novo events suggesting that
absence of a family history should not prevent molecular investigation for CMT
disease (Boerkoel et ah, 2002).
CMT disease is a genetically and clinically heterogeneous disease for which
genotype-phenotype correlations are difficult to define. Both the phenotypic features
and disease severity can either be consistent or differ widely within and amongst
families (Senderek et al., 2001). This ambiguity in genotype-phenotype correlation
probably reflects limitations in our knowledge and understanding of the effects of
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genetic background and environment on the biological function of the affected
proteins.
The genetics of CMT disease is a rapidly moving field and no less than six new
subtypes of CMT disease were discovered on the basis of genetic mutations in the
year 2001. No doubt, there are more to come. Understanding the molecular basis of
CMT disease can therefore be expected to contribute significantly to the current
limited understanding of the biology and pathophysiology of the peripheral nervous
system.
1.3. DOMINANT DEMYELINATING CMT DISEASE
1.3.1. CMT1A
Peripheral myelin protein 22kD (PMP22)
The first of the CMT subtypes to be classified was CMT1A. Some families with
autosomal dominant CMT showed linkage to part of chromosome 17, (17pl 1.2-pl2)
and these patients had duplication of the 1.5 MB area that included the normal
PMP22 gene (Lupski et al., 1991). These patients have increased expression of
PMP22 RNA (Yoshikawa et al., 1994) and transgenic mice over-expressing Pmp22
develop a peripheral neuropathy resembling CMT1A (Huxley et al., 1996).
Furthermore, a minority of CMT1A patients show point mutations in the PMP22
gene, adding to evidence that this protein is involved. Trembler and Trembler-J mice,
thought to be models of autosomal dominant CMT, were found to have mutations in
Pmp22 (Suter et al., 1992a; Suter et al., 1992b). Patients with hereditary neuropathy
with liability to pressure palsies (FINPP), who have reversible pressure-induced
segmental demyelination in the PNS, show lack of the same 1.5 MB DNA fragment
and so have only one copy of the PMP22 gene (Chance et al., 1993). This suggests
that the 'dosage' of PMP22 protein expressed is important in the function of myelin
sheaths.
PMP22 is a tetraspan transmembrane protein of unknown function, but the apparent
dosage sensitivity suggests it is involved in a multimeric complex within myelin that
requires exact macromolecular stoichiometry for proper functioning. PMP22 only
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accounts for 2-5% of myelin protein, suggesting that it does not play a structural role
(Reilly, 1998), however, it is necessary for both myelin formation and maintenance.
PMP22 and PO may complex together within the Schwann cell, suggesting that some
PMP22 mutations may cause disease by destabilising the PO interactions necessary
for the formation and stabilisation of compact myelin (D'Urso et ah, 1999). Some
mutant PMP22 molecules are not transported to the plasma membrane, and inhibit
the trafficking of wild-type PMP22 to the plasma membrane (Naef and Suter, 1999).
The retained wild-type and mutant PMP22 accumulate within the cell and appear to
have a toxic effect on the Schwann cell (Notterpek et ah, 1999). Therefore, most
PMP22 missense mutations cause disease by a combination of a dominant negative
effect, inhibiting the transport of mutant and wild-type PMP22 to the plasma
membrane and a toxic gain of function effect, resulting from the accumulation of
PMP22 within the cell.
Proteolipid Protein (PLP), the major central nervous system myelin protein, also
shows such dosage sensitivity. PLP and PMP22 show structural similarities, and
duplications and deletions of PLP lead to Pelizaeus-Merzbacher disease, a central
nervous system demyelinating condition (Pham-Dinh et ah, 1991).
PMP22 mutations are the most common mutations found in CMT. Most CMT1A
patients have the PMP22 duplication and 70% of all CMT1 patients carry the
duplication (Boerkoel et ah, 2002; Nelis et ah, 1996). Thus, PMP22 duplication
should be screened for first in a patient with suspected demyelinating CMT disease
(Bell and Haites, 1998).
1.3.2. CMT1B
Myelin protein zero (PO) (from the myelin protein zero (MPZ) gene)
PO is the major structural component of peripheral nerve myelin accounting for 50%
of peripheral myelin protein. It contains a single membrane-spanning domain, a large
glycosylated immunoglobulin-like extracellular domain and a smaller basic
intracellular domain (Lemke et ah, 1988). It is exclusively expressed by myelinating
Schwann cells and is thought to be involved in linking together adjacent myelin
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lamellae in compact myelin. The extracellular domain of PO forms a tetrameric array
that interlocks with similar arrangements in the opposing membranes, and the
intracellular domain interacts in a homophilic manner. PO may also be involved in a
heterophilic interaction with PMP22 via the L2/HNK-1 epitopes of their glycosidic
links (Bell and Haites, 1998).
PO-null mice have severely hypomyelinated axons, but also their myelin and axons
degenerate with age. This suggests the role of PO in the formation and maintenance
of the PNS myelin sheath (Giese et al., 1992).
Mutations in the extracellular, intracellular and transmembrane domains of the
proteins can all cause CMT1B (Warner et al., 1996b). Mutations disrupting the
interactions within the tetramer or between tetramers produce disease by a dominant
negative effect, whereas mutations retarding production of PO produce disease by a
loss of function effect (Warner et al., 1996a). However, some patients with MPZ
mutations have axonopathic features and are diagnosed with CMT2 (Boerkoel et al.,
2002).
1.3.3. CMT1D
Early growth response 2 transcription factor (EGR2)
The early growth response 2 gene (EGR2) is a Cys2His2 zinc finger transcription
factor thought to affect the expression of late myelin genes. Mutations in the EGR2
gene have been associated with CMT1, Dejerine-Sottas disease (DSS) and congenital
hypomyelinating neuropathy (CHD) and these can be inherited in both a dominant
and a recessive manner. Some EGR2 mutations occur within the zinc finger DNA-
binding domain. These mutations reduce DNA binding and therefore decrease
transcriptional activity of downstream genes. A recessively inherited mutation,
causing CHD, affects the inhibitory domain (Rl) that binds the NAB transcriptional
co-repressors. These repressors inhibit the transcriptional activity of multiple
members of the immediate - early response gene family including EGR1 and EGR2.
The Rl domain mutation prevents interaction of EGR2 with the NAB co-repressors
and thereby increases transcriptional activity. Hence, dosage sensitivity may be
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important with EGR2, as with PMP22 (Warner et al., 1999). Homozygous Krox20
(Egr2) knockout mice display hypomyelination of the peripheral nervous system and
Schwann cell arrest at an early stage of differentiation concurring with human cases
of CHD with recessive EGR2 mutations (Nelis et ah, 1999a; Warner et ah, 1998).
1.3.4. CMT1X
Connexin-32 (Cx32) or Gap junction protein 1 (GJB1)
Connexins are transmembrane proteins that assemble to form gap junctions, channels
that facilitate the transfer of ions and small molecules across membranes. Cx32 is a
tetraspan transmembrane protein which is located in the paranodal loops and the
Schmidt-Lanterman incisures in noncompact myelin, and is thought to function as a
channel for the transport of electrolytes and metabolites between the noncompact
regions of the myelin sheath.
Mutations in this gene appear to be the most common cause of non-duplication
CMT1 (Nelis et ah, 1996) with mutations appearing throughout the domains of the
protein (Warner et ah, 1996b). Cx32 mutations can cause a neuropathy with clinical
and electrophysiological features of either a demyelinating or an axonal neuropathy.
Male patients usually have a more severe and earlier onset neuropathy which is
frequently demyelinating, whereas female patients generally have a later, milder
disease often of an axonal type. The severity of disease among women may depend
on the vagaries of X-chromosome inactivation as well as the nature of the mutation,
genetic background and environment. The mutations in Cx32 that have been studied
result in either a loss of ability to form functional gap junction channels or an
alteration in the gating properties of the channels (Abrams et ah, 2000).
1.4. AXONAL NEUROPATHIES
1.4.1. CMT2A
Kinesin superfamily motor protein B gene (KIFlBp)
KIFlBp is a member of the kinesin superfamily of molecular motor proteins which
function in aspects of axonal transport (Hirokawa, 1998). The molecules all have
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similar motor domains but are otherwise divergent, presumably allowing the
association with different cargo molecules. KIF1B(3 transports synaptic vesicle
precursors. Knockout mice for this gene die within thirty minutes of birth, due to
central apnoea, but mice heterozygous for the mutated allele develop a late-onset
axonopathy similar to axonal forms of CMT disease. Synaptic vesicle proteins are
specifically decreased in the peripheral axons of these mice (Zhao et al., 2001). A
human family with CMT2A was found to have a mutation in the ATP binding site of
KIF1BP, which segregated with their disease (Zhao et al., 2001). As mature axons
are believed to lack protein synthesis machinery, proteins essential for neuronal
survival must be transported down the axons by molecular motors. Thus, reduced
levels of the motor protein may not sustain the requirements of the axons. The
finding that neuropathies tend to affect distal muscles first can be partially explained
by the idea that longer axons need higher levels of motor molecules.
1.4.2. CMT2B1
Lamin A/C nuclear envelope proteins (LMNA)
The gene encoding LMNA, which encodes lamin A/C nuclear-envelope proteins, is
mutated in CMT2B1, an autosomal recessive form of axonal CMT disease (De
Sandre-Giovannoli et al., 2002). The gene encodes four transcripts lamin A, AD 10, C
and C2 by differential splicing (Furukawa et al., 1994; Machiels et al., 1996). There
is a homozygous point mutation, causing a R298C amino acid substitution
segregating with the disease in three Algerian families. This mutation affects all four
transcripts produced by LMNA. This amino acid substitution lies in the rod domain
that is essential for protein-protein interactions. This domain is highly conserved
through evolution. Lmna knockout mice, which produce none of the Lmna
transcripts, show a phenotype indicative of a peripheral neuropathy and
ultrastructural evidence of neuropathy with a markedly reduced axon density, an
increase in axon diameter and the presence of non-myelinated axons (Sullivan et al.,
1999). LMNA mutations are also associated with limb-girdle muscular dystrophy
type IB (MIM159001) (Muchir et al., 2000), autosomal dominant Emery-Dreifuss
muscular dystrophy (MIM181350) (Bonne et al., 1999), dilated cardiomyopathy type
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1A (MIM115200) (Fatkin et al., 1999) and autosomal dominant partial lipodystrophy
(MIM1516600) (Shackleton et al., 2000). Thus mutations in this gene selectively
affect nerve, skeletal muscle, cardiac muscle or adipocytes. Since LMNA is
ubiquitously expressed, this suggests that there are distinct functional domains in
lamin AJC essential for the maintenance and integrity of different cell lineages.
These multiple functional domains may participate in chromatin organisation,
anchorage of nuclear envelope proteins, arrangement of nuclear pore complexes and
self-assembly (Nagano and Arahata, 2000). The nuclear lamins are part of the group
of intermediate fdament proteins along with NF-L and gigaxonin, mutations in which
cause CMT2E and giant axonal neuropathy respectively.
1.4.3. CMT2E
Neurofilament-Iight gene (NF-L)
The neuronal cytoskeleton is composed of interconnected actin microfdaments,
microtubules and intermediate fdaments. Neurofilaments (diameter lOnm) are the
major type of intermediate filaments in adult neurones. There are three neurofilament
proteins - light (NF-L), medium (NF-M) and heavy (NF-H). These share a central
coiled domain which is responsible for the assembly of lOnm filaments (Julien,
1999). The carboxy-terminals of the NF-H and NF-M subunits form side-arm
projections at the periphery of the neurofilaments. It is thought that the
phosphorylation of their KSP (Lys-Ser-Pro) repeats increases their negative charge
and causes increased neurofilament spacing (Julien, 1999). NF-L appears to play the
most important role in neurofilament assembly as it is the only neurofilament protein
capable of organising filaments by itself (Carpenter and Ip, 1996). NF-L also
regulates the expression of the other two types, as NF-L knockout mice only have
5% of the normal level of NF-M and NF-H expression. These NF-L null mice have
diminished axon diameter and delayed regeneration of myelinated axons following
crush injury of peripheral nerve but no CMT-like phenotype (Zhu et al., 1997).
A mutation in the NF-L gene was found in a Russian family with CMT2E in a
domain of the protein responsible for neurofilament assembly (Mersiyanova et al.,
2000). This mutation is predicted to disrupt neurofilament assembly, and alter the
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expression and regulation of the other neurofilament proteins. A further mutation in
this gene in a Belgian family has also been identified (De Jonghe et ah, 2001).
Neurofilament proteins are involved in the pathogenesis of other neurological
disorders such as giant axonal neuropathy, amyotrophic lateral sclerosis, Parkinson's
disease and Alzheimer's disease. The common feature in all these disorders is the
accumulation of neurofilament aggregates during the disease process.
Axonal loss also occurs in demyelinating CMT disease and altered neurofilament
phosphorylation has been observed in CMT1 (Watson et al., 1994). Additionally
Trembler mice, with a missense PMP22 mutation, undergo axon demyelination,
which results in decreased neurofilament phosphorylation, reduced axon diameter
and slow axonal transport, yet the myelinated regions have normal parameters (de
Waegh et al., 1992). This alludes to a final common pathway in the pathogenesis of
CMT diseases, and re-emphasises the importance of axo-glial interactions.
1.5. AUTOSOMAL RECESSIVE DEMYELINATING CMT DISEASE
1.5.1. CMT4A
Ganglioside-induced differentiation-associated protein-1 (GDAP1)
This gene spans 13.9 kb of genomic DNA, with the coding sequences split into 6
exons. It gives rise to a 3.9 kb transcript and encodes 358 amino acids. The amino
acid sequence of GDAP1 shows strong similarity to glutathione S-transferase
enzymes that have a role in the detoxification of cells. Amino acid residues 26-119
show the papappa topology of the glutathione binding site, and amino acid residues
210-287 show the a-helical domain II that may recognise xenobiotic substrates
(Armstrong, 1997; Hayes and Pulford, 1995; Salinas and Wong, 1999). The carboxy-
terminal region has two putative transmembrane domains. The protein is expressed
ubiquitously but with apparent predominance in nervous system tissue. It is
expressed in Schwann cells, axons and the central nervous system. The mouse
homologue Gdapl was identified after ganglioside-induced differentiation of the
mouse neuroblastoma cell line Neuro 2a (Liu et al., 1999). Mutations in this gene
have been associated with both autosomal recessive demyelinating CMT and axonal
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CMT neuropathy (CMT4A). The gene may be involved in a signal transduction
pathway between the Schwann cell and axon, so when this is interrupted, may cause
either axonal degeneration or demyelination in peripheral nerve. Mutated GDAP1
may prevent the correct catalysing S-conjugation of reduced GSH, resulting in




MTMR2 belongs to a family of dual specificity phosphatases. These proteins are
characterised by a protein tyrosine phosphatase/DSP signature and a SID domain.
The latter domain interacts with proteins containing a SET domain, which are able to
associate with chromatin, activating or repressing gene transcription. The mutations
in this gene create nonsense mutations or premature termination of the protein, and
so probably cause a loss of functional MTMR2 protein. This may result in
constitutive phosphorylation of an unknown substrate, leading to Schwann cell
proliferation with overgrowth of myelin (Bolino et ah, 2000). CMT4B families are
characterised clinically by focally folded myelin sheaths on nerve biopsy (Quattrone
et ah, 1996). Myotubularin, the first described member of this family, and MTMR2
both specifically dephosphorylate the D3 position of the inositol lipid,
phosphatidylinositol 3-phosphate (PI(3)P) (Blondeau et al., 2000; Kim et al., 2002;
Taylor et al., 2000). Therefore, they may be involved in the regulation of cellular
PI(3)P levels. PI(3)P can serve as a targeting motif for membrane-trafficking and
signalling proteins that contain lipid binding modules such as FYVE domains
(Gaullier et al., 1998). Of interest, myotubularin mutations lead to the condition X-
linked myotubular myopathy (Laporte et al., 2000).
1.5.3. CMT4D/HMSN-Lom
N-myc downstream-regulated gene 1 (NDRG1)
NDRG1 is ubiquitously expressed, and is thought to play a role in growth arrest and
cell differentiation, possibly as a signalling protein between the cytoplasm and the
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nucleus. There is a high level of expression of NDRG1 in the Schwann cell. A
mutation in this gene, encoding a premature-termination codon, has been associated
with CMT4D or HSMN-Lom. These patients all appear to descend from a single
founder, who had this mutation (Kalaydjieva et al., 2000).
1.6. DEJERINE-SOTTAS DISEASE AND CONGENITAL HYPO-
MYELINATING DISEASE
Dejerine-Sottas disease (DSS), Congenital Hypomyelinating Disease (CHD) and
CMT disease are not distinct pathophysiological entities but form a continuous
spectrum of peripheral myelinopathies. CHD is thought to be a congenital
impairment in myelin formation whereas DSS involves aberrant myelination and
subsequent remyelination. These diseases were initially thought to be autosomal
recessive but clearly some are autosomal dominant, and the genes in which mutations
are described are identical to those involved in CMT disease. The differences in
clinical severity and phenotype of these diseases may be related to specific types or
locations of mutations in the proteins with different subsequent effects on protein
function. For example, a mutation causing a loss of function of the protein may give
a milder phenotype (CMT disease) than one conferring a gain of function or
dominant negative effect (DSS/CHD) (Warner et al., 1996a). However, the same
mutation in different members of one family may produce a variety of different
phenotypes (Senderek et al., 2001). This may be secondary to variation in genetic
background.
Dejerine-Sottas disease is characterised by severe hypomyelination, markedly
reduced nerve conduction velocities and an infantile onset (Lyon, 1969). Patients
have DSS rather than CMT disease if they have three or more of the following
characteristics: onset of walking after 14 months, complete absence of deep tendon
reflexes, ataxia, and clinical enlargement of nerves or nerve conduction velocity of
less than 10m /s (Ouvrier et al., 1987).
In the past, this syndrome was called CMT3, but with the discovery of mutations in
the various genes causing other types of CMT disease, this categorisation has
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virtually disappeared from use. The syndrome is genetically heterogeneous,
occurring with mutations in PMP22, MPZ, PRXand EGR2 (Boerkoel et al., 2001a).
Congenital hypomyelinating disease is envisaged as a defect in myelin formation,
rather than a disorder of myelin maintenance and stability, because of the
pathological picture and the non-progressive evolution of the disease. Clinically,
abnormalities are present at birth or soon afterwards. The child is hypotonic, and
areflexic, with distal muscle weakness and very slow nerve conduction velocities of
less than 6-7m/s. Nerve biopsy from such children shows hypomyelination or
amyelination of most fibres, variable basal laminae onion bulbs and no florid
demyelination. There are no signs of active myelin breakdown (Harati and Butler,
1985). It has been described in patients with point mutations in PMP22 (Fabrizi et
al., 2001), MPZ (Warner et al., 1996a), EGR2 (Warner et al., 1998), and MTMR2
(Bolino et al., 2001).
1.7. HEREDITARY SENSORY NEUROPATHIES
1.7.1. Hereditary sensory neuropathy Type I
Serine palmitoyltransferase long chain base subunit-1 (SPTLC1)
Hereditary sensory neuropathy type 1 (HSN1) is the commonest inherited disease of
peripheral sensory neurones. It is an autosomal dominant progressive degeneration of
dorsal root ganglia and sensory neurones with onset in the second or third decades.
There is marked distal sensory loss predominantly affecting the lower limbs. Loss of
pain and temperature sensation leads to digital ulcerations and osteomyelitic bone
destruction sometimes necessitating amputation. There may be motor and autonomic
involvement. Morphometry demonstrates involvement of large fibres, but clinical
findings are predominantly related to the loss of small unmyelinated fibres.
Mutations in SPTLC1 are associated with HSN1 (Bejaoui et al., 2001; Dawkins et al.,
2001). This phenotype is also related to a second locus, 3ql3-q22, suggesting locus
heterogeneity for the phenotype (Kwon et al., 1995), though as there was also motor
involvement and axonal loss these patients were assigned to CMT2B.
19
SPTLC1 has fifteen exons and its transcript is expressed in many tissues including rat
dorsal root ganglia. It encodes a 473 amino acid protein designated 'Long Chain Base
1' (LCB1), subunit 1 of the serine palmitoyl transferase (SPT) enzyme. The SPT
enzyme is a pyridoxal 5'-phosphate dependent enzyme which catalyses the first step
of biosynthesis of sphingolipids, including ceramide and sphingomyelin. SPT
consists of two subunits (LCB1 and LCB2) both of which are required for enzyme
activity (Hanada et al., 1997). Ceramide produced by catabolism of sphingomyelin,
or an increase in SPT activity is known to mediate apoptosis (Herget et ah, 2000). An
increase in glucosyl ceramide was seen in lymphoblast cell lines from HSN1 patients
compared to those derived from healthy controls (Dawkins et ah, 2001). These
results suggest that haploinsufficiency, or a toxic gain of function per se, do not
cause the phenotype of autosomal dominant HSN1, but instead it is due to
augmentation of SPT activity. Increased ceramide production seems to mediate the
massive neuronal cell death associated with neural tube closure during development
of the spinal cord (Herget et ah, 2000). It may be that SPTLC1 mutations prevent
ceramide levels returning to normal after this, resulting in gradual attrition of
neurones over many years (Dawkins et ah, 2001). The gene encoding the second
subunit of SPT, SPTLC2 on chromosome 14q is a candidate gene for other cases of
HSN with no identified mutation.
1.7.2. Hereditary sensory neuropathy type III
IkB kinase complex associated protein (IKBKAP)
Familial dysautonomia (FD), Riley-Day syndrome or hereditary sensory neuropathy
type III is an autosomal recessive disorder that affects the development and survival
of sensory, sympathetic and some parasympathetic neurones. It is characterised by
widespread sensory and variable autonomic dysfunction. There is increased
sensitivity to pain and temperature, cardiovascular instability, recurrent pneumonia,
inappropriate sweating, postural hypotension, vomiting crises and gastrointestinal
dysfunction (Riley, 1949). The disease is fatal, with only 50% of patients reaching 30
years old. The pathology shows a striking, progressive depletion of unmyelinated
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sensory and autonomic neurones, beginning early in development. Dorsal root and
sympathetic ganglion neurone number is grossly reduced.
The disorder is primarily confined to those of Ashkenazi Jewish descent, with an
incidence of 1 in 3600 live births, and a carrier frequency of the defective gene of 1
in 30 (Maayan et al., 1987). This ethnic bias is due to a founder effect with more than
99.5% of disease alleles sharing a common ancestral haplotype (Slaugenhaupt et al.,
2001). Mutations occur in the IkB kinase complex-associated protein gene (IKBKAP)
located at chromosome 9q31 (Anderson et al., 2001; Slaugenhaupt et al., 2001). The
major haplotype mutation is located in the donor splice site of intron 20, which
variably results in skipping of exon 20 in the mRNA of patients with FD resulting in
a frameshift generating a truncated protein. This is particularly common in brain
tissue and the phenotype variability of FD may be explained by the variable
production of the mutant mRNA either in different tissues or at different times in
development (Slaugenhaupt et al., 2001). The mutation associated with most minor
haplotypes is a missense (R696P) mutation in exon 19, which disrupts a potential
phosphorylation site (Anderson et al., 2001; Slaugenhaupt et al., 2001).
IKBKAP was thought to bind the IkB kinases and NF-kB and assemble these
proteins into an active kinase complex (Cohen et al., 1998), hence its name.
However, recent studies have challenged this, suggesting that it is part of a
multiprotein complex playing a role in general transcriptional regulation (Krappmann
et al., 2000).
1.7.3. Hereditary sensory neuropathy type IV (HSN-IV)
NTRK1
Mutations of the NTRK1 (TRKA) gene coding for the neurotrophic tyrosine kinase
receptor type 1 cause the autosomal recessive disease congenital insensitivity to pain
with anhidrosis (CIPA), also called hereditary sensory and autonomic neuropathy
Type 4 (HSAN4) or hereditary sensory neuropathy (HSNIV) (Indo et al., 1996). The
disease is characterised by recurrent episodic fever, insensitivity to pain, anhidrosis,
self-mutilating behaviour and mental retardation. The TRKA gene is located on
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chromosome 1, consists of 17 exons and spans at least 23 kb. The gene encodes the
receptor tyrosine kinase for nerve growth factor (NGF). Defects in NGF signal
transduction at the TRKA receptor lead to failure to support the survival of
sympathetic neurones and nociceptive neurones derived from the neural crest. Thirty-
seven different TRKA mutations are now described, distributed in the extracellular
domain involved in NGF binding, and in the intracellular signal-transduction domain
(Indo, 2001). Nerve biopsy of these patients reveals loss of small myelinated fibres
and a variable loss of unmyelinated C-fibres (Houlden et al., 2001). Mice lacking the
gene for TrkA also show loss of responses to painful stimuli (Indo et al., 1996).
1.8. HEREDITARY MOTOR NEUROPATHIES
1.8.1. Distal hereditary motor neuronopathy type VI
Immunoglobulin p-binding protein-2 (IGHMBP2)
Distal hereditary motor neuronopathy type VI (also known as spinal muscular
atrophy with respiratory distress (SMARD)) is caused by mutations in the gene
encoding immunoglobulin p-binding protein-2 (IGHMBP2). This disease is
characterised by dysfunction and progressive loss of a-motor neurones in the
anterior horn of the spinal cord, leading to neurogenic muscular atrophy especially
distally and life-threatening respiratory distress with evidence of unilateral or
bilateral paralysis of the diaphragm. In mice, mutations in this gene cause the nmd
phenotype, with progressive limb paralysis and death due to respiratory failure.
IGHMBP2 consists of 993 amino acids and contains both DNA and RNA binding
domains. The cellular function of the protein is unknown but it is involved in
immunoglobulin class switching, pre-mRNA processing and in regulation of
transcription (Grohmann et al., 2001).
1.8.2. Distal Hereditary Motor Neuronopathy VII (dHMN-VII)
This is an autosomal dominant disorder characterised by distal muscular atrophy and
vocal cord paralysis. dHMN accounts for about 10% of the peroneal muscular
atrophy syndrome (Harding and Thomas, 1980b). Motor and sensory nerve
conduction velocities are normal, and electromyography shows features of
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neurogenic atrophy, consistent with degeneration of the anterior horn cell of the
spinal cord. As this disorder shows much overlap with CMT2C except for the lack of
sensory involvement, it was suggested that these were allelic disorders (McEntagart
et al., 2001), but they are now known to occupy different loci (Santoro et al., 2002).
1.9. INTERMEDIATE FORMS OF CMT DISEASE
Intermediate CMT disease is characterised by motor median nerve velocities of 25-
45m/s within a family with the disease, hence forming an overlap between the
accepted velocities for CMT1 and CMT2. Sural nerve biopsies show axonal
degeneration and segmental demyelination and remyelination with onion bulb
formation (Kennerson et al., 2001). Some affected families have very variable nerve
conduction velocities, ranging from normal to severely reduced, where there are
specific mutations in the MPZ gene (Thrl24Met) (De Jonghe et al., 1999) or NF-L
(Pro8Arg) (De Jonghe et al., 2001). Other autosomal dominant types have been
linked to 19pl2-pl3.2 (Kennerson et al., 2001) and 10q24.1-q25.1 (Verhoeven et al.,
2001) though the causal genes are not yet identified. CMT IX, due to Cx32
mutations, has a mixed demyelinating and axonal appearance on nerve biopsy, and
affected males have variable nerve conduction velocities (Timmerman et al., 1996b).
This is thought to be due to disruption of the connexin channel between myelin
lamellae and axons, resulting in degeneration of both.
1.9.1. HMSN-Russe (HMSNR)
This is a severe sensorimotor neuropathy with prominent sensory loss, an
intermediate reduction in nerve conduction velocity and severe disability, described
in the same population of Romany families as HMSN-Lom. Sural nerve biopsies
show a depletion of large myelinated nerve fibres, profuse regenerative activity and a
uniformly reduced thickness of the myelin sheath relative to the axon diameter
suggesting hypomyelination. EGR2 is contained in this locus, but this has been
excluded as the HMSNR gene (Rogers et al., 2000).
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1.10. MISCELLANEOUS INHERITED NEUROPATHIES
1.10.1. Giant Axonal Neuropathy
Gigaxonin
Giant axonal neuropathy is a severe autosomal recessive sensorimotor neuropathy
affecting both the peripheral nerves and the central nervous system. It is
characterised by neurofdament accumulation, leading to segmental distension of the
axons. Neurofdaments belong to the intermediate fdament family and abnormal
aggregation of multiple tissue specific intermediate filaments has been reported in
this disease: vimentin in endothelial cells, Schwann cells and cultured skin
fibroblasts, and glial fibrillary acidic protein in astrocytes. Keratin intermediate
filaments are also altered, and most patients have characteristic curly or kinky hair
(Ben Hamida et al., 1990). Families with giant axonal neuropathy have mutations in
the Gigaxonin gene which has 11 exons (Bomont et al., 2000).
Gigaxonin is an ubiquitously expressed protein of 597 amino acids composed of an
amino-terminal BTB (Broad-complex, Tramtrack and Brie a brae) domain followed
by six kelch repeats, which are predicted to a adopt a (3-propeller shape (Ito et al.,
1994). Related proteins sharing a similar domain organisation have functions related
to the cytoskeleton. One such protein, the human mayven protein, the orthologue of
Drosophila kelch, interacts with actin through the kelch domain and may be a
physical or functional link between the thin filaments and the intermediate filaments
(Soltysik-Espanola et al., 1999). Another such protein, Keapl protein, which is
sequestered in the cytosol, inactivates the transcription factor Nr£2 (NF-E2 related
factor 2) which modulates the expression of genes containing antioxidant responsive
elements (Itoh et al., 1999). Thus neurofilament disorganisation and oxidative stress
may have a role in this disease (Bomont et al., 2000).
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1.10.2. Waardenburg Syndrome with peripheral neuropathy
SOXIO
SOX 10 is a transcription factor that is expressed early in the neural crest and then is
preferentially expressed in the late embryonic glial cell lineage and in mature
Schwann cells and oligodendrocytes. SOXIO also modulates other myelin-related
transcription factors such as Oct6, PAX3 and EGR2, suggesting that it is important
for myelin development and maintenance in the peripheral and central nervous
system (Kuhlbrodt et ah, 1998). The SOX family of transcription factors is defined
by sequence similarity to the high mobility group DNA-binding motif (SRY box)
present in the mammalian sex-determining gene, SRY. Heterozygous SOXIO
mutations have been found in an animal model of Hirschsprung disease Dominant
megacolon (Dom) (Southard-Smith et al., 1998), and in families with Waardenburg
syndrome type 4, characterised by aganglionosis, pigmentation disorders and
deafness (Pingault et ah, 1998). Neither these patients nor Dom mice were reported
to have dysmyelinating features. However, a Japanese patient was described in 1999
with a heterozygous mutation in SOXIO. She had clinical features of Pelizaeus-
Merzbacher disease, a central nervous system demyelinating disease, and a
peripheral demyelinating neuropathy, in addition to features of Waardenburg
syndrome. There was a 12 bp deletion in the coding region of SOXIO which disrupts
the stop codon and extends the protein by 82 amino acids. This new sequence has
similarities with the proline-rich domains of WT1 (Wilm's tumour) which can
repress transcription. Thus, it was felt that this patient's unusual phenotype was due
to a dominant-negative action by the mutated protein (Inoue et ah, 1999).
A second patient was described in 2000 with a heterozygous mutation in SOXIO and
a hypomyelinating peripheral neuropathy, chronic intestinal pseudoobstruction,
dysautonomia and deafness. The mutation deletes one base in the last coding exon
which results in a frameshift mutation generating a new carboxy-terminal tail and
premature termination of the protein, with loss of the transactivation domain. A
peripheral nerve biopsy showed micropolyfasciculation with each nerve fascicle
subdivided into subfascicles. The myelin sheaths were thin or absent, but there was
no sign of active myelin breakdown or attempts at remyelination, suggestive of a
25
congenital hypomyelination neuropathy. This patient's slow conduction velocities
and clinical phenotype improved with age, again suggesting that this mutation
impaired development rather than promoting degeneration (Pingault et ah, 2000).
The neurological phenotype of these patients may be explained by the altered
synergy with downstream transcription factors (e.g. EGR2) or their downstream
genes.
There is now considerable interest in the autosomal recessive types of Charcot-
Marie-Tooth disease, which have been relatively less studied due to their lower
incidence and the need for consanguineous families to obtain sufficient linkage
information. The existence of autosomal recessive demyelinating peripheral
neuropathies that are not linked to known loci has intensified the search for novel
genes expressed in myelin-forming Schwann cells, and the PERIAXIN (PRX) gene is
one such candidate.
1.11. PERIAXIN (Prx)
The Periaxin gene encodes a novel Schwann cell protein initially only studied in
rodents. It was isolated in a screen based on detergent insolubility for cytoskeleton-
related proteins in peripheral nerve (Gillespie et ah, 1994). In rodents, the Periaxin
gene encodes two proteins with PDZ domains, L-periaxin and S-periaxin, of 147 and
16kD respectively, that are expressed in myelinating Schwann cells (Dytrych et ah,
1998). The two mRNA isoforms (4.7 kb and 5.2 kb respectively) are generated in
approximately equal amounts. The PDZ domain is named after the three proteins in
which it was first described: post-synaptic density protein-95 (PSD-95), drosophila
discs large tumour suppressor gene (dig) and the tight junction-associated protein
ZO-1 (Kornau et al., 1995). This domain is often present in proteins that link plasma
membrane proteins to the cytoskeleton (Sheng, 1996). S-periaxin is a truncated form
of L-periaxin which arises by an alternative splicing event which involves the
retention of intron 6. This intron introduces an in-frame stop codon that encodes a 21
amino acid C-terminus unique to S-periaxin. S-periaxin is present diffusely
throughout the cytoplasm of the Schwann cell. The rat Periaxin gene is a 20.6 kb
gene composed of seven exons (Gillespie et al., 1994) (Figure 6a). The mouse
equivalent is found on mouse chromosome 7 (Gillespie et al., 1997).
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L-periaxin consists of a basic domain near its N-terminus, (amino acids 118-196), a
region of a series of repeats, (amino acids 430-730) and an acidic domain near its C-
terminus (amino acids 1036-1163) (Dytrych et al., 1998) (Figure 6b). The repeat
region of L-periaxin consists of a pentameric core (aliphatic non-polar: proline:
glutamic acid or aspartic acid: aliphatic non-polar: variable) which is interrupted by a
tripeptide spacer (leucine: proline: lysine). The function of this region is unclear, but
it appears to be less flexible than the rest of the protein. It may act as a spacer
separating the functional basic and acidic domains. Supporting this, structure
prediction programmes suggest that L-periaxin has little secondary structure and a
linear conformation (Gillespie et al., 1994).
The basic domain sequence contains a nuclear localisation signal responsible for
nuclear targeting of the protein, which is developmentally regulated, as L-periaxin is
found in the nucleus until El7.5 (Sherman and Brophy, 2000). During myelination,
L-periaxin redistributes to the adaxonal membrane of the Schwann cell, and then to
the abaxonal membrane, Schmidt-Lanterman incisures and paranodal membrane with
maturation of the myelin sheath (Gillespie et al., 1994) (Figure 7). L-periaxin
recapitulates this pattern following nerve crush injury (Scherer et al., 1995). This
shift in L-periaxin localisation during myelination suggests that L-periaxin
participates in membrane-protein interactions that are required to stabilise the mature
myelin sheath. As a cytoskeleton-associated protein, L-periaxin may mediate such
stabilisation through its PDZ domain, which is implicated in the assembly of
signalling complexes at sites of cell-cell contact. Moreover, L-periaxin
homodimerises through its PDZ domain, and binds dystroglycan-dystrophin-related-
protein-2 (DRP2) through its basic domain, forming part of a complex linking the
Schwann cell cytoskeleton to the extracellular matrix (Sherman et al., 2001). DRP2
binds [3-dystroglycan, a transmembrane protein, linking to a-dystroglycan, which
directly interacts with laminin in the basal lamina. Thus, a complex is built up at the
abaxonal membrane of the Schwann cell, where periaxin homodimerises and serves
as a scaffold upon which to assemble the DRP2/dystroglycan complex (Wrabetz and
Feltri, 2001). This complex also contains Dpi 16, utrophin and actin (Figure 8). The
basal lamina has an essential role in enabling the development of the Schwann cell
and in stabilising the Schwann-cell-axon interaction (Carey et al., 1986; Eldridge et
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al., 1989). In muscle, the dystrophin/dystroglycan complex is thought to buffer
mechanical stress and it may be that the dystroglycan/DRP2/periaxin complex has a
similar role in maintaining the myelin sheath. The clustering of the complex may not
only convey a structural role by defining the basolateral membrane of the Schwann
cell, but may also transduce signals that regulate myelin thickness and stability,
similarly to the role of syntrophins, which also contain PDZ domains, in muscle
(Roberts, 2001). It may provide a signalling mechanism from the basement
membrane proteins to the Schwann cell interior by bringing other signalling
molecules that associate with L-periaxin into close proximity. In periaxin-null mice,
DRP2 is mislocalised and partially depleted indicating the importance of L-periaxin
at underpinning the complex (Sherman et al., 2001).
Periaxin-null mice develop an apparently normally myelinated peripheral nervous
system, so it appears that the presence of the periaxin proteins is not essential for
myelination to occur. However, these mice progress to develop a late-onset
peripheral demyelinating polyneuropathy (Gillespie et al., 2000). This suggests that
periaxin may be required for the stabilisation of the myelin sheath and its
maintenance. The process of myelin sheath repair may not entirely reiterate myelin
sheath development, as the environment in the two situations is different. The myelin
sheath in periaxin-null mice is unstable, leading to demyelination and reflex
behaviours that are associated with the painful conditions caused by peripheral nerve
damage. Older periaxin-null mice show extensive peripheral demyelination, with
mechanical allodynia and thermal hyperalgesia, which is reversible with the
intrathecal administration of a selective NMDA receptor antagonist. Pathology of the
peripheral nerves shows hypermyelination, with sheath infolding initially. Later,
most axons are naked or thinly myelinated, with redundant basal laminae and
supernumerary Schwann cells forming 'onion bulb structures,' which are diagnostic
of attempts to remyelinate demyelinated fibres (Gillespie et al., 2000). This
pathology is reminiscent of human demyelinating CMT disease.
The phenotype of the periaxin-null mouse with its late-onset demyelinating
peripheral neuropathy lent urgency to exploring its link with human disease. The
mouse Periaxin gene is found on chromosome 7, which is syntenic with the long arm
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of human chromosome 19 (Gillespie et ah, 1997). Early in 2001, a large
consanguineous Lebanese family was described with autosomal recessive CMT
disease (CMT4F) linked to the locus 19ql3.1-13.3 (Delague et ah, 2000). In Chapter
3, I describe the cloning of the human PRX gene and the discovery of mutations in
this gene in CMT4F and Dejerine-Sottas disease.
Although it is now clear that L-periaxin is essential to maintain healthy peripheral
nerve myelin, the functional role of L-periaxin is unclear. Recently, it was discovered
that a region at the C-terminus of L-periaxin binds to the F-box protein Fbl6, which
is known to target its ubiquitinated binding partners to the proteasome via the SCF
complex. This led to interest in the ubiquitination system.
1.12. UBIQUITINATION AS A METHOD OF PROTEIN REGULATION
Regulation of the abundance of cellular proteins is essential for cell survival and
normal function. Newly synthesised polypeptides are generally unstable in the highly
reactive cellular environment and tend to undergo spontaneous denaturation or
chemical modifications through oxidation, isomerisation or glycation. To avoid the
potentially dangerous effects of accumulation of unfolded or misfolded proteins, the
cell expends much energy on mechanisms that act to prevent aggregation, or promote
hydrolysis of abnormal proteins. A highly discriminative, energy dependent pathway
operates in the cytoplasm to ensure removal of damaged proteins. This pathway,
mediated by the protein ubiquitin, is a complex cascade of reactions involving multi-
enzyme complexes whose action is temporally and tightly controlled and plays an
important part in a broad range of cellular processes. In addition to destroying
damaged proteins, the pathway targets many naturally short-lived polypeptides that
are involved in the regulatory processes. The ubiquitin pathway of protein
degradation is responsible for the turnover of key short-lived regulatory proteins that
participate in processes as diverse as the cell cycle, cellular signalling in response to
stress and extracellular signals, morphogenesis, the secretory pathway, DNA repair
and organelle biosynthesis (Carrano and Pagano, 2001; Maniatis, 1999; Ulrich and
Jentsch, 2000). Aberrations in such a complex system may be pathogenic in many
diseases, both inherited and acquired. Protein regulation also occurs via an
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unregulated vacuolar pathway that is mediated by lysosomes, endosomes and the
endoplasmic reticulum.
1.12.1. The ubiquitination pathway
Hershko and Ciechanover discovered the ubiquitin/proteasome pathway in 1980
(Hershko et ah, 1980) and it has since been shown to provide highly efficient control
of the abundance of proteins involved in diverse cellular processes. The pathway
comprises of a cascade of reactions: El enzymes initially activate ubiquitin in an
energy dependent manner so that ubiquitin can bind a cysteine residue of the El
enzyme in a thiolester linkage. Activated ubiquitin is next transferred to a cysteine
residue of an ubiquitin conjugating enzyme (E2) which covalently transfers ubiquitin
onto lysine residues or the N-terminal residue of target proteins (Breitschopf et ah,
1998) or onto the last ubiquitin residue of a protein-bound multi-ubiquitin chain. E3
ubiquitin ligases recruit the target proteins for ubiquitination and these confer
specificity to the pathway (Ciechanover, 1998; Hershko and Ciechanover, 1998). The
structure of the system appears hierarchical: a single El activates ubiquitin, and can
transfer it to several species of E2 enzymes, and each E2 acts with either one or
several E3 enzymes (Ciechanover, 1998). The presence of ubiquitin residues on the
substrate serves as a cue for its recognition by the 26S proteasome, which then
removes the ubiquitin tag and degrades the target protein (Hershko and Ciechanover,
1998). Prior to its association with the proteasome, a class of enzymes, called
ubiquitin-carboxy-terminal hydrolases, monitors the protein-ubiquitin conjugate and
removes ubiquitin moieties from incorrectly targeted polypeptides. Ubiquitin is a 76
amino acid globular protein which may prevent it from proteolysis during the
hydrolysis of its bound proteins allowing recycling of the molecules via the action of
isopeptidases (Bebington et al., 2001) (Figure 9).
1.12.2. The proteasome
The 26S proteasome consists of the 20S core catalytic complex flanked on both sides
by the 19S regulatory complexes. The 26S proteasome mainly recognises ubiquitin-
tagged proteins. The complex is arranged as a stack of four rings, two a and two
p rings, organised in the general structure of aPPa (Groll et ah, 1997). Both a and p
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rings are composed of seven distinct subunits. The three catalytic sites, trypsin,
chymotrypsin and post-glutamyl peptidyl hydrolytic-like sites, reside on the p
subunits, arranged obliquely. The catalytically inactive a chains stabilise the ring
structure of the P chains. Substrate recognition by the 26S proteasome is probably
mediated by the interaction of specific subunits of the 19S complex with the poly-
ubiquitin chain (Ciechanover, 1998).
1.12.3. The SCF complex
One member of the family of E3 ubiquitin ligases is the SCF complex. This complex
consists of a core of four essential subunits: Skpl, a cullin, the RING finger protein
Rbxl/Rocl/Hrtl and an F-box protein (Chen et ah, 2000; Deshaies, 1999; Joazeiro
and Weissman, 2000) (Figure 10). The Cullin protein acts as a scaffold for the
complex, interacting with both a specific E2 protein and Skpl. The F-box protein
acts as an adapter component linking the substrate for ubiquitination to the complex
(Bai et ah, 1996; Craig and Tyers, 1999). The F-box protein comprises a C-terminal
motif, usually containing tryptophan-aspartic acid (WD40) repeats or leucine rich
repeats (LRR) (Kobe and Deisenhofer, 1995), which interacts with the substrate
which may be phosphorylated (Deshaies, 1999). The N-terminal F-box motif, named
for its presence in cyclin F (Bai et ah, 1996), is approximately fifty amino acids long
and binds Skpl. The F-box protein confers substrate specificity, interacting with a
number of target proteins but utilising the same core SCF complex for ubiquitination
of the different substrates. The ability of the SCF backbone to bind multiple F-box
proteins, each with specific substrate specificity, substantially increases the substrate
repertoire.
Phosphorylation is a major mechanism used by cells to transduce signals rapidly.
SCF complexes usually interact with phosphorylated substrates (Deshaies, 1999)
suggesting they are ideal for dynamic processes that require abrupt change to be
made irreversible via the degradation of key proteins. Hence SCF targets are key
regulators in many pathways of signalling, transcription and the cell cycle (Kipreos
and Pagano, 2000).
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A large number of F-box proteins have been identified recently, though the substrates
for many are unknown (Winston et al., 1999).
The subcellular localisation of F-box proteins has been studied using overexpressed
tagged proteins, and F-box proteins have been found in both the cytoplasm and the
nucleus. The localisation of the protein is not usually dependent on the F-box motif,
and its binding to Skpl, as wild type and mutant F-box proteins are co-localised
(Cenciarelli et ah, 1999; Winston et ah, 1999). Some F-box proteins are ubiquitous,
whereas others are clearly tissue specific.
1.12.4. The Wnt signalling pathway
The Wnt pathway, regulating P-catenin levels, is one of the best characterised
systems dependent on SCF-mediated ubiquitination and this depends on the action of
the F-box [3-TrCP. In mammals, P-catenin is involved in cell-cell adhesion and
growth factor signal transduction. It is membrane-associated, through its interaction
with E-cadherin and a-catenin, which form the adherens junction. It is also found in
a cytoplasmic pool, where it is important for signalling (Gumbiner, 1995). The Wnt-
1 ligand binds to the cell surface receptor Frizzled and initiates the Wnt signalling
cascade. This leads to inhibition of glycogen synthase kinase (GSK3P) which fails to
phosphorylate P-catenin. Thus, P-catenin is not recognised by the F-box protein p-
TrCP, and so accumulates in the cytoplasm. Excess P-catenin translocates to the
nucleus and functions as a co-activator for the transcription factor T cell factor/
lymphocyte enhancer binding factor (TCF/LEF-1) and modulates expression of its
target genes (Huber et ah, 1996). One such downstream gene is the oncogene c-myc
(Pennisi, 1998).
In the absence of Wnt signalling, a complex of GSK3P, adenomatous polyposis coli
(APC) and axin associates with and phosphorylates P-catenin at two specific serine
residues (Ikeda et al., 1998). The F-box protein P-TrCP binds P-catenin taking it to
the SCF complex for ubiquitination and proteasome degradation (Figure 11).
Enforced expression of P-catenin induces expression of its F-box protein P-TrCP, by
stabilisation of P-TrCP mRNA (Spiegelman et al., 2000). As P-catenin is a substrate
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of SCFp"TrCP, there is an accelerated degradation of P-catenin, and the negative
feedback loop provides an extra control mechanism. This is important as
deregulation of APC, P-catenin and E-cadherin expression leads to increased
transcriptional activity of TCF/LEF, and elevation of c-myc expression, resulting in
tumour formation (Sadot et ah, 2000).
Another substrate of the F-box protein P-TrCP is hedgehog, and mutations in desert
hedgehog in humans are known to cause a peripheral neuropathy, as well as gonadal
dysgenesis (Umehara et ah, 2000). This suggests that Schwann cells use the ubiquitin
pathway to regulate proteins involved in signalling.
1.12.5. Ubiquitination of L-periaxin and the regulation of its localisation
L-periaxin, similarly to P-catenin, appears to shuttle between the cytoplasm and the
nucleus. L-periaxin has a nuclear localisation signal, at the N-terminus of the protein
and in embryonic Schwann cells periaxin is located in the nucleus (Sherman and
Brophy, 2000). After this time, L-periaxin is found to be membrane-associated,
which is now known to be due to its interaction with the molecule dystrophin related
protein-2 (DRP-2) in the DRP-2/dystroglycan complex (Sherman et ah, 2001). The
mechanism of control of periaxin localisation is unknown but we now know that L-
periaxin interacts with the F-box protein Fbl6. Fbl6 interacts with the C-terminal
acidic region of L-periaxin by yeast two hybrid assay. The interaction of L-periaxin
with the C-terminal LRR region of Fbl6 has also been shown biochemically by in
vitro pull down assays (Vasiliou in preparation). This interaction appears to target L-
periaxin for ubiquitination as ubiquitinated forms of L-periaxin were
immunoprecipitated from sciatic nerve explant cultures and detected by
immunoblotting. The levels of L-periaxin in sciatic nerve explant cultures were
stabilised on inhibition of the proteasome by epoxomicin, demonstrating the
involvement of the proteasome in the turnover of L-periaxin (Vasiliou in
preparation). Thus, the ubiquitin/proteasome pathway appears to be involved in the
regulation of L-periaxin levels in the Schwann cell through its interaction with Fbl6.
One may speculate that this controls the localisation of L-periaxin in the Schwann
cell in a similar manner to P-TRCP and P-catenin. It is predicted that abnormalities
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in the SCF™6 pathway regulating L-periaxin levels in Schwann cells may cause
other as yet identified forms of CMT disease.
1.13. NERVE CRUSH AND REGENERATION
We now know more about the interactions of L-periaxin at a molecular level, and the
demyelinating effect of a lack of L-periaxin. However, we are still unclear as to why
periaxin deficient mice can apparently assemble normal compact myelin in the
development of the peripheral nervous system, indicating that the presence of
periaxin is not prerequisite for development of a myelin sheath, but later develop a
demyelinating peripheral neuropathy. This may suggest that periaxin is required for
maintenance of the stability of the sheath, and perhaps in its ability to repair the
myelin sheath in response to injury.
1.13.1. Nerve injury
Nerve injury is classified into five types. Sir Herbert Seddon (1943) first classified
nerve injury as neurapraxia, axonotmesis and neurotmesis and Sir Sydney
Sunderland (Sunderland, 1951) expanded this to include two more injury patterns.
Neurapraxia (Sunderland first-degree injury) involves a local area of conduction
block. Histologically there is segmental demyelination and a swift and complete
recovery is expected. Axonotmesis (Sunderland second-degree injury) involves
injury to the axon so that Wallerian degeneration occurs distal to the injury.
Recovery occurs by axonal sprouting within the intact endoneural tubes of the
Schwann cell basal lamina. The regenerated fibres are then remyelinated.
Regeneration is directed to the appropriate distal receptors and complete recovery is
expected. A Sunderland third-degree injury provides variable functional recovery, as
it is associated with axonal injury and endoneural scarring, which impedes or
misdirects axonal regeneration. A Sunderland fourth-degree injury describes a nerve
in physical continuity, but with a functional scar block, across which regeneration is
impossible. Neurotmesis (Sunderland fifth-degree injury) is a complete transection of
the nerve, with no functional recovery.
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There are several models of nerve injury in rodents. Nerve crush is a commonly used
experimental model in the rat to allow investigations of peripheral nerve injury and
regeneration. This has been evaluated and standardised by several groups. Bridge et
al., (Bridge et al., 1994) were concerned that the different methods of crush might
produce different injury patterns. They compared the time of crush - 15, 30 and 60
seconds, the number of crushes - single or double, and the type of instrument to
produce the crush - jeweller's forceps and serrated haemostat. There were no
significant differences between any of the experimental groups, either in histology,
behaviour, neurophysiology or recovery time. In rats at two weeks, the predominant
histological picture was that of Wallerian degeneration with some regeneration,
increased endoneural space and capillary thickening. Scarring within the
endoneurium was not seen. By week eight, almost complete recovery occurred,
though fibre size had not yet returned to normal. Functional recovery occurred by
week four, as assessed by walking track analysis. Electrophysiological testing
returned to normal by week eight. This study showed that despite the method used to
induce nerve crush, the result was very similar, producing a second-degree injury
(axonotmesis).
Brown and Hardman (Brown and Hardman, 1987) studied the accuracy of
reinnervation of motoneurones following crush injury in the rat sciatic nerve using
retrograde tracing techniques. They noted very few errors of projection, with only
3% of axons being misplaced. Hence, third-degree injury seems rare in this model.
Nawwar et al., (Nawwar et al., 1995) attempted to calibrate their nerve crush forceps
using transducers, but achieved no better results than using a jeweller's forceps
(Bridge et al., 1994).
Axonotmesis has also been achieved using cryoprobe lesions. Again, comparison of
complete cryoprobe injury and crush injury has not shown any difference in the
histology, behavioural tests or recovery of treated animals. However, cryoprobe
treatment was less likely to produce a complete full thickness lesion compared to the
crush treatment (Kerns et al., 1991).
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Thus a nerve crush model resulting in axonotmesis (Sunderland second degree
injury) provides an opportunity of studying remyelination of regenerated nerve
fibres. Experiments designed to evaluate the ability of periaxin-null mice to
remyelinate crushed nerve fibres are described in Chapter 4
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FIGURE 1 - PROPAGATION OF THE ACTION POTENTIAL
Node of Ranvler
Diagram of propagation of the action potential in a myelinated nerve by saltatory
conduction. Sodium channels are clustered at the Nodes of Ranvier and sodium
inflow here propagates the depolarisation and allows fast and efficient transmission.
Thus, the action potential appears to 'jump' from one node to the next.
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FIGURE 2 - DEVELOPMENT OF THE SCHWANN CELL
Myelinating
Schwann cell
cell precursor Schwann cells Schwann cell
Early migrating neural crest cells give rise to Schwann cell precursors, which
subsequently form immature Schwann cells. These are able to differentiate into
either myelin-forming or nonmyelinating mature Schwann cells (After lessen and
Mirsky, 1999).
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FIGURE 3 - THE MYELINATING SCHWANN CELL
Compact myelin
Schwann cell nucleus
a - A myelinating Schwann cell comes in contact with an axon, envelopes it, and
then forms compact myelin by spiralisation of the plasma membrane.
b- Diagrammatic representation of an unwrapped myelinating Schwann cell showing
non-compacted cytoplasmic channels (paranodal loops or lateral belts and Schmidt-
Lanterman incisures) coursing through compact myelin (black).
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Diagram of the Node of Ranvier to show the localisation of molecules at the node
and paranode. (after Tait)
Node Paranode Intemode
Na channel CASPR
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FIGURE 5 - PATIENTS WITH CMT DISEASE
a: Photograph of a patient's hand with CMT disease. There is prominent loss of
muscle bulk in the small muscles of the hand.
b: Photograph of a patient's legs with CMT disease. There is severe atrophy of the
muscles distally compared to proximally, and the patient has pes cavus.






a: Structure of the murine Periaxin gene.
Exons are numbered and indicated by blue boxes. Introns are shown as white boxes
between the exons, except for intron 6, which is depicted as a striped box.
b.
PDZ Basic Repeat Acidic
N i ■
13-98 118-196 430-730 1036-1163 1383
b: The domain structure of rat periaxin.
The repeat-rich region separates a strongly basic N-terminal segment from the acidic
C-terminus.
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FIGURE 7 - THE LOCALISATION OF PERIAXIN CHANGES
DURING DEVELOPMENT
a: At post-natal day 7, periaxin is localised at both the adaxonal and the abaxonal
membranes of the Schwann cell (arrows).
b: At post-natal day 42, periaxin is localised at the abaxonal membrane.
(from Dytrych et al., 1998)
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FIGURE 8 - THE PERIAXIN / DRP2 / DYSTROGLYCAN






L-periaxin homodimerises, and binds to the spectrin-like repeats of DRP2 through its
basic domain. DRP2 binds to the transmembrane protein p-dystroglycan (p), which
binds a-dystroglycan (a) and links into the laminin in the basal lamina, p-
dystroglycan also binds Dpi 16 and utrophin. SG - Sarcoglycans. (after Sherman et
al., 2001)
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FIGURE 9 - THE UBIQUITINATION DEGRADATION PATHWAY
1) Ubiquitin (Ub) is activated by the formation of a thiolester bond with an El
enzyme, that requires ATP.
2) Ubiquitin is subsequently ligated to an E2 conjugating enzyme, in an energy
independent manner releasing El.
3) The E3 ubiquitin ligases mediate the transfer of ubiquitin residues from E2 to the
substrate protein.
4) Ubiquitin C-terminal hydrolases (Uch) and ubiquitin specific proteases (UBP)
remove ubiquitin molecules from erroneously tagged proteins.
5) Substrates for degradation are targeted to the proteasome to be destroyed in an
energy dependent manner. The Ubiquitin tag is removed by proteases of the 19S
subunit and recycled.
6) The 20S core of the 26S proteasome cleaves the substrate into small peptide

































FIGURE 10 - E3 UBIQUITIN LIGASE - THE SCF COMPLEX
The core consists of Cullin 1, a RING-finger protein Rbx and Skpl. The substrate is
recruited by an adaptor protein (F-box protein) that binds to Skpl via its F-box
domain and the substrate to be ubiquitinated via its WD40 or LRR domain.
(adapted from Vasiliou)
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(3-catenin links the cytoplasmic region of E-cadherin to a-catenin and the actin
cytoskeleton in the adherens junction. Displacement of p-catenin by G12 results in a
pool of free cytoplasmic protein. Upon Wnt signalling, cytoplasmic p-catenin
translocates to the nucleus where it acts as a transcription factor. In the absence of
Wnt, the protein is targeted for destruction in the ubiquitin/proteasomal pathway.
(after Vasiliou)
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Table 1: CMT genes and disease types
MIM numbers refer to the reference numbers assigned to the disease or the gene in
the online database 'Online Mendelian Inheritance in Man'
(www3.ncbi.nlm.nih.gov/omim/).








(Lupski et ah, 1991;




CMT IB (MIM 118200) Autosomal Dominant MPZ (lq22-23)
(MIM 159440)
(Hayasaka etal., 1993)
CMT1C (MIM601098) Autosomal Dominant 16p 13.1-p 12.3 (Street et ah, 2002)
CMT ID Autosomal Dominant EGR2 (10q21.1 -q22.1)
(MIM 129010)
(Nelis et ah, 1999b;
Warner etal., 1998;
Warner etal., 1999)
CMT IX X-linked Cx-32/GJBl (Xql3.1)
(MIM304040)
(Bergoffen et ah, 1993)
CMT2 - axonopathies




(Ben Othmane et ah,
1993b; Zhao et ah,
2001)
CMT2B (MIM600882) Autosomal dominant
Prominent sensory loss
Similar to HSN-1 but
not allelic
3ql3-q22 (De Jonghe et ah, 1997;
Kwon et ah, 1995)
CMT2B1
(MIM605588)




Giovannoli et ah, 2002)
CMT2B2
(MIM605589)
Autosomal recessive 19ql3.3 (Leal et ah, 2001)
(CMT4C2) Autosomal recessive
Pyramidal features
8q21.3 (Barhoumi et ah, 2001)
CMT2C (MIM606071) Autosomal dominant
Diaphragm and vocal
chord paralysis
Unknown (Santoro et ah, 2002)
CMT2D (MIM601472) Autosomal dominant
Prominent hand
weakness
May be same as
HMNV
7pl4 (Ionasescu et ah, 1996)
CMT2E (MIM 162280) Autosomal dominant NF-L (8p21)
(MIM 162280)






3pl3.1 (Takashima et ah,
1999)










(Baxter et al., 2002;
Ben Othmane et al.,








(Bolino et al., 2000;





11 p 15 (Othmane etal., 1999)










CMT4E (MIM605253) Onion bulbs EGR2 10q21-q22
(MIM 129010)
(Warner et al., 1998)
CMT4F (MIM145900) Onion bulbs PRX 19q 13.1-13.3
(MIM605725)
(Boerkoel et al., 2001b;
Delague et al., 2000;













Autosomal recessive 10q22-q23 (Rogers et al., 2000)
Dejerine-Sottas
Disease (MIM145900)
CMT3A Autosomal dominant PMP22 point mutations (Roa et al., 1993a)
CMT3B Autosomal dominant MPZ (Hayasaka et al., 1993;
Warner et al., 1996a)
CMT3D Autosomal dominant EGR2 (Timmerman et al.,
1999)




PMP22 point mutations (Ceuterick-de Groote et
al., 2001; Fabrizi et al.,
2001; Simonati et al.,
1999)
MPZ (Mandich et al., 1999;
Warner et al., 1996a)
EGR2 (Warner et al., 1998)
MTMR2 (Bolino et al., 2001)
Hereditary sensory
neuropathy






(Bejaoui et al., 2001;
Dawkins et al., 2001)
(Auer-Grumbach et al.,














(Bodzioch et al., 2001;
Houlden et ah, 2001;
Indo et ah, 1996;
Shatzky et ah, 2000)















May be same as
CMT2D




















Autosomal dominant SOX10 22ql3
(MIM602229)
(Inoue et ah, 1999;




Autosomal recessive GAN (16q24.1)
(MIM605379)
(Bomont et ah, 2000)
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2. MATERIALS AND METHODS
2.1. CLONING THE HUMAN PERIAXIN GENE
Several different methods were used to obtain the human PERIAXIN sequence.
2.1.1. Polymerase chain reaction (PCR)
Reverse transcription polymerase chain reaction (RT-PCR) was carried out on RNA
extracted from human sciatic nerve, using primers matching rat Periaxin sequence.
150 ng of random primers (hexamers and nonomers of random sequence) were added
to 4 pg of sciatic nerve RNA in DEPC water and incubated at 70 °C for ten min to
denature. The sample was left for two min on ice to anneal. Then 4 pi of 1st strand
buffer, 2 pi 0.1M DTT, 1 pi 10 mM dNTPs and 1 pi superscript Reverse
Transcriptase were added, incubated at 25 °C for ten min and then at 42 °C for forty
five min. The sample was heated at 75 °C for fifteen min and put on ice. 1 pi of this
was used as a template for each PCR reaction. The PCR mix consisted of 5 pi of
each 5 pM primer solution, 5 pi of 2 pM dntp solution, 5 pi of lOx buffer, 1 pi of
template, and 0.5 pi of PFU enzyme made up to 50 pi with water.
Similarly, PCR was used with genomic DNA as a template using rat or human
specific Periaxin primers, as listed in Table 2.
2.1.2. Plasmid Artificial Chromosomes
We obtained a human Plasmid Artificial Chromosome (PAC) library from the
Human Genome Mapping Project in Cambridge, and screened this with a probe
consisting of the complete rat periaxin cDNA to select PAC clones that contained
human PERIAXIN. Two PAC clones were obtained - PAC68 and PAC71. Working
with these PAC clones was difficult due to the poor yield from plasmid preparations,
as they have a copy number of one. Thus, large cultures of bacteria are required to
obtain a small amount of PAC, and there is proportionally more contamination with
protein and genomic DNA unless steps are taken to account for this.
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2.1.3. PAC preparation (A variation of the Qiagen Midi-prep method)
A glycerol stock of PAC was grown in 250-500 ml of Luria Broth and 25 pg/ml
Kanamycin for 18 hours. This was spun down at 6000 rpm at 4 °C for fifteen min.
The pellet was resuspended in 10 ml of PI (50 mM TrisCl pH 8, 10 mM EDTA and
100 pg/ml RNase A). Solution P2 (10 ml) was added (200 mM sodium hydroxide
and 1 % SDS w/v), mixed gently and left at room temperature for five min. Solution
P3 (10 ml) was added (3 M potassium acetate pH 5.5), mixed gently and left on ice
for thirty min. This was spun down at 15000 rpm at 4 °C for thirty min, the
supernatant decanted into clean tubes and spun again at 15000 rpm at 4 °C for fifteen
min. The supernatant was then precipitated with isopropanol (0.75 volumes), and
spun at 15000 rpm at 4 °C for thirty min, to decrease the volume before putting it
through the column. The pellet was resuspended in 10 ml of QBT (750 mM NaCl, 50
mM MOPS pH 7, 15 % isopropanol v/v, 0.15 % triton X-100 v/v) and passed
through a midi column primed with the same buffer. The column was washed twice
with 10 ml of QC wash buffer (1 M NaCl, 50 mM MOPS pH 7, 15 % isopropanol
v/v) and then the DNA was eluted from the column with 6 ml of QF buffer (1.25 M
NaCl, 50 mM TrisCl pH 8.5, 15 % isopropanol v/v) warmed to 50 °C. The DNA was
again precipitated with 0.75 volumes of isopropanol, and spun at 13000 rpm for
thirty min at 4 °C. The pellet was washed with ice cold 70% ethanol and spun for
five min. The pellet was left to dry for ten min and then resuspended in TE (0.01 M
Tris/HCl pEl 8.0, 5 mM EDTA pH 8.0) containing Rnase cocktail (Ambion) by
leaving overnight at 4 °C. Pipetting the solution up and down was avoided as this can
shear large pieces of DNA. The amount and quality of the DNA was checked using
absorbance at 260 nm and by running a sample out on an agarose gel.
2.1.4. Instability of PAC clones
PAC clones can sometimes be unstable, and over time PCR and Southern blots using
PAC71 as a template ceased working, suggesting that the PERIAXIN gene was lost
from this PAC clone. Fortunately, PAC68 was stable. I determined the sequence of
exons II, III and IV, and intervening introns 2 and 3 by PCR directly from the
PAC68 using rat-specific primers (Table 2).
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2.1.5. Digestion of PAC 68 clone and detection of fragments by Southern blot
The PAC was digested with frequent cutting restriction enzymes to generate smaller
fragments. These were electrophoresed on a pulsed field gel for high resolution of
the fragments. An 0.8 % agarose TBE gel was run in cooled (13 °C) 0.5 x TBE
buffer at 6 Volts/cm for 18 hours with the pulse setting at 0.1 — 10 and then stained
with ethidium bromide. This was transferred to a nylon membrane and hybridised
with the whole length rat periaxin cDNA probe by Southern blot.
2.1.6. The hybridisation probe
The whole length rat periaxin cDNA probe was obtained by digestion of the 4.6 kb
fragment from its plasmid pSPORT (Stratagene) with SalUNotl.
2.1.7. Southern blotting of PAC DNA
The DNA was transferred to a nitro-cellulose membrane (Schleicher and Schuell)
under a pressure of 45 mbar. The gel was first covered with denaturing solution for
twenty min, then with neutralising solution (87.7 g NaCl, 121.1 g Tris, 2 ml 0.5 M
EDTA, 800 ml H20 pH 7.2) for twenty min and finally with 20x SSC (3 M sodium
chloride, 0.3 M trisodium citrate) for one hour. The membrane was dried overnight at
80 °C.
2.1.8. Radioactive labelling of hybridisation probe
The probe (30 ng) was labelled using the random prime DNA labelling kit (Gibco
BRL). The DNA was boiled in distilled water (23 pi total volume) for three min to
denature it and put onto ice. Following a brief spin nucleotide mix (6 pi) and random
primer mix (15 pi) were added. The probe was then incubated with 1.85 Mbeq P
labelled phosphate (ICN) and 3 U Klenow fragment enzyme at 25 °C for one hour.
The reaction was terminated with 5 pi of STOP solution and 100 pi of 10 mg/ml
sheared salmon sperm DNA.
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2.1.9. Hybridisation process
The membrane was soaked briefly in distilled water and placed into a 50 ml Falcon
tube with 5 ml of Quik-Hyb solution (Qiagen) and allowed to warm to 65 °C for
thirty min. The probe was boiled at 98 °C for ten min and allowed to hybridise to the
filter at 65 °C for two hours. Then the filter was washed twice with low stringency
buffer (2 x SSC (0.3 M sodium chloride, 0.03 M sodium citrate) / 0.1 % SDS) for ten
min each time, at room temperature. It was subsequently washed twice with high
stringency buffer (0.2 x SSC (0.03 M sodium chloride, 3 mM sodium citrate) / 0.1 %
SDS) for thirty min each time at 65 °C. The filter was dried at room temperature and
wrapped in Saran film. Autoradiography was carried out over 48 hours.
2.2. DETECTION OF PERIAXIN MUTATIONS
2.2.1. Detecting the mutation R196X
The Paris group amplified exon VII of PERIAXIN in ten overlapping fragments. The
PCR products were purified using QiaQuick PCR Purification kit (Qiagen) and
sequenced by BigDye terminator chemistry (Perkin-Elmer) on an ABI377 (Perkin-
Elmer). The PCR product of the first fragment of exon VII was digested with the
enzyme Rsal (three hours at 42 °C) followed by analysis on a 2 % agarose gel.
2.2.2. Detecting PERIAXIN protein, or its truncated form by
immunofluorescence
Nerve biopsies taken from humans are usually fixed in formalin and then embedded
in paraffin blocks. This preserves the tissue structure well but the formalin fixation
can mask antigens, disrupting antibody binding. There are five periaxin antibodies
which label periaxin antigen well on frozen mouse or rat peripheral nerve sections
(Table 3), but these have never previously been used on human sections, or on
paraffin sections.
2.2.3. Human C-terminal periaxin antibody
As the rabbit and sheep C-terminal periaxin antibodies do not recognise human
Periaxin, we raised a human-specific C-terminal antibody to the peptide sequence
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KARSGSGDQEEGGLRVRLPS in rabbits. To enhance its antigenicity, the peptide
was coupled to Keyhole Limpet haemocyanin by an N-terminal Cysteine residue.
The peptide was synthesised by Invitrogen. The supplied dehydrated salt was
dissolved in MilliQ water to a concentration of 1 mg/ml and 2 ml aliquots were
stored at -40°C. Prior to injection, each 2 ml aliquot was mixed with 3 ml of Freund's
complete adjuvant (Sigma) and mixed by vigorous shaking overnight. This mix was
spun briefly and three 1.5 ml aliquots were prepared in 3 ml syringes (Becton
Dickinson). Each aliquot was injected into a male New Zealand White rabbit. Two
boost injections were given three and five weeks later when the aliquots were
prepared in 3 ml of Freund's incomplete adjuvant (Sigma). The rabbits were bled ten
days after the first boost to test for antibody production and then bled out at seven
weeks. Professor P.J.Brophy carried out all injections and cardiac exsanguination at
the CTVM Facilities, Easter Bush, Edinburgh.
2.2.4. Western blotting
Proteins were resolved according to size on a SDS-PAGE gel and transferred to a
nitro-cellulose membrane (0.45 pm, Schleicher and Schuell) in a buffer containing
25 mM Tris-HCl, 250 mM glycine and 20 % methanol. The transfer was carried out
in a Hoefer Mighty Small Transphor Unit (Pharmacia Biotech) cooled apparatus for
two hours at 0.48 amps. The nitro-cellulose filter was then blocked in 5 % dried
skimmed milk, 0.1 % Tween-20 in PBS (Appendix A) overnight. It was rinsed with
0.2 % gelatin, 0.1 % Tween-20 in PBS and incubated with the primary antibody
diluted in the same buffer, for one hour on a shaker. The filter was washed three
times for ten min in 0.2 % gelatin, 0.1 % Tween-20 in PBS and incubated with the
secondary antibody, which is HRP-labelled, diluted in the same buffer for one hour
on a shaker. Excess secondary antibody was then washed off with three ten minute
washes in 0.1 % Tween-20 in PBS. The peroxidase was detected using the enhanced
chemiluminescence (ECL) method (Amersham) or by adding 3,3 diaminobenzidine
(DAB) solution (0.05 % DAB in 50 mM TRIS pH 8.0) and 0.02 % hydrogen
peroxide. If DAB was used for developing the blots, then 0.1 % Triton X-100 was
used in place of Tween-20 in all of the solutions.
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2.2.5. Assessment of rabbit anti-serum by Western blotting
Test bleeds (3 ml) were collected from the rabbits in 5 ml Bijoux tubes and allowed
to clot at 4 °C overnight. The serum was taken into 1.5 ml microfuge tubes and spun
at 13000 rpm for two min to remove the clotted blood. Aliquots were stored at -40
°C. To assess the specificity of the anti-serum, a Western blot was performed using
human cauda equina post-mortem material boiled in 2 % SDS solution and run out
on an 8 % SDS-PAGE gel. The final bleed of the human C-terminal antibody (2186)
was used at a dilution of 1:1000, and the secondary antibody, donkey anti-rabbit IgG-
HRP (Diagnostics Scotland), at a dilution of 1:500, when developing with DAB
solution, and 1:4000 and 1:2000 respectively for developing with the ECL technique.
Affinity purified anti-serum was tested in the same manner, used at a dilution of
1:200 (DAB).
2.2.6. Affinity Purification of anti-serum
The anti-serum was affinity purified using an a-aminohexyl sepharose 4B column,
conjugated to non-KLH coupled peptide, a-aminohexyl sepharose 4B (1 ml) was
pipetted into a 15 ml Falcon tube, spun briefly to remove the excess ethanol and
washed four times with 3 ml of PBS (Appendix A). It was then resuspended in 2 ml
of PBS and 5 mg of MBS (m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester)
added, dissolved in 200 pi of dimethylformamide. The tube was placed on a rotating
wheel at room temperature for two hours and then spun down and washed four times
with 3 ml of PBS. The final spin (five min) was to pack the gel. Non-KLH coupled
peptide (10 mg) was dissolved in 800 pi of 10 mM hydrochloric acid and the pH
adjusted to 6.0 with 100 mM sodium hydroxide. The gel was incubated with this
peptide solution on a windmill at room temperature overnight.
The peptide/sepharose conjugate was washed with two volumes of 1 M Tris-HCl pH
7.5, then with two volumes of 50 mM citric acid, pH 2.5 and lastly with three washes
of two volumes of PBS. Anti-serum (5 ml) was added to the column and allowed to
mix on a windmill at 4 °C overnight.
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The slurry was then loaded into a 10 cm x 1 cm column (Biorad) and allowed to
settle. The column was washed with 5 ml 20 mM sodium citrate until the absorbance
at 280 nm was zero. Citric acid (50 mM pH 2.5) (6 ml) was added to elute the
antibody and 0.5 ml fractions collected into microfuge tubes containing 0.35 ml 1 M
HEPES pH 7.5. The yield was determined by reading the absorbance at 280 nm of
the collected fractions. To clear the column, it was washed with elution buffer to
remove all antibody, then washed with 20 mM sodium citrate pH 7.7 and four times
with PBS. It was stored in PBS with 0.01 % sodium azide at 4 °C.
2.2.7. Immunohistochemistry
2.2.7.1. Paraffin sections
Sections (5 pm) of formalin-fixed sural nerve biopsies embedded in paraffin were
collected on 3-aminopropyltriethoxysilane (TESPA)-subbed slides. The paraffin was
removed by immersing in two changes of xylene over thirty min, and the tissue was
rehydrated through alcohol (100 % for five min, then 95 %, 70 %, 50 % 30 % for
thirty seconds each) to water (two 1 minute changes). The sections were then washed
in 0.85 % NaCl for five min and microwaved at 700 W in 0.1 M citrate buffer (pH 6)
for ten min. They were allowed to cool in the same buffer for twenty min and then
fixed in 4 % paraformaldehyde for ten min (Cattoretti et al., 1992). The sections were
washed in two changes of PBS (Appendix A) over ten min.
Double-label immunofluorescence was carried out. Sections were blocked for one
hour at room temperature in a solution of 5 % (v/v) fish gelatin, 0.1 % (v/v) Triton
X-100 in PBS. Blocked sections were incubated overnight with primary antibody
diluted in the same solution, under humid conditions at room temperature. Slides
were then washed three times in PBS containing 0.1 % (v/v) triton X-100 over one
hour and then incubated with the appropriate dilution of FITC or TRITC-conjugated
secondary antibodies in the blocking solution for ninety min. The slides were washed
three times in PBS over forty-five min, mounted with Vectashield (Vector Labs), and
examined under a fluorescence microscope. Dilutions and sources of antibodies used
are shown in Table 4.
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2.2.7.2. Frozen sections
Frozen sections of tissue (5 pm) were collected similarly on 3-
aminopropyltriethoxysilane-subbed slides. The OCT (optimal cutting temperature) in
which the samples were embedded was washed away with PBS (Appendix A) and
the sections were fixed in 4 % paraformaldehyde for five min. Then, the sections
were blocked and treated in the same way as in Section 2.2.7.1.
2.2.8. Sural nerve pathology
Semi-thin sections (1 pm) were cut from osmicated resin-embedded nerve, stained
with toluidine blue and viewed under the light microscope. Ultrathin sections were
cut from the same blocks, stained with uranyl acetate and lead citrate and examined
on a Phillips BioTwin electron microscope.
2.3. OVER-EXPRESSION VECTOR
The periaxin overexpression vector consists of mouse L-Periaxin cDNA under the
control of the MBP promoter and Schwann cell enhancer 1 (SCE1). The vector,
clone 8, contains 9 kb of MBP promoter plus the SCE1. The SCE1 enhancer is a 600
bp fragment that will function regardless of orientation and position upstream or
downstream of the gene (Forghani et al., 2001). Mouse L-periaxin cDNA (4.6 kb)
was excised from the plasmid pIBI30 with EcoRl and BamHl enzymes in buffer
React3. This was cloned into plasmid pSP72 (Promega) at the EcoRHBamHl sites,
and excised with Clal/Sall restriction digest in buffer H. This fragment was then




2.3.1. Preparation of DNA for injections
The transgene (13.6 kb) was excised with a BamHl/Sstll double digest in React2
buffer overnight at 37 °C (50 pg). The digest was run out on a 0.8 % low melting
point agarose gel in Tris-acetate buffer ((TAE) 0.04 M Tris-acetate, 1 mM EDTA) at
4°C and the linearised transgene cut out with minimal agarose. This was weighed,
0.04 volumes of 25 x agarase buffer (Boehringer) added (i.e. 2 pi for 50 mg), and
incubated at 65°C for fifteen min. The sample was incubated at 45 °C for ten min to
cool down, 0.8 units of agarase enzyme per 100 mg agarose were added, and left for
two hours at 45 °C. Following agarase treatment, the DNA sample was diluted in 10
ml of low salt buffer and purified using Elu-tip D-column set (Schleicher and
Schnell) NA01010 according to the manufacturers instructions. The DNA was eluted
from the Elutip column into a pre-cleaned microfuge tube (rinsed with filter-sterile
water), and ethanol precipitated. The pellet was washed with 500 pi of 70% ethanol,
spun for five min at room temperature and allowed to dry. This was taken up in 50pi
Millipore-filtered injection buffer (10 mM Tris-HCl pH 7.5, 0.1 mM EDTA pFI 8.0)
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and a sample was run out against high DNA mass ladder on an agarose gel to check
size and amount. Approximately 2 gg of DNA was dialysed against 1 litre of
injection buffer at 4 °C for 48 hours, with three changes of buffer over this time. The
concentration was checked against a DNA high mass ladder by running a sample on
an agarose gel, diluted with filtered injection buffer to 2.5 ng/gl, and stored in 20 gl
aliquots at -70 °C ready for injection.
2.4. CONDITIONAL CONSTRUCT
We made a conditional construct which, using homologous recombination, inserts
loxP sites either side of exon V of murine Periaxin. When this fragment of DNA
between the loxP sites is removed by Cre recombinase activity, the translation frame
is altered in exon VI introducing a downstream stop codon. A protein of thirteen
amino acids (nine from exon IV and four from exon VI) could be translated, but this
would most probably be unstable.
Conditional construct
Clal(Xhol) loxP/EcoRl ExonV Xhol Xhol
i 1—► t/tnl ►4~
■4 5'arm ►-4—3 'arm -
4 ►-« ^4 ^4
2 kb 1.5 kb 3.6 kb 2.5 kb
The full-length genomic mouse Periaxin DNA sequence was put together by Lee
Dytrych and Stewart Gillespie (Dytrych et al., 1998).
2.4.1. The 5' arm of the construct
The 5' arm of the construct was put together from two fragments digested from the
full-length Periaxin clones. The XhoVKpnl fragment of the 5' arm was subcloned
into bluescript vector (Stratagene). The KpnUXhol fragment was subcloned into
pGEM7 (Promega). Then, the first fragment was digested from its position in
61
bluescript with ClaUKpnl and subcloned into pGEM7 containing the Kpnl/Xhol
fragment.
Cla\{Xhol) Kpnl Smal ExonV X1io\(Xba\)
The next step was to insert the single loxP site in the Smal site of the 5' arm. These
oligonucleotides were designed to contain the loxP site with ends designed to ligate
into a Smal site and a 3' EcoRl site (GAATTC) for screening purposes. The forward
and reverse oligonucleotide sequences were obtained from Oswel and high





These oligonucleotide sequences were annealed together by taking 30 pmoles of each
and, in the presence of NEB buffer 2 (New England Biolabs), they were incubated on
a PCR machine at 98 °C for 5 min, and then at -1°C per cycle until reaching 25 °C.
These annealed oligonucleotides were then ligated into the Smal site of the 5'arm.
The most efficient ligation occurred at the molar ratio of 10:1 of oligonucleotides:
vector.
The subclones were screened for the presence of a new EcoRl site and the absence of
a Smal site by enzymatic digestion, and five of these were sequenced using the intron
4 reverse primer MP2 (GAGGCACCTTAAGCCATGCG) to ensure that the cassette
was in the correct orientation. Three out of five of these clones were in the correct
orientation.
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2.4.2. The 3' arm
A 2.5 kb fragment was digested from the subclone 5.5 with Xhol and subcloned into
the Sail site of pSP72 (Promega).
2.4.3. Putting the 5' and 3' arms together
The 5' arm containing loxP in the Smal site was digested with Clal and Xbal and
subcloned into the pSP72 vector (Promega) containing the 3' arm.
Clal(Xhol) Kpnl loxP/EcoRl ExonV Xhol(Xbal) Xhol
L_J ¥ 1 1 '
5'arm 3'arm
The last step was to put the cassette containing herpes simplex thymidine kinase (T)
and neomycin resistance (N) flanked by loxP sites (L), (LTNL), into the Xbal site at
the end of the 5' arm. This cassette was digested from its vector with high
concentration Xbal enzyme in React2 buffer (Gibco). The pSP72 (Promega) vector
containing both 5' and 3' arms was also digested with Xbal in the same way, then
phenol/chloroform extracted, and ethanol precipitated in the presence of 3 M sodium
acetate. This was taken up in 17 pi of water, 2 pi of 10 x buffer and 1 pi of calf
intestinal alkaline phosphatase and incubated at 37 °C for thirty min to
dephosphorylate the ends of this vector and reduce the likelihood of simple
recircularisation. Each digest was run out on a 0.8 % agarose TAE gel (0.04 M Tris-
acetate, 1 mM EDTA) and the 9 kb linear fragment of the vector, and the 3.6 kb
LTNL cassette were purified from the gel using the Qiaex method (Qiagen). These
fragments were then ligated overnight at 4 °C in the presence of T4 DNA ligase, and
its buffer (MBI Fermentas). The subclones were screened by an Xbal digest to show
release of a 3.6 kb fragment. The orientation of the cassette was determined by
digesting with BamHl in React3 buffer as the LNTL has a BamHl site 0.4 kb from its
3' end. The correct orientation gave fragments of 6.3 and 5.3 kb, and the incorrect of





Clal BamHl V I I
1—► LTNL ► + 2-4 kb
0.4 kb OA kb oXkb PSP72 vector
■4 ►
3.5kb 3.6 kb 2.5 kb
Large quantities of the completed construct were obtained using the maxiprep
(Qiagen) kit using the low copy method, as the vector was large (12 kb).
2.4.4. Testing the loxP sites
To ensure that the loxP sites were correct and that Cre recombinase could stimulate
recombination between them, I transformed competent Cre-expressing BCC132 cells
with the conditional construct. The conditional construct (0.2 pg) was added to
competent BCC132 cells and incubated at 42 °C for ninety seconds. SOC medium
(800 pi) (Appendix A) was added and this was incubated at 30 °C for one hour to
allow Cre expression. Then, the cells were incubated at 37 °C to allow growth and
plated out on L-AMP (L-agar/ 100 pg/ml ampicillin) plates. Plasmid DNA was
recovered from the colonies and screened for recombination events. Restriction
digestion with Clal and a double digest with ClaUEcoRl confirmed that all three
possible recombination events had occurred.
Clal EcoRl ExonV EcoRl EcoRl
1 ¥ 1—► ' LTNL'
1 2 3
< ►-< ►<
In pSP72 - 2.4 kb
►
2 kb 1.5 kb 3.6 kb 2.5kb
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Clal digest Clal/EcoRl digest
No recombination 12 kb 2, 1.6, 1.7, and 6.7 kb
Recombined between loxP sites 1+3 6.9 kb 6.9 kb
Recombined between loxP sites 2+3 8.4 kb 2 and 6.4 kb
Recombined between loxP sites 1+2 10.5 kb 2.1, 1.7, and 6.7 kb
Out of five clones selected, there were none in which no recombination occurred.
One recombined between loxP sites 1 and 3, and two between sites 2 and 3 and two
between sites 1 and 2. Therefore, all loxP sites are functioning as expected.
The vector (300 pg) was then linearised with the enzyme Clal (in the presence of
bovine serum albumin, and buffer NEB4 (New England Biolabs)) overnight at 37 °C.
A sample was run out on a 0.8 % agarose TAE (0.04 M Tris-acetate, 1 mM EDTA)
gel to check that it was fully linearised. Then the remaining DNA was extracted with
phenol-chloroform and 2.2 volumes of absolute ethanol were added. This was then
taken to the Centre of Genome Research for electroporation into embryonic stem
(ES) cells.
After electroporation, they cultured the ES cells in Geneticin (G418) which selects
for those clones containing the construct at any site, as it contains the sequence for
neomycin resistance. The DNA was extracted from these positive clones and
screened with the 5' and 3' probes to ensure that the construct had undergone
homologous recombination and was incorporated into the correct site. The 5' probe,
generated by PCR using the primers LMD2/MP1 (see Table 5), is a 334 bp sequence
containing sequence from exons II to IV lying outwith the construct, and adjacent
intron sequence. When wild-type genomic DNA is digested with the restriction
enzyme EcoRl, this probe hybridises to a 10.5 kb fragment on a Southern blot as
opposed to a 6 kb fragment in the targeted genomic DNA (Figure 12a). The 3' probe
(LMD13/MP5) is a 400 bp sequence containing exon VI sequence 5' to the Smal site,
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plus some intron 5 sequence. When wild-type genomic DNA is digested with the
restriction enzyme Smal, this probe hybridises to an 8.5 kb fragment on a Southern
blot as opposed to a 9.2 kb fragment in the targeted genomic DNA (Figure 12a).
A plasmid containing Cre recombinase was electroporated into these clones able to
grow in G418 and that showed the correct pattern on Southern blots with the 5' and 3'
probes. The Cre was transiently expressed allowing the recombination events to
occur between the loxP sites. Those clones with recombination between loxP sites 1
and 2 were selected out with gancyclovir, as these cells contain the thymidine kinase
gene that converts this to a toxin. The other two recombination events generate a
knock-out of the Periaxin gene (loxP sites 1 and 3) or the floxed exon V of Periaxin
(loxP sites 2 and 3). When 'knock-out' DNA is digested with the restriction enzyme
EcoRl, the 5' probe hybridises to a 9 kb fragment on a Southern blot as opposed to a
6 kb fragment in the floxed Periaxin DNA (Figure 12b). When 'knock-out' DNA is
digested with the restriction enzyme Smal, the 3' probe hybridises to an 18.5 kb
fragment on a Southern blot as opposed to a 20 kb fragment in the floxed Periaxin
DNA (Figure 12b).
2.5. SCIATIC NERVE CRUSH
University of Edinburgh Care of Animals regulations were observed throughout
these experiments.
Six-week-old mice were anaesthetised with midazolam (3 pg/g), fentanyl (0.5 pg/g)
and fluanisone (16 pg/g), and an incision made to expose the right sciatic nerve. At
the sciatic notch, the nerve was crushed for ten seconds, three times, with jeweller's
forceps (T5254 Agar Scientific). The wound was closed with a clip. After two or six
weeks, the mice were anaesthetised with halothane, and then perfused with 2.5 %
glutaraldehyde and 2 % paraformaldehyde in 0.1 M sodium cacodylate buffer (pH
7.3). The sciatic nerves were removed. The proximal end was cut at the site of crush,
at the sciatic notch, or equivalent level on the contra-lateral leg, and muscle was left
on the distal end of the nerve, to allow easy orientation after fixation. The nerves
were fixed for two hours in the same fixative, post-fixed in osmium tetroxide and
embedded in araldite.
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Transverse semi-thin sections of one micron were cut immediately distal to the crush
site, and stained with Toluidine blue. The myelin thickness of fibres regenerated after
crush depends not only on the ability of the Schwann cell to remyelinate but also on
the efficiency of axonal sprouting and elongation, and so great care was taken to
perform measurements at the same distance from the crush site.
The total cross-sectional area of nerve was measured using the IP Lab Spectrum
software. Measurements of myelinated axon number, density, diameter and myelin
thickness were then performed on 30 % of the area of each nerve chosen randomly,
using the IP Lab Spectrum software (Figure 13). Random areas of the nerve were
selected by superimposing a numbered grid and using a random number table to
select squares. Analysis of significance was carried out using the t-test for normally
distributed data and the Kolmogorov-Smirnov test for non-parametric data.
Regression lines were compared using ANOVA. Each experimental group consisted
of between three and five mice.
2.6. FBL6 ANTIBODIES
Sylvia Vasiliou constructed a GST fusion protein containing amino acids 49-115 of
Fbl6 previously and this was used as an antigen to produce an antibody, as described
in Section 2.2.3.
2.6.1. Purification of GST-fusion protein
The GST-fusion clone of Fbl6 in codon-plus bacteria was grown in 2 x 500 ml of L-
broth culture containing 100 pg/ml ampicillin at 37 °C until reaching an optical
density at 600 nm (OD600) of 0.5-0.6, and then induced with 1 mM IPTG for three
hours at 37°C. The cultures were spun at 4000 rpm at 4 °C for ten min and the pellet
resuspended in 12.5 ml of buffer (50 mM Tris pH 8.0, 50 mM NaCl, 2 mM DTT, 1
mM PMSF, 1 mM benzamidine and one protease inhibitor tablet (Boehringer-
Mannheim)). This was then sonicated for 6 x ten seconds and spun for twenty min at
14000 rpm at 4°C. Glutathione sepharose 4B (Pharmacia) was washed with PBS
(Appendix A) three times and the supernatant added, and incubated on a rotating
wheel at room temperature for one hour and then at 4 °C for one hour. The matrix
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was loaded into a column (Biorad) and washed with PBS. The fusion protein was
eluted with 10 mM glutathione in 50 mM Tris pH 8.0.
The protein yield was estimated by reading the absorbance at 280 nm and checked on
a SDS-PAGE gel compared to BSA standards.
2.6.2. Affinity Purification of Fbl6 antibody (2194)
As the antibody was raised to a GST fusion protein, with a pi of 8.69, affi-gel 10 (for
neutral or basic proteins) was used as a matrix. GST-fusion protein (fused to amino
acids 49-115 of Fbl6) (5 mg) was concentrated into 2 ml and dialysed against 2 litres
of 20 mM Hepes pH 7.5 overnight at 4 °C to remove GST molecules and Tris
molecules as the latter bind to the amino groups of affi-gel. Packed affi-gel 10(1 ml)
was pipetted into a 15 ml Falcon tube, spun briefly to remove the excess ethanol and
washed four times with 6 ml of PBS (Appendix A). A final spin (five min) was
performed to pack the gel and the 5 mg of GST fusion protein was added and mixed
on a windmill at 4 °C overnight.
The GST fusion protein/affi-gel conjugate was washed with two volumes of 1 M
Hepes pH 7.5, then with two volumes of 50 mM citric acid, pH 2.5 and lastly with
three washes of two volumes of PBS. Ethanolamine (1 M, pH 8.0) was added for one
hour at room temperature to block free amino sites on the gel. Excess was washed
away with PBS. Anti-serum (5 ml) was added to the tube and allowed to mix on a
windmill at 4 °C overnight.
The slurry was then loaded into a 10 cm x 1 cm column (Biorad) and allowed to
settle. The column was washed with 5 ml 20 mM sodium citrate until the absorbance
at 280 nm was zero. Citric acid (50 mM pFI 2.5) (6 ml) was added to elute the
antibody and 0.5 ml fractions collected into microfuge tubes containing 0.35 ml 1 M
Hepes pH 7.5. The yield was determined by reading the absorbance at 280 nm of the
collected fractions. To clear the column, it was washed with elution buffer to remove
all antibody, then washed with 20 mM sodium citrate pH 7.7 and four times with
PBS. It was stored in PBS with 0.01 % sodium azide at 4 °C.
68
2.6.3. Using Fbl6 antibody 2194
The antibody (2194) was used at 1:2000 in western blots with ECL development and
1: 200 on immunohistochemistry. The affinity-purified antibody was used at 1:500
on western blots with ECL development and 1:10 on immunohistochemistry.
Immunohistochemistry was done on frozen Sections and teased fibres from mouse
sciatic nerve perfused intracardially with 4 % paraformaldehyde in 0.1 M sodium
phosphate buffer pH 7.5, and fixed in the same solution for one hour. The tissue was
then washed in three changes of 0.1 M sodium phosphate buffer for one hour. Sciatic
nerve to be frozen was then cryoprotected by taking it through sucrose solutions (5
%, 10 % for an hour each, then 25 % overnight at 4 °C). It was then embedded in
Optimal Cutting Temperature (OCT) matrix by freezing in isopentane cooled to -70
°C with liquid nitrogen. It was stored at -70 °C and cut into 5 pm Sections onto
TESPA coated slides (Section 2.2.7) using a cryostat. Immunohistochemistry was
carried out as described in Section 2.2.7. Staining with the mouse antibody SI00
(Affiniti 1259) (used at 1:400) requires pre-treatment of tissue in methanol for ten
min at -20 °C.
Sciatic nerve taken for teasing fibres was post-fixed in the perfusant as described
above for one hour and washed three times in 0.1 M sodium phosphate buffer over
one hour. Then, it was transferred to a small dish with PBS (Appendix A) and the
perineurium removed under a dissection microscope. Individual nerve fibres were
teased out onto TESPA slides with acupuncture needles and allowed to dry. Prior to
use for immunohistochemistry, the slides were immersed in acetone for ten min at -
20 °C and allowed to dry at room temperature. Immunohistochemistry was then
carried out as described in Section 2.2.7. Staining with the mouse antibody S100
(Affiniti 1259) (used at 1:400) again requires pre-treatment of tissue in methanol for
ten min at -20°C. The 170pepl (repeat region) periaxin antibody was used at 1:4000
as before.
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2.7. BUILDING FLAG-TAGGED Fbl6 CONSTRUCTS
Stewart Gillespie had previously constructed the full-length Fbl6 clone in plasmids
pCMV5 and pGEMll (Promega).
2.7.1. N-terminal Flag-tagged Fbl6
The 5' end of Fbl6 was made by PCR so that it did not contain the start codon. PCR
primers F9 containing a 5' BamHl site and reverse primer RIO (Table 6) were used to
amplify a 1 kb fragment, missing the start codon, which was digested with
BamHl/Hindlll in buffer React2 (Gibco) and the 650 bp fragment subcloned into
plasmid pCMV-Tag2b (Stratagene) at these sites. Then, the rest of Fbl6 (950 bp) was
digested from the full-length Fbl6 in pGEMll with HindllUSall (React3), and
subcloned into the same plasmid pCMV-Tag2b. This plasmid contains an in-frame
N-terminal FLAG with an upstream start codon and Kozak sequence. The
constructed plasmid was sequenced to check it.
2.7.2. C-terminal Flag-tagged Fbl6
The 3' end of Fbl6 was made by PCR so that it did not contain the stop codon. PCR
primers F2 and reverse primer F8 (the latter containing a Sail site in place of the stop
codon) (Table 6), were used to amplify a 960 bp fragment, missing the stop codon,
which was digested with Hindlll/Sall in buffer H and subcloned into plasmid
pCMV-Tag4a (Stratagene) at these sites. Then the remaining part of Fbl6 was
digested from its place in plasmid pGEMll with EcoRl/Hindlll, and subcloned into
the same plasmid pCMV-Tag4a, which contains an in-frame C-terminal FLAG with
a downstream stop codon. The constructed plasmid was sequenced to check it.
2.8. TRANSFECTION EXPERIMENTS
2.8.1. Making Cos-7 cells permanently transfected with periaxin
Cos-7 cells were grown in 10 % fetal calf serum (complement inactivated), 2 mM
glutamine, 1 u/ml penicillin, 0.1 mg/ml streptomycin in Dulbecco's Eagle Medium
(DMEM) (all from Sigma) (referred to as complete medium). Cos-7 cells were made
to permanently express periaxin. A plasmid containing full-length L-periaxin and
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geneticin (G418) resistance was transfected into low passage Cos-7 cells and the
successful transfectants selected for with geneticin (0.4 mg/ml). These cells were
then split and grown up so that clonal expansions were obtained.
2.8.2. Transfections
Cos-7 cells were transfected using Fugene 6 (Roche). The cells were split the day
before transfection and plated out in 35 mm dishes (Iwaki) so that they were 80-90 %
confluent on the day of transfection. Fugene 6 (3 pi) was added to 100 pi of Optimen
medium (Gibco) and this was added to 2 pg DNA to be transfected. This was left for
fifteen min for the cationic complexes to form. Fresh medium (2 ml) was added to
the Cos-7 cells and then the Fugene/DNA solution was added to each dish and gently
mixed. The cells were harvested twenty-four hours later.
For lactacystin treatment, the cells were incubated in medium with 30 pM lactacystin
sixteen hours after transfection for a further eight hours, and then harvested.
2.8.3. Western blotting with transfected cells
The transfected cells were washed in Hanks balanced salts solution (HBSS) (Sigma)
and the scraped from the plate in the presence of HBSS and proteinase inhibitors
(leupeptin 10 pg/ml, TLCK 0.5 mM, benzamidine 1 mM, antipain 10 pg/ml, PMSF 1
mM - all from Sigma). The cells were pelleted by centrifugation at 13000 rpm 4 °C
for two min and taken up in 100 pl-200 pi 2 % SDS and boiled for ten min. The
sample was spun down again for ten min at 13000 rpm and the supernatant removed
and stored at -20 °C. An estimation of protein concentration in these samples was
obtained using the BCA kit (Pierce).
2.8.4. Immunohistochemistry on transfected cells
Circular coverslips (13 mm) were washed for one minute in 1 M HC1 and this rinsed
away with MQ water. They were then stored in high quality 70 % ethanol made with
MQ water. When ready to use, the coverslips were placed in culture dishes and the
ethanol washed away with sterile MQ water. Poly-D-Lysine solution (0.1 mg/ml)
(Sigma) was placed onto each coverslip and left for thirty min at room temperature.
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The coverslips were then washed twice with sterile MQ water, and then the dishes
used to grow and transfect cells.
For immunohistochemistry, the medium was aspirated away and the cells fixed in 4
% paraformaldehyde (Sigma) for twenty min. They were washed in PBS (Appendix
A) three times and placed into a moist chamber. Blocking solution (5 % fish
gelatin/0.1 % triton/ PBS) was added for twenty min. Primary antibodies (170pepl
periaxin antibody 1:1000 and FLAG antibody M2 Sigma 1:100) were added for one
hour, diluted in the same blocking solution. Excess was washed away with 0.1 %
triton in PBS. The fluorescently labelled secondary antibodies (goat anti-rabbit
Cappell FITC 1:200 and goat anti-mouse Southern Biotech TRITC 1:200) were
added for forty-five min. Excess was washed away with PBS. The coverslips were













0.5 g Bactoyeast extract
0.05g NaCl
Add 1 ml 250 mM KC1, pH to 7.0 and make up to 100 ml.
Autoclave.
Add 0.5 ml 2 M MgCl2 just before use.
To convert to SOC medium:
To 10 ml SOB, add:
50 pi 2 M MgCl2
200 pi 1 M glucose
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FIGURE 12 - SCREENING FOR THE FIRST STEP FOR THE
CONDITIONAL PERIAXIN MOUSE
a: Diagram of the targeted DNA as the first step in the formation of a conditional
knock-out of Periaxin, with comparison to the wild-type. The clones growing in the
presence of Neomycin are screened with the 5' and 3' probes and selected according
to the correct size of fragment as indicated.
b: Diagram of the desired floxed situation, produced after transient expression of Cre
recombinase, with comparison to the periaxin knock-out situation. The clones
growing in the presence of gancyclovir are screened with the 5' and 3' probes and
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FIGURE 13 - MORPHOLOGICAL MEASUREMENTS
Photograph with overlay of Iplab colour enabling measurements of axon number,
diameter and myelin thickness. The myelin is coloured in green, with preset levels of
density recognised by the program. The perimeter of each fibre is encircled in red,
and the axon given a number.
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Table 2: Primers used in cloning and sequencing human PERIAXIN.
Primer Sequence 5' to 3' Orientation and position
Human 1 TCTGGGGGTCCCCGCTGAGC Reverse exon 7
Human 5 CTGGGGCTCAGGCTCCTGTT Reverse exon 4
Human 11 GCTGACCTGGCCCCTGTTGA Forward exon 7
Human 12 TCAGTGGGCCTCCAGACGC Reverse exon 1
AW5 GTACAGGCACTCCTGCCAG Reverse end of exon 7
AW6 GTCGAACCTCTGGAAGGGCTG Reverse exon 7
AW7 TGGCTGCAGGAGCTCGTT Forward exon 7
AW10 TCAACAGAGGGCACTCGG Reverse exon 7
AW12 AGCTGCATTCCACTGACG Reverse exon 7
AW13 AGTTCAAGGTGATCGTGC Forward exon 7
AW 15 CGTCAGTGGAATGCAGCT Forward exon 7
LMD1 AACTCTGGAGGTGTCTGGAGG Forward exon 2




LMD30 CGGTGAGTCCTCTCGCAGCTC Reverse exon 5
LMD48 CTTTGGGTGACATCACAGCA Forward 5' to exon 1
CSG27 CGATAATCTCCACCAACT Reverse exon 5
CSG36 GAGCTGCGAGAGGACTCACCG Forward exon 5
78
Table 3: Peptide sequences used to raise the periaxin antibodies







































Differences in the human peptide sequence compared to the rodent sequence are
shown in bold.
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1 in 4000 In house
170pepl (Repeat) periaxin
(rabbit)




1 in 500 (affinity purified)
In house






1 in 200 Cappell
TRITC-conjugated goat
anti-mouse IgGl
1 in 100 Southern Biotechnology
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Table 5: Primers used in construction of conditional construct
Primer Sequence 5' to 3' Orientation and position
LMD2 AAGTAGCTGGAACTGACCCTCA Forward exon 2
MP1 TCCTTCTGCTGCAGGACCAC Reverse exon 4
LMD13 GGAGAGTGAAGAGACAACCA Forward intron 5
MP5 ACAGTGCGCTTCAAGCAGA Reverse exon 6
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Table 6: Fbl6 primers used to build Flag-tagged Fbl6 constructs
Primer Sequence 5' to 3' Orientation
F9 TAGAATTCGGATCCGCTCCTGTGGCCC
CTGGGCGAGT
Forward, with BamHl and






Reverse, with Sail site in
place of stop codon
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3. RESULTS - THE HUMAN PERIAXIN GENE.
3.1. Cloning the human PERIAXIN gene
We wished to determine the sequence of the human PERIAXIN gene to enable us to
screen patients with undefined CMT disease for mutations in this gene. We initially
relied on the supposition that the human PERIAXIN sequence was similar to that of
rat and mouse and used primers and probes designed from rodent sequence to
identify human sequence. However, there were known to be some differences, as the
human Periaxin protein ran with a lower mobility than the mouse version in SDS
gels (Gillespie, unpublished observations).
The methods used to obtain the sequence are described in Section 2.1.
RT-PCR was used to obtain most of the sequence of exons II, III, IV and V. PCR of
genomic DNA using rat specific Periaxin primers revealed the sequence of exon VI
and a small amount of exon VII. The sequence of exons II, III and IV, and
intervening introns 2 and 3 was determined by PCR directly from the PAC68 using
rat-specific primers (Table 2)
The PAC clone 68 was digested with the frequently cutting enzymes EcoRl and
Hindlll (Figure 14a), and the DNA fragments hybridising to a full-length rat periaxin
cDNA probe by Southern blot were subcloned into pGEM7. In the digests using
EcoRl, two bands hybridised to the periaxin probe. The bands were approximately 14
kb and 7 kb in size. Again, on the Hindlll digest there were two bands of
approximately 15 kb and 8 kb (Figure 14b). These bands were cut from a gel,
purified, and ligated into pGEM7 plasmid cut with the corresponding enzyme -
EcoRl or Hindlll. Hence four plasmids containing four different inserts were
generated. To ensure that the correct fragments had been subcloned, these plasmids
were digested to release the insert and probed again with the rat full-length periaxin
cDNA on a Southern blot (Figure 14c and d). The ends of the inserts in these
plasmids were sequenced using vector primers M13F and M13R. This revealed that
the sequence generated from the M13R primer in both plasmids generated from the
Hindlll digested fragments were identical to each other and to the PAC vector
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sequence in the databank lkb from the PAC vector insert site. The other end of each
insert was different, and had some sequence similarity to human intronic sequence in
the data bank. For the plasmids generated by the EcoRl digest, the sequences
generated from the M13F vector primer were identical to each other but had no
significant similarity to databank sequence, and the other ends were different. This
suggested that partial digests of the PAC had occurred and that the smaller fragments
were identical to part of the larger ones (Figure 15a).
At this point, the human genome project groups who were working on chromosome
19 entered a working draft of sequence on the database (Genbank accession no.
ACO10271). This corresponded almost exactly to the sequence I had already
obtained and showed 80-90% sequence similarity to rat and mouse Periaxin
sequence across exons. This allowed me to characterise my plasmids more fully.
The unique sequence at the end of the smaller insert (8kb) of the plasmids generated
by the Hindlll digest is identical to that in intron 4, and the orientation of this
sequence meant that it contains most of intron 4, all of exon V and 4 kb of intron 5.
As the other ends of the subcloned Hindlll fragments are identical, and the bigger
fragment is 15 kb, this subclone contains all the sequence upstream of this point in
intron 5, ending upstream of exon I. The 5' sequence of the larger Hindlll subclone
corresponds to sequence more than 1 kb upstream of exon I.
The identical ends of the subcloned inserts generated by an EcoR 1 digest lie in intron
5. Again, the smaller subclone has its 5' end in intron 4, and the larger subclone has
its 5' end upstream of exon I (Figure 15b).
It is surprising that none of the subcloned fragments of PERIAXIN contain exon VII,
as 90% of the whole length rat periaxin cDNA probe used consists of exon VII
sequence. In fact, the smaller subclones were detected with the probe binding to only
157 bases, the size of exon V. However, this does explain the failure of trials of PCR
with primers corresponding to rat exon VII sequence using the PAC as template, and
with southern blots using exon VII rat probes. These results were previously put
down to probable dissimilarity between human and rat exon VII sequence.
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Exon I, and the remaining parts of exon V, were sequenced from these subclones
directly using human specific primers. New primers were made corresponding to the
working draft sequence of exon VII in the databank to allow PCR of this sequence
from human genomic DNA. We wished to ensure that the human exonic sequence of
PERIAXIN was correct before looking for possible mutations. Human expressed
sequence tags (ESTs) from the database were found that matched part of the
sequence of exon V and also exon VII (AA984421, AW590908, AI637869,
AW125547 and AW337783). The subcloned fragments and ESTs are shown aligned
to the PERIAXIN sequence in diagrammatic form in Figure 16.
The DNA sequence of the human PERIAXIN gene differs from that of rat and mouse.
Exonic structure is very similar, with the major differences occurring in exon VII.
Exon VII in humans is larger than in rodents, encoding for more of the repeat units of
the protein: rat L-periaxin has 45 repeats, mouse 47 repeats and human 55 repeats.
Comparison of the intronic size shows more differences. These results are
summarised in Table 7 and Figure 17. The larger size of exon VII accounts for the
larger size of the human L-periaxin protein, which was seen formerly by western
blot. The human L-periaxin protein is a 1462 amino acid protein, 71 amino acids
longer than the mouse protein. Human and mouse L-periaxin proteins share 77.6%
sequence similarity.
A comparison of the amino acid sequence of the L-periaxin isoform of human, rat
and mouse is shown in Figure 18.
The human PERIAXIN DNA sequence also encodes for the alternative isoform S-
periaxin. Similarly to rodent Periaxin sequence, there are suboptimal 5' and 3' splice
sites in the final intron causing possible retention of intron 6. This introduces a stop
codon preceded by sequence encoding a unique 20 amino acid C-terminus.
Comparison of the mouse and rat S-periaxin isoforms shows just two amino acid
differences at the C-terminus. However, the human isoform is more dissimilar
(Figure 19).
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3.2. Mutations in PERIAXIN causing human CMT disease
We formed a collaboration with Dr. LeGuern and his group at the Hopital de la
Salpetriere in Paris. They localised the PERIAXIN gene to the long arm of human
chromosome 19 by fluorescent in situ hybridisation (FISH), confirming our
prediction based on mouse / human chromosome synteny (Gillespie et al., 1997).
In June, 2000, Delague et al. published a paper describing a large consanguineous
Lebanese family with autosomal recessive demyelinating CMT disease (CMT4F)
showing linkage to chromosome 19ql3.1-13.3 (Delague et al., 2000). Clinically, the
patients had delay in motor development, with an early ataxic gait, but obvious
weakness and sensory changes in the lower limbs by age 10 years, and in the upper
limbs by age 15 years. Progression of the disease was slow, and only one patient out
of the thirteen investigated was unable to walk. All patients presented with a
demyelinating neuropathy with undetectable sensory or motor nerve velocities on
neurophysiology. Of particular importance, sensory loss was severe. Pathology of a
sural nerve biopsy done in one patient revealed a severe depletion of myelinated
fibres, and Schwann cell proliferation with onion bulbs surrounding the remaining
myelinated fibres. This suggested axonal loss secondary to chronic demyelination
and remyelination. The group screened the gene for myelin associated glycoprotein
(MAG) for mutations in two patients of this family as this gene is at the locus
19ql3.1. However, sequenciag of the entire gene in these patients revealed no
mutations. Further linkage analysis placed the MAG gene outwith the homozygous
candidate region for the gene responsible for the disease.
We felt that it was a matter of urgency to screen this family for mutations in the
PERIAXIN gene.
3.2.1. R196X mutation
Our Paris collaborators designed primers from our human PERIAXIN sequence to
specifically amplify and sequence the four coding exons of PERIAXIN (IV-VII) and
their flanking splice sites and the intron 6 in patients from the Lebanese CMT family.
Fourteen members (three parents, three non-affected members and eight affected
86
patients) of this Shiite Muslim family were investigated. They identified a
homozygous C-T transition at position 860 which leads to a premature stop codon at
the beginning of exon VII (R196X) (Figure 20a). This nonsense mutation truncates
the C-terminus of L-periaxin by 1266 amino acids and leads to the absence of the
large repeat-rich domain and the C-terminal acidic domain. It also abolishes a
recognition site for the restriction enzyme Rsal, which was used to confirm the
segregation of the mutation with the disease (Figure 20b). Rsal restriction analysis of
one hundred chromosomes from Lebanese controls confirmed that the R196X
mutation was specific to the affected patients.
The genetic evidence for a mutation in the PERIAXIN gene is supported by
comparative immunocytochemical analyses of control and patient sural nerve
biopsies. Although the number of myelinated fibres was severely reduced in the
patient nerve, it was possible to detect a restricted number of small diameter fibres
that were positive for the myelin constituent myelin basic protein (MBP) (Figure
21a). MBP was also detected in the myelin sheaths of fibres in control nerve (Figure
21c). However, Periaxin was undetectable by immunohistochemistry in the affected
nerve using an antibody that recognises the N-terminus of L-periaxin (Figure 21b),
whereas it was readily demonstrable in the control sample (Figure 2Id). In support of
the view that the deficit was unique to Periaxin, P0, a characteristic component of
PNS myelin co-localised with MBP in the myelin sheaths of both control and
affected nerves.
The dearth of myelinated axons in the CMT4F patient's sural nerve was confirmed
by light microscopy of plastic sections (Figure 22a). On electron microscopy, a
striking feature of the CMT4F nerve was the incidence of both 'onion bulb' structures
(Figure 22b) and hypermyelinated outfoldings (Figure 22c). The former represent
supernumerary Schwann cells associated with abortive attempts to remyelinate
demyelinating nerves. The similarities of the pathology to that of the periaxin-null
mouse are striking and support the case that the mouse mutant is a convincing model
for the human disease (Figure 22d). This data was reported in a paper in Human
Molecular Genetics in 2001 (Guilbot et ah, 2001).
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In the same month three more families with mutations in PERIAXIN and CMT4F
disease/ Dejerine-Sottas disease were described by Boerkoel et al. (Boerkoel et al.,
2001b).
3.2.2. C715X mutation
Another collaboration was made with the Antwerp group interested in CMT disease
led by Vincent Timmerman, and with James Lupski's group in the USA. By DNA
sequencing, Lupski's group screened each coding exon of PERIAXIN for mutations
in 29 peripheral neuropathy patients who had tested negative for mutations involving
PMP22, MPZ, GJB1, and EGR2. Two siblings were found, born to consanguineous
parents, who were homozygous for the mutation 2145T>A that by conceptual
translation causes a nonsense stop codon at amino acid 715 that normally encodes a
cysteine (C715X). The unaffected parents, sister and brothers either did not carry the
mutation or were heterozygous carriers (Figure 23). They did not observe this
mutation in 180 control chromosomes. In this family, another sister had died at the
age of 48 years due to a cardiomyopathy, but the alive, affected sister and brother
were available for study. Both had gait problems from early childhood and developed
scoliosis, and the sister attended a school for children with a motor handicap. They
were examined at age 50 and 54 respectively, and both showed weak foot and hand
muscles, but severely decreased sensitivity for all sensory modalities to the level of
the knees and elbows. Thus, the sensory impairment was much worse than the motor
deficit. There was no palpable nerve hypertrophy. Electrophysiological studies of the
median and ulnar nerves of the sister showed slow motor nerve conduction velocities
(motor NCV, 3 m/sec), reduced compound muscle action potentials (CMAP, median:
1.1 mV, ulnar: 0.45 mV, control: > 6mV), and undetectable median sensory nerve
action potentials. Despite early onset of disease, these siblings had a relatively slow
disease progression and adult motor impairment typical for classical demyelinating
CMT neuropathy. We were fortunate to obtain a frozen sural nerve biopsy specimen
from the sister.
Immunofluorescence analysis of a normal (frozen) human sural nerve biopsy showed
positive double labelling for myelin basic protein (MBP) and for Periaxin labelled
with the anti-N-terminal, the anti-170pepl (repeat region) and the C-terminal L-
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periaxin antibodies (Figure 24J). In this patient, there was also labelling with the N-
terminal and 170pepl antibodies, but not with the anti-C-terminal antibody even
though there is MBP-positive labelling (Figure 24G-I). This result demonstrates that
a truncated L-periaxin is made and indicates that the carboxyl terminal domain of the
L-periaxin protein has an important function. Furthermore, these data suggest that
interaction with DRP2 (approximately at amino acid positions 118 to 196) is not
sufficient for L-periaxin's function.
Light microscopy, carried out in Antwerp, revealed a severe loss of myelinated axons
of all diameters and increased connective tissue (Figure 25). Although some
remaining myelinated fibres were normal, many showed tomacula formation or small
onion bulb formations. On electron microscopy, the tomacula consisted of concentric
or eccentric thickenings of the myelin sheath with focally folded myelin surrounding
a constricted axon. Multiple paranodal abnormalities were identified including a
reduced number of myelin loops and an absence of septate-like junctions between the
paranodal myelin and the axon (Figure 26).
An unrelated patient was also discovered homozygous for 247AC that results in
frameshift mutation R82fsX96 in Periaxin, so affecting both L- and S- periaxin.
Unfortunately no nerve biopsy was available for immunohistochemistry. She also
had marked sensory involvement but otherwise had a disease course consistent with
congenital hypomyelinating disease (CHD). Light microscopy revealed a severe loss
of thick myelin sheaths, numerous demyelinated or thinly remyelinated fibres, onion
bulbs and occasional tomacula. The details on these two families are published in
Annals of Neurology, 2002 (Takashima et al., 2002).
3.2.3. Turkish Mutation R1070X
We entered a further collaboration with Dr. Battaglou's group in Istanbul. This group
had discovered a Turkish family with CMT disease caused by the homozygous
Periaxin mutation R1070X. We were able to analyse a sural nerve biopsy, which
again showed staining with the N-terminal and 170pepl (repeat region) periaxin
antibodies, but no immunoreactivity with the C-terminal antibody (Figure 27). Thus,
in these patients, truncated L-periaxin protein is made, missing the C-terminal part.
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This is the most 3' site of PERIAXIN mutations yet described. The mutation truncates
the protein prior to the acidic domain preventing binding to the F-box protein Fbl6
which targets periaxin to the proteasome (Vasiliou in preparation).
3.3. Discussion
We have now identified the fourth gene involved in autosomal recessive CMT
disease. There are eight different mutations described so far, in seven different
families, as one patient (Boerkoel et al., 2001b) was heterozygous for two different
PERIAXIN mutations (Figure 28 and Figure 29). The variety of mutations, and the
different ethnic groups of the families indicates that this is not a disease with a
common founder, such as in HMSN-Lom (Kalaydjieva et al., 2000), but that separate
mutations have arisen independently. Obviously, autosomal recessive disease is more
evident in families where consanguineous marriages are common, however, sporadic
cases of ARCMT disease are becoming more recognised, and PERIAXIN mutations
are worth considering in such cases.
We have shown that, in three of the cases, the L-periaxin protein is either absent or
truncated, concurring with the determined genetic defect. The R196X mutation leads
to a truncation at the end of the basic domain of L-periaxin, and this truncated
protein is not seen, either due to nonsense mediated RNA decay (Lykke-Andersen,
2001) or instability of the truncated protein. In the other two patients (C715X and
R1070X), truncated forms of L-periaxin are generated, but this is not sufficient to
prevent demyelination. L-periaxin is an integral constituent of a dystroglycan-
dystrophin-related protein 2 (DRP2) complex and possibly other plasma membrane
complexes, where it presumably participates in interacting with the basal lamina
surrounding the Schwann cell (Sherman et al., 2001). The peripheral demyelinating
neuropathy seen in periaxin-null mice (Gillespie et al., 2000) and our patients
emphasises the importance of such complexes for stabilising the axon-Schwann cell
unit. However, although the interaction between periaxin and DRP2 may be essential
for complex formation, the disruption of this interaction is not required to cause
demyelinating CMT disease. The patients C715X and R1070X are shown by
immunohistochemical studies on nerve biopsy to make stable yet truncated L-
periaxin protein containing the DRP2 binding domain. Thus, these truncated proteins
90
can presumably still interact with DRP2, and this is not sufficient for L-periaxin's
function. The C-terminal acidic domain of L-periaxin binds to the F-box protein Fbl6
which targets the protein for ubiquitin-mediated proteolysis (Vasiliou in preparation).
The absence of this domain may cause disruption through a loss-of-function but also
the truncated protein may have enhanced stability and gain-of-function effects that
disrupt interactions of the Schwann cell with the basal lamina.
In each of these three patients (R196X, C715X, and R1070X), it is possible that S-
periaxin is still expressed, since the mutations are all downstream of the retained
intron that encodes the C-terminus of this shorter isoform. However, the absence of
full-length L-periaxin alone appears to be sufficient to lead to demyelination. It is
unfortunate that no biopsy material was available from the patient R82fsX96, as this
is the first mutation to be described that would disrupt both L- and S-periaxin
(Takashima et al., 2002). However, clinically, this patient was indistinguishable from
the other patients with PERJAXIN mutations. S- and L- periaxin have distinct
locations and are likely to have distinct functions. In adult mice, L-periaxin is
concentrated at the abaxonal Schwann cell membrane whereas S-periaxin is
distributed throughout the cytoplasm (Dytrych et ah, 1998). We may gain further
understanding of the role of L- and S-periaxin in CMT4F by studying the
involvement of these isoforms in the assembly and stabilisation of mouse peripheral
nervous system myelin.
There are marked similarities in the histopathology of peripheral nerve from these
patients compared to those of the periaxin-null mice (Gillespie et ah, 2000). In the
patients, there were supernumerary Schwann cells surrounding thinly myelinated or
naked axons forming 'onion-bulb' structures, and hypermyelinated regions of the
nerve in which the myelin was extensively folded. The accumulation of this excess of
myelin is a likely forerunner of massive demyelination. There was also detachment
of terminal paranodal myelin loops from the axon with loss of septate-like junctions
(Takashima et ah, 2002). The formation of axoglial junctions at the paranode has
been shown to require at least three proteins: contactin and Caspr on the axonal
surface and an isoform of neurofascin, NF155, on the glial surface, which together
form an adhesion complex (Charles et ah, 2002). These disrupted axoglial junctions
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may suggest that L-periaxin is necessary for the formation or maintenance of the
adhesion complex.
As with other mutations in CMT genes, there is a spectrum of clinical phenotypes
associated with PERIAXIN mutations, including CMT4F and Dejerine-Sottas
disease. Again, the phenotype is not clearly related to the position of the mutation,
though correlations are difficult due to the scarcity of patients with PERIAXIN
mutations as yet. However, in contrast to mutation of other CMT genes, mutation of
PERIAXIN causes a prominent sensory neuropathy.
An unusual and early feature of the periaxin-null mouse phenotype is the presence of
neuropathic pain behaviour characterised by mechanical allodynia and thermal
hyperalgesia. In the mouse mutant, this neuropathic pain behaviour can be abrogated
by intrathecal injection of an NMDA antagonist, suggesting that there have been
plastic changes in the spinal processing of sensory input from the extremities
(Gillespie et al., 2000). Thus, drugs licensed for neuropathic pain may help CMT4F
patients, and the periaxin-null mouse may be a useful model in which to study
neuropathic pain generated from demyelination. These similarities support the view
that the mouse model will lead to a better understanding of human disease.
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FIGURE 14 - SOUTHERN BLOTS OF DIGESTED PAC68
a: PAC68 digested with EcoRI (1-4) and Hindlll (5-8)
b: Southern blot of digested PAC68, probed with the full-length rat periaxin cDNA
probe. Lane 1 - EcoRI digest. Lane 2 - Xhol digest. Lane 3 - Hindlll digest.
c: Southern blot of subclones from Hindlll digest probed with full-length rat periaxin
cDNA. Lane 1 - PAC68. Lanes 2-11 - subclones of Hindlll smaller fragment
(positive in lanes 3, 5, 6, 7, 9, 11. Sample 8 is partially digested). Lanes 12 and 13 -
subclones ofHindlll larger fragment (both positive).
d: Southern blot of subclones from EcoRI digest probed with full-length rat periaxin
cDNA. Lane 1 - PAC68. Lanes 2-11 - subclones of EcoRI smaller fragment (positive
in lanes 3 and 5. Extra bands represent uncut plasmid). Lanes 12 -15 - subclones of
EcoRI larger fragment (positive in lane 12).
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a: Plasmids generated by digestion of PAC68 with EcoRI (ET and EB) and Hindlll
(HT and HB) and subcloned into pGEM7. Coloured boxes indicate similarities or
differences of insert ends by sequencing.
b: Plasmids as in (a) with exons of human PERIAXIN marked in roman numerals as
determined by comparison to the Genbank sequence.
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FIGURE 16 - DNA FRAGMENTS USED TO OBTAIN HUMAN
PERIAXIN SEQUENCE
Diagram of the fragments of sequence used to obtain the human PERIAXIN gene
sequence. EST sequences are labelled. HB and HT sequences and EB and ET




FIGURE 17 - STRUCTURE OF THE HUMAN PERIAXIN GENE
Exon I II III IV V VI
HI M1





I (32) 1 (4954)
II (44) 2 (83)
III (99) 3 (127)
IV (126) 4 (4090)
V (157) 5 (4816)
VI (197) 6 (649)
VII (4005)
Structure of the human PERIAXIN gene with exon and intron sizes.
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FIGURE 18 - COMPARISON OF HUMAN, RAT AND MOUSE L-
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** *** *************** **** * ********** ************* * *** ********* ******
human 3 41GAEVEARGEAPEVALKMPRLSFPRFGARAKEVAEAKVAKVSPEARVKGPRLRMPT FGLSLLEPRPAAP-EWESKLKLPTIKMPS 424
rat 341GAEVEAQGEVPEVALKMPRLSFPRFGVRGKEATEAKWKGSPEAKAKGPRLRMPTFGLSLLESRPSGPEVAAESKLKLPTLKMPS425
mouse 341GAEVEAQGEVPEVALKMPRLSFPRFGIRGKEATEAKWKGSPEAKAKGPRLRMPTFGLSLLEPRPSGPEAVAESKLKLPTLKMPS425
****** ** **************** **** * **** *************** ********
r a: fifVii ;;VAGPEVKAPKGPEVKLPKVPEIKLPKAPEAAIPDVQLPEVQLPKMSDMKLPKIPEMAVPDVHLPEVKLPKVPEMKVP 50fi
mouse 4 2 6FGICJVAGPEVKAPTGPF.VKT.PKVPEVKTiPKVPFAAI PDVQLPSVQLPKMSDMKLPKIPEMWPDVRLPEVQLPKVPEMKVP ' 0(
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**** ************** *** * ** * *** ** * * ********** **** ** *** * **** *****
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human934PKFGLSGPKVAKAEAEGAGRATKLKVSKFAISLPKARVGAEAEAKGAGEAGLLPALDLSIPQLSLDAHLPSGKVEVAGADLKFKG1018
rat 872 PKFGLSGPKAVKAEVEGPGRATKLKVSKFAISLPRARAGTDADAKGAGEAGLLPALDLSIPQLSLDAQLPSGKVEVAGAESKPKG95 6
mouse 882PKFGLSGPKAVKGEVEGPGRATKLKVSKFTISLPKARAGTEAEAKGAGEAGLLPALDLSIPQLSLDAQLPSGKVEVADS--KPKS964
********* * * ** *********** **** ** * * ************************ ********* * *
hum 1019PRFALPKFGVRGRDTEAAELVPGVAELEGKGWGWDGRVKMPKLKMPSFGLARGKEAEVQGDRASPGEKAESTAVQLKIPEVELVT1103
rat 957SRFALPKFGAKGRDSEADVLVAGEAELEGKGWGWDGKVKMPKLKMPSFGLSRGKEAEIQDGRVSPGEKLEAIAGQLKIPEVELVT1041
mouse 9 6 5SRFALPKFGVKGRDSEADVLVAGEAELEGKGWGWDGKVKMPKLKMPSFGLSRGKEAETQDGRVS PGEKLEAIAGQLKIPAVELVT104 9
******** *** ** ** * ************ ************* ****** * * ***** * * ***** *****
hum 1104LGAQEEGRAEGAVAVSGMQLSGLKVSTAGQWTEGHDAGLRMPPLGISLPQVELTGFGEAGTPGQQAQSTVPSAEGTAGYRVQVP1188
rat 1042PGAQET EKVTSGVKPSGLQVSTTRQWAEGQEGAQRVSSLGISLPQVELASFGEAGP EIAAPSAEGTVGSRIQVP1116
mus 1050PGAQET EKVTSGVKPSGLOVSTTGQWAEGQESVQRVSTLGISLPQVELASFGEAGP EIVAPSAEGTAGSRVQVP1124
**** ** *** *** *** ** * ********** ***** ****** * * ***
hum 118 9QVTLSLPGAQVAGGELLVGEGVFKMPTVTVPQLELDVGLSREAQAGEAATGEGGLRLKLPTLGARARVGGEGAEEQPPGAERTFC1273
rat 1117 QVMLELPGTQVAGGDLLVGEGIFKMPTVTVPQLELDVGLGHEAQAGETAKSEGGLKLKLPTLGAGG—KGEGAEAQSPEAQHTFH119 9
mus 1125QVMLELPGTQVAGGDLLVGEGIFKMPTVTVPQLELDVGLGHEAQAGEAAKSEGGIKLKLPTLGTGS—RGEGVEPQGPEAQRTFH1207




******* ****** ** * ********* *** **** * *** **************** ^*********
hum 1359EEEGSGEGASGRRGRVRVRLPRVGLAAPSKASRGQEGDAAPKSPVREKSPKFRFPRVSLSPKARSGSGDQEEGGLRVRLPSVGFS1443
rat 12 81EEEGSGEGASGRRGRVRVRLPRVGLAS PSKGSKGQEGDAASKS PVGEKS PKFRFPRVSLSPKARSGSKDREEGGFRVRLPSVGFS1365
mus 128 9EEEGSGEGASSRRGRVRVRLPRVGLAS PSKVSKGQEGDATSKS PVGEKS PKFRFPRVSLS PKARSGSRDREEGGFRVRLPSVGFS1373
********** *************** *** * ****** **** ********************* *^**** **********
hum 1444 ETGAPGPARMEGAQAAAVN 1462
rat 1366 ETAAPGSARIEGTQAAAI 1383
mus 1374 ETAVPGSTRIEGTQAAAI 1391
** ** * ** ****
PDZ domain(red), basic domain (green), repeat domain (blue) and acidic domain
(yellow)
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FIGURE 19 - COMPARISON OF HUMAN, RAT AND MOUSE S-
PERIAXIN AMINO ACID SEQUENCE.
human 1 MEARSRSAEELRRjAELVEIIVETEAQTGVSGINVAGGGKEGIFVRELRED 50
rat 5 MEARSRSAEELRRAELVEIIVETEAQTGVSGFNVAGGGKEGIFVRELRED 50






















This alternative isoform is generated by retention of intron 6 that codes for 21 or 22
amino acids (green) forming a new C-terminus, before reaching an in-frame stop
codon. PDZ domain (red).
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FIGURE 20 -R196X MUTATION
a: ABI tracing from the sequence of the proband showing a C to T transition
resulting in a premature stop codon. This disrupts an Rsal restriction site.
b: Family tree of the Lebanese family showing that digestion of a PCR product
containing the sequence of interest with Rsal produces two bands of 380bp and
320bp in normal PERIAXIN sequence and a 700bp band in PER1AXIN sequence
containing this mutation. Inheritance of the homozygous absence of this Rsal site co-
segregates exactly with the disease (black circles or squares).
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FIGURE 21 - IMMUNOFLUORESCENCE ANALYSIS OF SURAL
NERVE BIOPSY FROM PATIENT R196X.
a, b: Nerve fibres from patient R196X show staining with MBP (a) but no staining
with the N-terminal PRX antibody (b). The myelinated fibres are much smaller and
sparser than in the control.
c, d: Nerve fibres from control show staining with MBP (c) and N-terminal PRX
antibody (d).
(Confocal pictures of these slides were taken by Diane Sherman)



















FIGURE 22 - PATHOLOGY OF SURAL NERVE BIOPSY FROM
PATIENT R196X.
a: Semi-thin section stained with toluidine blue. There is almost complete absence of
normal myelinated fibres. Arrows indicate onion bulb structures and arrowheads
thinly myelinated fibres. Scale bar 10pm.
b: Electron micrograph of an onion bulb structure showing supernumerary Schwann
cells. Arrows indicate Schwann cell nuclei. Scale bar 2pm.
c: Electron micrograph showing abnormal foldings of myelin sheath with the axon
marked A. Scale bar 1pm.
Sections cut and photographed by Diane Sherman.
(Published in Guilbot et al., 2001)
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a: Family tree of patients with C715X mutation,
b: Family tree of patient with R82fs96X mutation.
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FIGURE 24 - IMMUNOFLUORESCENCE ANALYSIS OF SURAL NERVE
BIOPSY FROM PATIENT C715X.
A, B, C : Nerve fibres from patient C715X show staining with N-terminal PRX
antibody (A), and MBP (B), which co-localise (C).
D, E, F : Nerve fibres from patient C715X show staining with 170pepl (repeat
region) PRX antibody (D), and MBP (E), which co-localise (F).
G, H, I : Nerve fibres from patient C715X show no staining with C-terminal PRX
antibody (G), but staining with MBP (H), indicating that a truncated PRX protein is
formed.
J, K, L : Nerve fibres from a normal control show staining with the C-terminal PRX
antibody (J), and MBP (K) , which co-localise (L).
Scale bar 5pm
(Published in Takashima et al., 2002)
109






J '&&& K ^ , ... ***** ^***^
FIGURE 25 - LIGHT MICROSCOPY OF SEMI-THIN RESIN SECTIONS
FROM SURAL NERVE BIOPSIES OF PATIENTS C715X AND R82fsX96
A: Biopsy from Patient R82fsX96
Transverse section showing loss of myelinated fibres of all sizes, onion bulbs
(arrows) which were sometimes denervated (arrowheads) and tomacula formations.
A complex of grouped, proliferated Schwann cell processes surrounded a myelinated
axon (inset). Magnification x 637.
B: Biopsy from Patient C715X
Longitudinal section showing increased connective tissue and demyelinated (thin
arrows) or thinly remyelinated (arrowheads) nerve fibres. A tomaculous fibre is
indicated by a thick arrow. Magnification x 900.
(Sections cut and photographed by colleagues in Antwerp) (Published in Takashima
et al., 2002)
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FIGURE 26 - ELECTRON MICROSCOPY OF LONGITUDINAL SECTIONS
IN PATIENTS R82fsX96 AND C715X
A: Biopsy from Patient R82fsX96.
Heminode showing paranodal myelin folds and a Schwann cell process separating
terminal myelin loops from the axon. Scale 1 pm.
B: Biopsy from Patient C715X.
There are abnormalities of paranodal myelin loops and the absence of septate-like
junctions or transverse bands (arrows). The myelin loops and axon are separated by a
Schwann cell process (*). Scale bar 0.1 pm.
C: Normal sural nerve biopsy.
Normal myelin. There are well-developed septate-like junctions or transverse bands
(arrows) of normal paranodal myelin and desmosome-like structures (big arrow).
Scale bar 0.1 pm.
(Published in Takashima et al., 2002)
(Sections cut and photographed by colleagues in Antwerp)
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FIGURE 27 - IMMUNOFLUORESCENCE ANALYSIS OF SURAL
NERVE BIOPSY FROM PATIENT R1070X.
a, b, c : Nerve fibres from patient R1070X show staining with N-terminal PRX
antibody (a), and MBP (b), in the same fibres (c).
d, e, f : Nerve fibres from patient R1070X show staining with 170pepl (repeat
region) PRX antibody (d), and MBP (e), in the same fibres (f).
g, h, i : Nerve fibres from patient R1070X show no staining with C-terminal PRX
antibody (g), but staining with MBP (h), indicating that a truncated PRX protein is
formed.
j, k, I : Nerve fibres from a normal control show staining with the C-terminal PRX
antibody (j), and MBP (k), in the same fibres (1). These fibres are much larger than
those of the patient.
Scale bar 5 pm
113
 

















All currently known PERIAXIN mutations causing CMT4F/Dejerine-Sottas disease
marked on the protein structure of Periaxin, with the corresponding position in the
exons above.
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FIGURE 29 - LINE-UP OF THE AMINO ACID SEQUENCE PRODUCED BY

































































































































































Table 7: Comparison of human, rat and mouse Periaxin genes.
Human Rat Mouse
Exon I 32 30 32
Intronl 4954 - 4900
Exon II 44 44 44
Intron 2 83 - 88
Exon III 99 99 99
Intron 3 127 - 116
Exon IV 126 126 126
Intron 4 4090 - 2900
Exon V 157 157 157
Intron 5 4816 - 7500
Exon VI 197 197 197
Intron 6 649 - 592
Exon VII 4005 3972 3787






Kozak sequence TCCATGC GCTATGG GCTATGG
The sizes of the rat introns are as yet unknown.
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4. RESULTS - MORPHOLOGICAL INVESTIGATION OF THE
MOUSE MODEL OF CMT4F - THE PERIAXIN-NULL
MOUSE
The function of L-periaxin is unknown. However, it is known that periaxin deficient
mice can assemble apparently normal compact myelin in the development of the
PNS, and so the presence of periaxin is not prerequisite for development of a PNS
myelin sheath. Abnormalities in the myelin sheath appear with time in these mice,
suggesting that periaxin is required for maintenance of the stability of the sheath, and
perhaps in its ability to repair.
We hypothesised that periaxin is essential for the repair or turnover of myelin sheaths
which occurs continually in vivo; hence we carried out sciatic nerve crush on wild-
type and periaxin-null mice to determine whether regeneration of the myelin sheath
could occur. We assessed myelinated axon number, axon diameter, and myelin
sheath thickness.
4.1. Nerve crush experiments
Nerve crushes were performed on the sciatic nerves of wild-type and periaxin-null
mice at six weeks of age as described in Section 2.5. This age was chosen as
myelination is thought to be complete but there is little sign of peripheral nerve
pathology in the periaxin-null mice. This was to ensure that any demyelination and
remyelination was due to nerve crush and recovery rather than disease. Analysis of
regeneration was carried out at two and six weeks after crush (eight and twelve
weeks of age). On each occasion the uncrushed, contra-lateral sciatic nerve was
taken as an internal control. We examined the nerves four days after crush to ensure
that the crush technique was efficient at causing demyelination (secondary to
axonotmesis) and found that the efficiency of our crush technique is adequate to
affect most myelinated axons (Figure 30). Hence we can confidently attribute the
presence of myelin two weeks after crush to remyelination.
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4.1.1. Myelinated axon number
We counted the number of myelinated axons to determine if periaxin-null mice and
wild-type mice have equivalent baseline numbers of myelinated axons, and if, after
crush, the nerves could regenerate the normal number of myelinated axons. It is
known that in human demyelinating CMT disease axonal loss contributes much to
the symptoms of the disease (Krajewski et ah, 2000), so we wanted to determine
whether axonal loss was increased after experimental nerve crush in periaxin-null
mice.
At baseline, in uncrushed nerves, periaxin-null and wild-type mice have an
equivalent number of myelinated axons. At two weeks after crush, the number of
myelinated axons in both wild-type and periaxin-null mice is back to normal,
suggesting that recovery of the number of myelinated axons is complete by two
weeks after crush (Figure 31).
4.1.2. Cross-sectional area of nerve
It has been reported previously that the cross-sectional area of nerves increases in
animal models of demyelinating CMT disease (Sahenk, 1999). The average cross-
sectional area of a periaxin-null mouse sciatic nerve is significantly larger than that
of the wild-type (unpaired t-test pO.OOl) (Figure 32d). As Figure 31 shows, the
number of myelinated fibres is equivalent, so the density of axons in periaxin-null
mice is markedly reduced (unpaired t-test pO.OOl) (Figure 32c). There is no change
in density with age over this period.
The reduced density of fibres (Figure 32) and the increase in total area of the nerve in
periaxin-null mice is due to an increase in ECM. There is a clinical correlate of this
observation in that human patients with inherited demyelinating peripheral
neuropathies often have thickened nerves which are palpable on clinical examination.
This suggests that this difference is real and not an artefact of the tissue processing.
At higher power, this is confirmed, as empty space is not apparent.
120
4.1.3. Frequency distribution of axon diameters in the nerve
Myelination of an axon causes phosphorylation of neurofilaments, which is believed
to increase the axon diameter. Therefore, in causing demyelination, nerve crush
reduces neurofilament phosphorylation, which leads to more densely packed
neurofilaments and a smaller axon diameter (de Waegh et ah, 1992). We determined
if there were baseline differences in the frequency distribution of axon diameters
between periaxin-null and wild-type mice, and whether this changed after crush.
The frequency distribution of axon diameters in wild-type or periaxin-null mouse
sciatic nerve does not fit a normal distribution, but is skewed to the left indicating a
higher representation of smaller myelinated axons (Figure 33).
In uncrushed nerves, the axon diameter size distribution does not change with time
between eight and twelve weeks of age. Periaxin-null nerves have a higher
proportion of smaller axon diameters compared to wild-type nerves, both in the
crushed and uncrushed situations (Kolmogorov-Smimov test p<0.001).
Nerve crush, in both wild-type and periaxin-null mice, shifts the curve further to the
left, indicating an increase in the proportion of smaller diameter myelinated axons.
The difference is not fully resolved by six weeks after crush, indicating that the axon
diameters have still not returned to their previous size, even in wild-type mice
(Kolmogorov-Smimov test p<0.001).
4.1.4. Myelin thickness
We determined whether the thickness of myelin is different between periaxin-null
and wild-type nerves at baseline and after crush. The g-ratio is a measure of the
thickness of the myelin sheath around an axon, compared to its diameter, and is
derived by dividing the axon diameter by the fibre diameter. Therefore, as the myelin
thickness increases, the g-ratio decreases and vice versa. If there is no myelin sheath,
then the g-ratio is 1.
The g-ratio is plotted against the axon diameter to directly compare the amount of
myelin around a fixed sized axon. Figure 34 shows regression lines for the average g-
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ratio values for each axon diameter range from all nerves tested in each experimental
group. The regression lines for the crushed and uncrushed wild-type nerves are
superimposed at both two weeks and six weeks after crush, indicating repair of the
myelin sheath to normal by two weeks. However, in periaxin-null mice, the crushed
nerve regression line is significantly higher than the uncrushed line at two weeks
after crush (p=0.007). The difference is less marked, but still present, at six weeks
after crush (p=0.002). Thus, crushed nerves have less thick myelin sheaths compared
to uncrushed nerves in the periaxin-null mouse. However, on comparing these
regression lines to wild-type mice, uncrushed periaxin-null nerves show a lower g-
ratio than the corresponding wild-type nerves (p=0.02 at 2 weeks, p=0.01 at 6
weeks), indicating hypermyelination, especially of smaller diameter fibres. The two
regression lines for crushed periaxin-null and wild-type nerves are very similar two
weeks after crush, indicating that there had been repair of the myelin sheath at the
same rate after demyelination. At six weeks after crush these diverge as the periaxin-
null nerve g-ratios decrease, thus indicating hypermyelination. Therefore, crushed
periaxin-null nerves become more hypermyelinated and more abnormal with time.
This is shown in a different way in Figure 35 which shows the results of g-ratios for
a single experimental mouse at each time point. In the wild-type mice, the g-ratio
values from crushed and uncrushed nerves are indistinguishable at two and six weeks
after crush, suggesting that myelin thickness returns to normal within two weeks. In
the periaxin-null mice, the g-ratio values are lower in the uncrushed nerve compared
to the crushed nerve at two weeks, though the difference is less at six weeks after
crush when the g-ratio values are lower, indicating hypermyelination.
4.2. Discussion
Nerve crush is a commonly used experimental model in rodents to allow
investigations of peripheral nerve injury and regeneration. This has been evaluated
and standardised by several groups (Bridge et al., 1994; Nawwar et al., 1995). The
failure of patients with demyelinating CMT disease to remyelinate normally or fully
is still not understood. Hence there is value in studying this issue in good mouse
models of the disease.
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There are now several mouse models of human CMT disease, (reviewed in (Young
and Suter, 2001)), and the periaxin-null mouse is a model of an autosomal recessive
type. Hence, these mice provide an excellent opportunity to study the
pathophysiology of disease.
4.2.1. Baseline differences between periaxin-null and wild-type mice
We have shown that there is no difference in the number of myelinated axons in
wild-type and periaxin-null sciatic nerves up to twelve weeks of age. Thus, periaxin-
null mice have the capacity to form normal numbers of myelinated axons. It is
known that peripheral nerve development involves bidirectional axon-glial
interactions (de Waegh et ah, 1992) suggesting that periaxin is not critical in this
signalling at least at early stages. In human demyelinating CMT disease it is thought
that most symptoms occur when axons are lost, secondary to demyelination, although
myelin abnormalities can be seen earlier on electrophysiological testing (Krajewski
et ah, 2000). Indeed, at nine months of age, periaxin-null mice also show a reduction
in myelinated axons (Sherman et ah, unpublished).
However, at the age of this experiment (two to three months), prior to axonal loss,
there is a higher proportion of smaller diameter axons in periaxin-null nerves.
Shiverer and Trembler mice, which have disordered myelination due to myelin basic
protein and peripheral myelin protein-22 mutations respectively, also show this (de
Waegh et al., 1992; Kirkpatrick et ah, 2001). This may be secondary to the presence
of thin myelin around some axons, as it is postulated that the myelin sheath signals to
the axon, causing an increase in the number of neurofilaments and state of
neurofilament phosphorylation both of which increase axon calibre (Kriz et al.,
2000). However, many of the axons in the periaxin-null mouse are hypermyelinated,
as shown in Figure 34 and Figure 35. It is known that the rate of slow axonal
transport is reduced in Trembler and Shiverer mouse peripheral nerve, where axon
diameters are small (de Waegh et al., 1992; Kirkpatrick et al., 2001), and so it may
be that these axo-glial units are less stable over time. Therefore, there appears to be




Periaxin-null sciatic nerves are larger in total cross-sectional area than wild-type
nerves, due to an increase in ECM. In some patients with demyelinating CMT
disease, peripheral nerves are visible or palpable (Harding and Thomas, 1980a). This
is thought to be due to a combination of an increase in ECM and the presence of
onion-bulb structures around remyelinated axons. By electron microscopy, patients
with an axonal form of CMT also had increased ECM (Barhoumi et al., 2001). The
dystroglycan-dystrophin-related protein-2 complex links the Schwann cell
cytoskeleton to the extracellular matrix, and it may provide a signalling link as well
as a physical one. The absence of periaxin may alter this signalling affecting both the
Schwann cell and the ECM.
4.2.3. Differences between periaxin-null and wild-type mice after nerve crush.
After crush, the number of myelinated axons in wild-type and periaxin-null sciatic
nerve returns to normal within two weeks. However, the axon diameters decrease in
both wild-type and periaxin-null mice, and do not fully recover to normal even after
six weeks. Similarly, Bridge et al. (Bridge et ah, 1994) found that eight weeks after
nerve crush in wild-type rats, axon size had also not returned to normal yet
electrophysiological and behavioural testing results were normal.
Crushed wild-type axons repair their myelin sheath to normal by two weeks after
crush. Crushed periaxin-null axons initially remyelinate at the same rate as wild-type
crushed axons by two weeks after crush, but then become hypermyelinated.
Thus, periaxin-null mice can remyelinate regenerated fibres after nerve crush.
Periaxin-null nerves have very similar measurements of myelin thickness to wild-
type nerves shortly after crush, but later, hypermyelination occurs. This suggests that
although these axons can remyelinate, the mechanisms that regulate myelin thickness
are deranged, so abnormally thick myelin sheaths occur. Thus, periaxin may be
involved in the regulation of myelin sheath thickness, and it may be that this
hypermyelination later leads to the progressive demyelination and dysfunction seen
both in the mouse model and in human CMT patients.
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At three months of age, in this strain background, the periaxin-null mouse has little
pathology and a mild phenotype, but by six months of age the mice are severely
affected (Gillespie et al., 2000). The human form of the disease seems more variable
with both severe phenotypes (Boerkoel et ah, 2001b; Takashima et ah, 2002)
(Dejerine-Sottas disease) and milder forms described (Guilbot et ah, 2001;
Takashima et ah, 2002). This may partly reflect the different genetic backgrounds on
which the PERIAXIN mutations are superimposed.
This work was published in the Journal of Anatomy (Williams and Brophy, 2002).
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FIGURE 30 - EFFICIENCY OF CRUSH TECHNIQUE.
a: Uncrushed sciatic nerve from wild-type mouse.
Scale bar 9.7jum.
b: Crushed sciatic nerve from wild-type mouse, taken four days after crush, showing
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Myelinated axon number in periaxin-null mice is normal at baseline (uncrushed) or 2
and 6 weeks after sciatic nerve crush (crushed). Values shown are mean ± SEM for
3-5 experimental mice.
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FIGURE 32 - DENSITY OF MYELINATED AXONS
a + b: Light micrographs of wild-type (a) and periaxin-null (b) sciatic nerve show the
reduced density of myelinated axons and increased extracellular matrix in the
periaxin-null mice. Scale 10pm.
c: The density of myelinated axons is significantly reduced in periaxin-null sciatic
nerve. Values shown are means ± SEM for 19 wild-type and 23 periaxin-null mice.
d: The cross-sectional area of periaxin-null sciatic nerve is significantly larger than
that of the wild-type.
Asterisks indicate statistically significant differences (p<0.001, unpaired t-test).
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FIGURE 33 - AXON DIAMETER
Axon diameter frequency distribution in sciatic nerve from wild-type and periaxin-
null mice in uncrushed nerves, and 2 and 6 weeks after crush respectively. The
percentage frequency is plotted against axon diameter (pm). Uncrushed periaxin-null
nerves have a higher percentage of small diameter fibres. After crush, the proportion
of small diameter axons increases in both wild-type and periaxin-null nerves and
although this reverts slowly towards normal, at 6 weeks there are still more smaller
axons. Values shown are means ± SEM of an average of 957 axons per each of 3-5
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FIGURE 34 - MEAN g-RATIO
Graphs of the mean g-ratio plotted against axon diameter for wild-type and periaxin-
null mice at 2 and 6 weeks after crush. The axon diameter values are grouped
according to size, and the mean g-ratio is plotted for each size range. For ease of
comparison, the mean g-ratio is plotted against the natural log of the axon diameter,
giving a straight regression line. The equations for the regression lines are displayed.
Mean g-ratios are from an average of 957 axons for each of 3-5 sciatic nerves in each
experimental group. The mean g-ratio values for the crushed and uncrushed wild-
type mice are superimposed at both 2 and 6 weeks after nerve crush and show that
remyelination is carried out to completeness by 2 weeks after crush. The mean g-
ratio values for the uncrushed periaxin-null nerves are lower than their wild-type
equivalents, indicating hypermyelination. After nerve crush, the periaxin-null axon
g-ratios are very similar to their wild-type counterparts at two weeks, indicating a
similar initial rate of remyelination. However, at 6 weeks after crush, the g-ratio
values have decreased, indicating progressive hypermyelination, moving closer to the
hypermyelinated state of the uncrushed nerves.
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FIGURE 35 - g-RATIO DISTRIBUTION PER AXON
Graphs of the g-ratio for each axon measured in crushed and uncrushed nerve,
plotted against its axon diameter, for one experimental animal for each group. This
emphasizes that there is no difference in g-ratio values for crushed and uncrushed
wild-type axons at 2 or 6 weeks after crush, indicating complete remyelination.
However, there are distinct populations of g-ratio values from crushed and uncrushed
periaxin-null axons, at two weeks after crush. The uncrushed values are lower,
indicating hypermyelination, and the crushed values are similar to that of crushed
wild-type axons at this time point. At 6 weeks after crush, the crushed and uncrushed
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5. RESULTS - EXPERIMENTS WITH FbI6
Sylvia Vasiliou identified the F-box protein Fbl6 as a binding protein of L-periaxin
in a yeast-2 hybrid screen using the C-terminal part of L-periaxin (Vasiliou in
preparation). She narrowed down the region of interaction to an 84 amino acid
stretch involving part of the acidic domain and sequence upstream of this (Figure
36). L-periaxin was shown to interact with the leucine-rich repeat region of Fbl6 by
in vitro pull down assays (Vasiliou in preparation). However, in vivo interaction was
not confirmed.
5.1.Fbl6 antibody
We generated an antibody to GST fused to the amino acids 49-115 of the rat Fbl6
protein. This stretch of the sequence was chosen as it was previously thought that the
methionine at amino acid 48 was the first amino acid of the protein, by comparison
with the mouse sequence in the database. However, on closer examination there is
another in-frame methionine residue 48 amino acids upstream of this (Figure 37).
The ATG here has a more classical Kozak sequence, and is probably the preferred
start codon. This is corroborated by the human equivalent sequence, which is also
thought to start at this first methionine (Figure 38).
The antibody was tested on western blot and immunohistochemistry. On western
blot, non-specific bands were produced. On immunohistochemistry on mouse sciatic
nerve, there was specific staining of the cytoplasm of myelinating Schwann cells.
Teased fibre preparations showed that Fbl6 co-localised with SI00, a marker of
Schwann cell cytoplasm (Figure 39). Double labelling with the sheep C-terminal
periaxin antibody on the teased fibres showed periaxin localisation at the membrane
of the Schwann cell and in the Schmidt-Lanterman incisures, and Fbl6 in the
Schwann cell cytoplasm (Figure 39). From the flattened, confocal image the
localisation of the Fbl6 looks to be peripheral to periaxin localisation. However,
when confocal images of mouse sciatic nerves are taken in cross-section, it is clear
that this is due to the non-cylindrical distribution of Schwann cell cytoplasm (Figure
40 and Figure 41). Periaxin is localised in areas where there is little underlying
cytoplasm, and bulges of Fbl6-filled cytoplasm lie in between these areas. Thus,
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taking planes through this non-cylindrical structure, and superimposing the pictures,
give the erroneous impression that Fbl6 is located peripheral to the position of
periaxin (Figure 41).
5.2. Developmental expression of Fbl6
As the Fbl6 antibody is not specific on westerns, I took sections of mouse sciatic
nerve from ages postnatal day 2 (P2), P10, P21 and sections through embryonic
hindquarter at embryonic day 14.5 (E14.5). At each of these ages, Fbl6 expression
was seen in the cell bodies of Schwann cells. Thus, Fbl6 is expressed at a time when
it could be involved in the regulation of periaxin, as periaxin is expressed in
Schwann cells from day El3.5-14.5.
5.3.Transfection Experiments
Cos-7 cells permanently expressing periaxin were generated and grown up from a
single clone under the selection of geneticin. Periaxin expression was not uniform in
these cells, but many cells were expressing periaxin at a detectable level by
immunofluorescence. Three constructs were made to investigate the interaction of
periaxin and Fbl6 in vivo. The first construct contained the full-length Fbl6 sequence
with an N-terminus Flag tag, the second was the same with a C-terminal Flag tag and
the third consisted of clone 26a with an N-terminal Flag-tag. Each was under the
control of a CMV promoter. Sylvia Vasiliou generated clone 26a which contains
amino acids 122-487 of Fbl6, incorporating the leucine rich repeat region, but not the
F-box (Figure 42). Thus, the protein generated by this construct would theoretically
be able to bind L-periaxin but not target it to the SCF complex for ubiquitination.
These constructs were transiently transfected into the permanently L-periaxin
expressing Cos 7 cells with the aim of assessing the levels of L-periaxin in the
transfected cells, and its localisation. The success of transfection was assessed by
growing transfected cells on coverslips and carrying out immunofluorescence with
an anti-Flag antibody. There were very few Flag-positive cells found after
transfection, in spite of a high transfection efficiency with a control plasmid. Thus,
this was thought to be due to a low stability of Fbl6 as F-box proteins themselves can
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also be ubiquitinated and degraded in the proteasome pathway (Galan and Peter,
1999; Xirodimas et ah, 2001). Lactacystin, a proteasome inhibitor, was added to the
culture medium after transfection, and this improved the number of Flag-positive
cells seen by a factor of three and allowed the visualisation of Fbl6 and periaxin in
the same cell.
Cells transfected with full-length Flag-tagged Fbl6 (N-terminus) showed targeting of
Flag labelling to the nucleoli. In cells also expressing L-periaxin, L-periaxin was not
seen in these nucleoli (Figure 43). Transfection with the Flag-tagged 26a construct
showed no increase in stability of the protein with the addition of lactacystin, and
Flag labelling was not directed to the nucleoli (Figure 44).
5.4. Discussion
It is traditionally taught that a myelinated nerve forms a symmetrical, cylindrical
uniform structure in the internodes, like the common analogy of insulation on wires.
However, Ramon y Cajal identified an apparent cobblestone effect on the surface of
myelinated nerves, and recently it was described that periaxin and its binding partner
DRP2 are clustered in patches at the myelinated nerve surface, over cytoplasmic-
poor areas, with cytoplasmic-rich areas in between (Sherman et al., 2001). It is now
clear that Fbl6 is predominantly localised in these cytoplasmic bulges in Schwann
cells. The reason for this complex architecture is open to speculation. Periaxin
underpins the DRP2-dystroglycan complex which may stabilise the Schwann cell by
its interaction with the basal lamina externally and with the actin cytoskeleton
internally. It is unclear why large quantities of cytoplasm are excluded from these
areas, but it is clear that the cytoplasm of a cell is not a homogeneous structure, but
has well regulated areas with structural and functional differences. The Schwann cell
is already known to be an excellent example of this due to its formation of the
compact myelin sheath. Perhaps the exclusion of large quantities of cytoplasm from
these areas where the periaxin/DRP2 complex lies is to allow closer contact of the
compact myelin sheath to its anchor in the basal lamina, and so promote stability
further. This might make the compact myelin sheath more resistant to shear forces.
We also know that these complexes do not cluster in periaxin-null mice, and
demyelination occurs, possibly through this lack of stability (Sherman et al., 2001).
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An alternative hypothesis is that Fbl6 is predominantly removed from these areas as
Fbl6 targets L-periaxin for degradation via the ubiquitination pathway. Thus, spatial
separation of these molecules may play a role in the regulation of periaxin
breakdown.
In transfected Cos7 cells, Fbl6 appears to be predominantly targeted to the nucleoli,
whereas the sequence without the F-box domain (26a) is absent from these
structures. When L-periaxin is transfected into the same cells, it is mislocalised, in
that it is found both in the cytoplasm and the nucleus, but the not the nucleoli, rather
than associated with the membrane, as in Schwann cells. This mislocalisation of
periaxin is thought to be due to the absence of the DRP2-dystroglycan complex in
the cell membrane of these cells, so L-periaxin is not targeted to these areas. It is
possible that Fbl6 is localised in a different area of the transfected cell compared
with its in vivo localisation for similar reasons.
Fbl6 contains two sequences which may be nucleolar targeting sequences: QLQRL
(amino acids 187-191) and ALQRG (amino acids 314-318). The optimal nucleolar
targeting sequence is thought to be the highly basic sequence RRQRR with the most
important amino acids being the QR (Scott et al., 2001). However, these sequences
are also present in the clone 26a, which is not targeted to the nucleolus. Other work
has shown that proteins may be targeted to the nucleolus not only by endogenous
target sequence, but also via other interacting proteins (Henderson et al., 1995). In
Schwann cells, the interaction of Fbl6 with other members of the SCF complex and
with its target proteins may localise the protein to the cytoplasm, yet in cell lines
these mechanisms may not all be in place, hence the disparity of localisation.
Ribosomal proteins and proteins involved in ribosomal RNA proteins are located in
the nucleolus. However, an increasing number of other proteins are also found to be
localised in the nucleolus, including proteins involved in cell cycle and growth
regulation, DNA protective factors and recognition factors regulating translation on
cytoplasmic ribosomes (Carmo-Fonseca, 2002).
E3 ubiquitin ligase proteins have also been found to be localised to the nucleolus in
cell culture systems. The E3 ubiquitin ligase Mdm2 ubiquitinates the tumour
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suppressor gene p53, targeting it for degradation by the proteasome in response to
hyperproliferative signals such as activation of the myc oncogene. This process is
antagonised by another tumour suppressor protein ARF, thereby stabilising p53.
ART is predominantly localised in the nucleolus, while Mdm2 and p53 are mostly
nucleoplasmic. Export of Mdm2/p53 complexes is required for p53 degradation in
the cytoplasm. However, when Mdm2 was transfected into HI299 cells, in the
presence of a proteasome inhibitor, it was shown to accumulate in the nucleoli. This
was also shown to happen when Mdm2 and pl4ARF were co-transfected into cells,
suggesting that the appearance in the nucleoli was related to the increase in levels of
Mdm2. Similarly, the nucleolar localisation of Mdm2 was decreased by
overexpression of its substrate p53 (Xirodimas et al., 2001). ARF may sequester
Mdm2 in the nucleoli, preventing the interaction of p53 and Mdm2, and allowing
accumulation of p53 in the nucleoplasm, consistent with its role as a tumour
suppressor protein (Weber et al., 1999) and inhibiting export of p53/Mdm2
complexes from the nucleus to the cytoplasm (Tao and Levine, 1999; Zhang and
Xiong, 1999). Tumour-associated mutations in ARF disrupt both its nucleolar
localisation and its ability to stabilise p53 (Weber et al., 1999; Zhang and Xiong,
1999). However, more recently, mutant forms of ARF have been described that do
not accumulate in the nucleolus and yet retain the ability to stabilize p53. Hence it
may be that the small quantity of nucleoplasmic ARF is the functionally active
protein (Llanos et al., 2001). It is thought that sequestration of Mdm2 in the
nucleolus may still play a part in inactivating Mdm2 in response to some p53-
activating signals. Mdm2 has been found to contain a cryptic nucleolar localisation
signal that does not function in unstressed cells, but in response to abnormal
proliferative signals ARF is expressed and Mdm2 is necessary to cooperate with
nucleolar localisation signals in ARF to allow relocalisation of both proteins
(Lohrum et al., 2000).
Another putative E3 ubiquitin ligase was also found to localise to the nucleoli in
embryonic stem cells, colocalising with small nucleolar RNP proteins (snRNP) (Tate
et al., 1998).
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It may be that the Fbl6, which forms part of the SCF complex E3 ligase, is localised
in a similar manner. Thus, overexpression of Fbl6 in transfected Cos-7 cells allows
targeting to the nucleolus, whereas endogenous Fbl6 in vivo in Schwann cells is
mainly cytoplasmic. Fbl6 may be sequestered in the nucleoli in this system, to
prevent the interaction with L-periaxin, which is present in the nucleoplasm and it
may be that the lower amount of nucleoplasmic Fbl6 is the functionally active
protein, directing ubiquitination of periaxin. As the 26a construct, lacking the N-
terminal of Fbl6 including the F-box domain, does not localise to the nucleolus, it
suggests that this region is required for this targeting, either directly, through an as
yet unrecognised nucleolar targeting sequence or by interaction with another protein
which performs this function.
There is a precedent for F-box proteins to be intrinsically unstable. Epitope-tagged
Cdc4p and Grrlp, F-box proteins involved in regulating the cell cycle in yeast, have
half lives of only 5 minutes and 15 minutes respectively when expressed in yeast
cells. If a proteasomal inhibitor was added to the culture system, Grrlp levels were
shown to stabilise on a Western blot. Ubiquitinated forms of Grrlp and Cdc4p were
detected, and ubiquitination required all the core components of the SCF complex
indicating that ubiquitination of the F-box occurs via an autocatalytic mechanism. A
mutant form of Grrlp lacking the F-box was intrinsically stable in yeast, unaffected
by use of the proteasome inhibitor, and not degraded in an ubiquitin-dependent
manner. Thus the autocatalytic mechanism relies on an intact F-box (Galan and
Peter, 1999). My experiments indicate that Fbl6 is also intrinsically unstable, and as
stability of Flag labelling in Flag-Fbl6 transfected cells is enhanced by use of the
proteasomal inhibitor lactacystin, they also suggest that Fbl6 is degraded via the
ubiquitin/proteasomal pathway. The mutant protein 26a is unaffected by the use of
lactacystin similarly to the mutant Grrlp mutant missing the F-box region,
suggesting that Fbl6 is also degraded in an autocatalytic manner within the SCF
complex requiring an intact F-box domain.
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FIGURE 36 - Fbl6 INTERACTS WITH PeriCl AND PeriA7
L-periaxin









Fbl6 was found to interact with the construct PeriCl in a yeast - 2 hybrid screen.
PeriA7 is the smallest construct tested that still interacts with Fbl6 in this system.
(Vasiliou in preparation)
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Amino acid sequence of rat Fbl6 with F-box domain (green) and Leucine-rich repeat
domain (blue). The red letters indicate the amino acids fused to GST to make the
Fbl6 antibody.
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FIGURE 38 - ALIGNED AMINO ACID SEQUENCE OF RAT, MOUSE AND
HUMAN FbI6
rat 1 MAPVAPGRVRRRVRGSKRPDARGRSAEDWWWDRLAPRGSGYHLLQADSMLLVLPDLEPTR 60
mouse 1 MLLVLPDLEPPR 12
human 1 MAAPASRQVRRRARAAPRP RSAEDWWWDRLAPRGSGYHLLQSDSMLLVLSEPGPAR 56
★ ★ k k k k k
rat 61 ARAHRRAPRRAPRSLARGPTAVAKPRAKPR PEPSLDQGLDSGWGDRIP108
mouse 13 ARAHRRARRRAPRSLARGPTAVAKPRTKPR PEPSLDQGLDSGWGDRIP 60
human 57 PRAQRRASRRTPRQPPRGPSAAAKPKAGLRSEAAAAPAPAPAPTPTPEEGPDAGWGDRIP116
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rat 34 9 SLEELCLAGSTCSFVSNEVLGRLLHCSPKLRLLDLRGCARITPTGLCHLPCQELEQLYLG408
mouse 301SLEELCLAGSTCNFVSNEVLGRLLHRSPKLRMLDLRGCARVTPSGLCHLPCQELEQLYLG360
human 357SLEELCLASSTCNFVSNEVLGRLLHGSPNLRLLDLRGCARITPAGLQDLPCRELEQLHLG416









rat 529 -PSSRESTNLKTAPRFALP 546
mouse 481-PSAKEPT 487
human 537SPS 539
Aligned amino acid sequence of rat, mouse and human Fbl6 indicating the first
methionine in rat and human, compared to that in mouse.
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FIGURE 39 - IMMUNOFLUORESCENCE ON TEASED FIBRES OF MOUSE
SCIATIC NERVE SHOWING Fbl6.
a, b, c: Fbl6 labels the Schwann cell cytoplasm (a) and periaxin labels the abaxonal
membrane (b), with little co-localisation (c).
Scale bar 5.5pm.
d, e, f: Fbl6 labelling (d) co-localises with SI00 labelling (e) in the Schwann cell
cytoplasm (f).
Scale bar 8 pm.
146
 
FIGURE 40 - IMMUNOFLUORESCENCE ON CROSS-SECTION OF
MOUSE SCIATIC NERVE SHOWING Fbl6
Immunofluorescence study of a cross-section of mouse sciatic nerve showing Fbl6
labelling (green) in the Schwann cell cytoplasm and periaxin labelling (red) in
clusters in-between this labelling. The continuous brighter periaxin staining




FIGURE 41 - LOCALISATION OF FbI6 IN SCHWANN CELLS
a: Cross-section of a myelinated axon showing periaxin labelling (red) and Fbl6
labelling (green). This is illustrated in the diagram, indicating clustering of periaxin
and DRP2 with cytoplasmic rich areas in-between.
b: Labelling of periaxin (red) and Fbl6 (green) in a teased fibre of sciatic nerve
appears to show Fbl6 labelling outside of periaxin labelling. However, the diagram
shows that the photograph is constructed from multiple photographs taken at planes
through the axon and merged. Thus, this impression is produced by flattening an
image of a non-uniform structure.
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FIGURE 42 - RAT Fbl6 AND 26a PROTEINS
Rat Fbl6
F-box Leucine Rich RepeatsN
Clone 26a




Diagrammatic representation of the rat Fbl6 protein showing the F-box and Leucine
rich repeat domains. Clone 26a contains amino acids 122-487 of Fbl6, lacking the F-
box domain.
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FIGURE 43 - FLAG-TAGGED Fbl6 IS LOCALISED TO NUCLEOLI IN
TRANSFECTED COS-7 CELLS.
a, b, c: In this permanently expressing Cos-7 cell, periaxin is localised to the
cytoplasm and nucleus (a), but Fbl6 is localised to the nucleus and nucleolus (b).
Merged picture in (c).
d, e, f : Periaxin is localised to the nucleus, and not the nucleoli (d), where Fbl6 is
seen (e). Merged picture in (f).
g, h, i: Again, periaxin is present in the nucleus (g) with Fbl6 located in the nucleoli
and the cytoplasm (h). Merged picture in (i).
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FIGURE 44 - FLAG-TAGGED 26a DOES NOT LOCALISE TO NUCLEOLI
IN TRANSFECTED COS-7 CELLS.
a, b, c : Three transfected cells showing the distribution of Flag-tagged 26a in the
cytoplasm, and nucleus but not the nucleoli. These cells were grown in the absence
of lactacystin.
d, e, f : A cos-7 cell permanently transfected with periaxin present in the nucleus and
cytoplasm (d), and transiently transfected with 26a, which is present mainly in the
cytoplasm and not localised to the nucleoli (e). Merged picture in (f). This cell was




The discovery of mutations in the human PERIAXIN gene that cause CMT disease
expands the classification of CMT disease subtypes. The position of the mutations in
the L-periaxin protein that produce truncated proteins has helped in the
understanding of the function of periaxin, since we now know that binding to DRP2
is not sufficient to rescue the Schwann cell from demyelination. As yet, none of the
truncated proteins formed by the mutations are likely to be able to bind the F-box
protein Fbl6 so it will be interesting to see whether mutations are described further
towards the C-terminal of the periaxin protein. This will help us determine whether
there are other interactions of the periaxin protein that are important in maintaining
myelination.
The antibodies generated by the group have been invaluable in characterising these
mutations. We can use these antibodies in a quick and simple test to screen potential
patients by immunofluorescence by looking for truncated Periaxin protein in
peripheral nerve biopsy material.
Much effort has been put into making genotype and phenotype correlations within
CMT disease but with limited success. There are phenotype differences between
patients who have the same mutation in the same causal gene between unrelated
families (Thomas et al., 1997). There are also intrafamily differences in phenotype,
in that different siblings with the same mutation are variably affected (Auer-
Grumbach et ah, 2000a; Senderek et ah, 2001). This suggests that the CMT
phenotype is not only reliant on a mutation in the causal gene, but on genetic
background and environmental influences.
The genetic background in mice is known to affect the phenotype of transgenic mice
(Dubois et ah, 2002; Shusterman et ah, 2002). Thus, transgenic mice can be bred
onto different backgrounds to investigate phenotype modulating genes. Microarray
analysis of gene expression in mice transgenic for CMT genes with different genetic
backgrounds may help identify modifying factors determining the vulnerability of
Schwann cells and axons to the CMT mutation leading to the CMT phenotype.
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Similarly this could be performed in human monozygotic twins or patients with
identical mutations but disparity of phenotype.
There are reports of CMT disease occurring in human monozygotic twins, where
genetic background is identical. Two pairs of identical twins were studied with
PMP22 duplication (Garcia et al., 1995), and another pair with a novel PO mutation
(Marques et al., 1999), and each pair showed variation in clinical expression between
siblings. This variation included age of onset of the disease, degree of disability,
presence or absence of sensory symptoms and neurophysiological test results. The
phenotype differences in these patients with identical genetic backgrounds suggest
that the expression of these mutations is susceptible to external, non-genetic
influences that modulate the CMT phenotype.
If environmental modulators influence phenotype, what could these be? Nutrition
may have an influence, as nutritional deficiency, for example of vitamin E, is known
to cause acquired peripheral neuropathy (Martinello et al., 1998). Thus, minor
nutritional changes in susceptible individuals may change the time of onset of the
disease, and its severity. Functional use of neurones has also been associated with
vulnerability to damage and death. Motor activity enhances the peripheral nerve
toxicity of lead (Ray, 1997). In models of Amyotrophic Lateral Sclerosis (ALS),
glutamate excitation of neurones contributes to neurodegeneration (Cluskey and
Ramsden, 2001). Hence, difference in phenotype in CMT disease may be associated
with differences in nerve activity.
There are too few mutations in the PERIAXIN gene to allow any meaningful
phenotype-genotype correlations at present. The human disease appears variable with
both severe phenotypes (Boerkoel et al., 2001b; Takashima et al., 2002) (Dejerine-
Sottas disease) and milder forms described (Guilbot et al., 2001; Takashima et al.,
2002). The mouse phenotype within the mouse strain C57BL/6 is much less variable,
though these mice appear to be affected at a later age than may be expected from
correlation with the human condition, substantiating the argument for the role of
genetic background in the production of the phenotype.
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However, the human condition has a prominent sensory disturbance compared to
patients with most other forms of CMT disease. There is pathological evidence to
substantiate this from work with the periaxin-null mouse. Experiments have
suggested selective vulnerability of sensory nerves compared to motor nerves in the
periaxin-null mouse. In this mouse, at six months of age, there is more loss of
myelinated axons in the pure sensory nerves (saphenous and dorsal roots) than in the
pure motor nerves (quadriceps and ventral roots) (Sherman et ah, in preparation).
There is no evidence that unmyelinated fibres, that carry most pain and temperature
sensation, are affected in the periaxin-null mouse. The mechanism for the increased
sensory nerve vulnerability is unknown, but there are precedents for differential
vulnerability of motor and sensory neurones in disease.
Motor neurones are specifically damaged in motor neurone disease. In ALS, putative
mechanisms for this specificity in nerve degeneration include persistent viral
infection, glutamate-mediated excitotoxicity, oxidative stress, altered neurofilament
and peripherin expression, disrupted axonal transport, neurotrophin deficiency and
mitochondrial dysfunction (reviewed in (Cluskey and Ramsden, 2001)). Familial
ALS accounts for approximately 10% of patients, and 20% of these have mutations
in the gene encoding cytosolic Cu/Zn superoxide dismutase (SOD1). The mutant
SOD1 causes neuronal degeneration by a gain of toxic property (Cleveland and
Rothstein, 2001). Although these mechanisms are not unique to motor axons,
selective disruption of the motor axons can be explained by the increased energy
requirements of long, large diameter motor axons and so their heightened
vulnerability to insults. There may also be a glial role in the neurodegeneration of
ALS, as astrocytes also express mutant SOD1. Selective expression of a mutant form
of SOD1 (G85R) in astrocytes provoked glial pathology but not motor neurone
death, indicating that only part of the toxicity is derived from glia (Gong et al.,
2000).
Other diseases are selective for the sensory peripheral nerves. A variety of
chemotherapy drugs cause acquired peripheral neuropathy, as a side-effect.
Vincristine is a Vinca alkaloid which binds intracellular tubulin. This leads to
oedema of the fast and slow conducting axons, and dorsal root ganglion (DRG) cell
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damage, manifesting as a painful and primarily sensory neuropathy (Postma et al.,
1993). Cisplatin, a platinum compound, has a predilection for sensory nerves. This
drug forms intra- and interstrand crosslinks in DNA, inducing apoptotic cell death in
dividing cells, but it may also act in peripheral nerve by a disturbance of axonal
transport. It is not clear why platinum compounds affect sensory nerves and spare the
motor nerves, however, it may be related to the preferential accumulation of the drug
in DRG cells. Damage to these cells prevents repair once the drug is removed.
Pathologically, the small and thinly myelinated axons are most affected (Quasthoff
and Hartung, 2002). Suramin is another chemotherapeutic agent, which acts by
inhibiting growth factors and by blocking P2 purinergic receptors, which are divided
into two subtypes: the metabotropic P2Y and the ionotropic P2X receptors. In the
PNS, P2X receptors are found on DRG neurones and P2Y receptors on Schwann
cells (Wachtler et al., 1996). Activation of these P2 receptors induces intracellular
calcium ion transients which play an important role in intracellular signal
transduction pathways (Mayer et al., 1998). Pathology shows demyelination with
axonopathy, and sensory symptoms are much more frequent than motor.
In the periaxin-null mouse, the increased sensory fibre loss is equally not explained.
It may be that sensory fibres, with smaller diameter fibres and with corresponding
thinner myelinated sheaths are either more prone to demyelination or to sustaining
permanent damage after demyelination. Periaxin-null sensory nerves may be more
vulnerable due to their cell bodies lying in the dorsal root ganglia, outside of the
central nervous system, thus they are proportionately more reliant on Schwann cells
as their glial support. In comparison, motor neurones, whose cell bodies lie in the
anterior horn of the spinal cord, use proportionately more oligodendrocytes for glial
support, which do not express periaxin. Sensory nerves may have different axon-
Schwann cell interactions than motor nerves, which may confer the properties of a
small axon diameter and a thin myelin sheath, but also may confer vulnerability to
damage in the absence of periaxin.
Behavioural tests in periaxin-null mice substantiate the pathological findings as there
is evidence of an early sensory disturbance. At six weeks of age these mice show
behaviour suggestive of neuropathic pain with allodynia in response to mechanical
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stimulation with Von Frey hairs, and thermal hyperalgesia, in spite of a normal
mechanical grip test. These sensory disturbances were abrogated by intrathecal
injection of NMDA antagonist, suggesting that a central sensitisation occurs in
response to disruption of the myelin sheath (Gillespie et ah, 2000).
Initially, periaxin-null mice develop an apparently normal myelin sheath, thus
periaxin is not prerequisite for myelination in development. However, it is not fully
understood why both in these mice, and in the comparable human CMT diseases,
demyelination should occur later. Our morphology experiments addressed this issue,
as it was speculated that periaxin was required for remyelination after demyelinating
damage, as this may not exactly recapitulate developmental myelination. These
experiments clearly showed the ability of periaxin-null Schwann cells to remyelinate
crushed, regenerated sciatic nerve at six weeks of age, but the periaxin-null Schwann
cells failed to limit the thickness of the regenerated myelin sheath. Hypermyelination
is thought to be the forerunner of massive demyelination, but it may also lead to
axonal loss, in addition to that generated by several rounds of demyelination and
remyelination. There is clinical evidence that much of the disability from CMT
disease occurs when axons are lost, rather than purely through demyelination, which
probably explains the lag of symptomatology behind pathology in humans
(Krajewski et ah, 2000; Sahenk, 1999). We also know that there is considerable
interaction between the Schwann cell and the axon to maintain the health of both.
Myelination controls the phosphorylation of neurofilament within axons, and we
know that in trembler mice, a point mutation in Pmp22 causes a change in
neurofilament phosphorylation, increased neurofilament density and decreased
axonal transport (de Waegh et ah, 1992). Conversely, myelin sheaths are not
sustainable in the absence of axons. It is not clear how myelin thickness is controlled,
but a clue may be present in the binding of L-periaxin to DRP2 in the
DRP2/dystroglycan complex at the Schwann cell membrane, linking in to the basal
lamina. These complexes are clustered in areas of the abaxonal membrane of the
Schwann cell overlying cytoplasmic poor regions, thus presumably anchoring the
compact myelin sheath more strongly by bringing it closer to the basal lamina and
therefore making it more resistant to shear forces. It may also function as a signalling
complex, perhaps controlling the number of myelin lamellae. In periaxin-null mice,
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these complexes are not able to cluster, making the Schwann cell more structurally
vulnerable. There is no expression of periaxin in the CNS, and one can speculate that
this is because of the absence of a basement membrane here, thus making its
anchoring/signalling function redundant. Thus, the later onset of demyelination in
periaxin-null mice and their human counterparts may be related to an accumulation
of damage to the myelin sheath via reduced mechanical stability and an alteration in
the correct communication between Schwann cell and axon necessary to produce an
appropriately sized myelin sheath, and a healthy axon and Schwann cell. Although
periaxin-null Schwann cells can remyelinate axons, the repeated cycle of
demyelination and remyelination may fail with age, either due to a reduced ability of
Schwann cells to remyelinate with age, or because of increased axonal loss, which
prevents remyelination. There is evidence of reduced nerve repair potential with age
in mice. When nerve grafts were used from young rats to repair femoral nerve
transection in old rats, preferential reinnervation of motor pathways by motor axons
was vigorous, compared to using grafts from older rats in old rats (Le et al., 2001).
Nerve grafts rely on intact endoneural pathways for regenerating axons to grow
down, and the presence of glial cells, and so this disparity of repair potential with age
may reflect glial cell competence. It may be that periaxin-null Schwann cells 'age'
early accounting for the lack of successful repair later. This could be tested by doing
the same sciatic nerve crush experiments in periaxin-null mice at a later age, to
examine the remyelination potential.
In development, the transcription factor EGR2 activates periaxin expression
(Nagarajan et al., 2001). However, the control of levels and localisation of periaxin
later in development may be regulated by Fbl6 and the ubiquitin/proteasome
pathway. Free L-periaxin, not bound to the membrane DRP2/dystroglycan complex,
may bind Fbl6 in the cytoplasm and be targeted for degradation. L-periaxin that is
not able to bind Fbl6 may be transported to the nucleus where it has unspecified
downstream effects. It may act as a transcription factor regulating other genes
encoding proteins involved in myelination, as it is present in the nucleus of Schwann
cells prior to the expression of the myelin proteins P0, MBP and MAG (Scherer et
al., 1995; Sherman and Brophy, 2000). The disparity in localisation of Fbl6 in
Schwann cells in vivo and Fbl6 transfected into Cos-7 cells is yet to be fully
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explained, but may be related to the mislocalisation of periaxin in Cos-7 cells due to
the lack of the DRP2-dystroglycan complex, so failing to target L-periaxin to the
membrane. Alternatively, the Fbl6 antibody labelling in sciatic nerve may be
misleading. The antibody appears specific on immunohistochemistry, as the labelling
in Schwann cell cytoplasm disappears when the antibody is blocked with the GST
fusion protein used to raise the antibody. However, this cannot be checked fully as
the antibody does not work on western blots. Formation of another Fbl6 antibody,
currently in progress, may resolve this issue.
F-box proteins usually bind phosphorylated target proteins but although we know
that L-periaxin has potential phosphorylation sites, we do not know whether this is
the regulatory mechanism. Abnormalities in the molecules involved in this pathway
may disrupt Schwann cell function, and so these molecules, including Fbl6, are
candidate genes for as yet undefined CMT disease. The DRP2 gene, located at
Xq22.1, has been screened for mutations occurring in autosomal recessive CMT
disease but as yet has not been linked to any families with CMT disease, at least in
the 168 potential patients examined thus far (Takashima et ah, 2002).
There is an underlying similarity between the phenotype and pathology in all types of
demyelinating CMT disease and even considerable overlap with axonal CMT
disease. This suggests that abnormalities in many parts of the network of molecules
maintaining health and function in the Schwann cell and axon can produce the same
end result of demyelination and axonal damage.
This work has shown the benefit of studying rare human disease and the cell biology




The characterisation of further PERJAXIN mutations in patients with CMT disease
should help to define the functional areas of periaxin further as well as assisting in
diagnosis.
Screening for truncated forms of Periaxin using our spectrum of antibodies would be
a quick and simple way of screening for mutations in patients with autosomal
recessive or sporadic forms of CMT disease. This becomes increasingly important as
the number of autosomal recessive genes to screen increases. However, peripheral
nerve biopsies, usually of the sural nerve, are associated with risk and morbidity. A
sural nerve biopsy produces a permanently numb area on the side of the foot, which
can generate neuropathic pain. An alternative would be to examine the myelinated
nerves present in skin biopsies. This procedure is associated with much less risk and
morbidity, leaving a small (4mm diameter), round scar which can be positioned
under the arm, so it is less noticeable. Myelinated nerves are visible in both the
dermis and epidermis of skin in both mouse and human by immunofluorescence
using antibodies against neurofdament (labelling axons - Figure 45b and e), and
periaxin (Figure 45a and d). Skin biopsies have been used occasionally in the
diagnosis of CMT disease to provide nerve for electron microscopy (Ceuterick-de
Groote et al., 2001). They have also been used to look for small fibre neuropathy in
some cases of diabetic neuropathy and impaired glucose tolerance neuropathy where
the density of intraepidermal nerve fibres is calculated (Griffin et al., 2001; Smith et
al., 2001). Assays of nerve growth factors have been performed on skin biopsies in
order to investigate the peripheral neuropathy associated with diabetes mellitus
(Diemel et al., 1999; Kennedy et al., 1998). Immunohistochemistry has been carried
out on skin biopsies from Leprosy patients showing a reduction in staining with
antibodies to the pan-neuronal marker PGP (protein gene product) 9.5 in lesions
(Facer et al., 1998). Thus, nerve tissue is available from skin biopsies. If a battery of
antibodies was generated against the proteins involved in autosomal recessive CMT
disease, then this technique may be extremely useful in providing a quick and
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inexpensive screen directing the clinician to the correct gene involved with minimal
discomfort to the patient.
7.2. Periaxin-null mouse nerve morphology
The morphological experiments showed that periaxin-null Schwann cells are able to
remyelinate axons at the age of six weeks albeit producing hypermyelinated axons,
due to an abnormal limit on myelin thickness. Although there are signs of attempts at
remyelination later in life in both the mice and in biopsies from human CMT
patients, permanent damage ensues, with axonal loss and demyelination. It is
possible that the periaxin-null Schwann cells lose the ability to remyelinate with age,
and so it would be interesting to perform the same experiment on older mice to test
this hypothesis.
Further work is currently underway to quantify the loss of sensory and motor axons
in periaxin-null mice with age. The sensory myelinated fibres appear more
vulnerable than motor fibres, and counts of the DRG neurone number, and
expression of ATF3, which is expressed in damaged axons, are helping to
substantiate this. Unmyelinated fibres appear unaffected, and previous work in other
forms of CMT disease concurs with this. In one case of autosomal recessive axonal
CMT disease, there was a normal number of unmyelinated axons yet a decrease in
myelinated axons (Barhoumi et al., 2001). Another patient, with CHD from a PMP22
point mutation, showed an increase in the total area of the cross-section of the sural
nerve, a decrease in number of myelinated fibres and a normal number of
unmyelinated fibres (Simonati et ah, 1999). Yet, these patients did not show a
predominant sensory neuropathy and so we wish to investigate unmyelinated fibres
in these mice at the electron microscopy level, as these C-fibres carry the sensations
of pain and temperature.
7.3. Vectors constructed for future transgenic and targeted mice
7.3.1. Overexpression of Schwann cell molecules
The molecular architecture of the myelin sheath depends on a precisely regulated
stoichiometry of myelin proteins. Naturally occurring and induced mutations reveal
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the importance of correct gene dosage for normal myelination. Gain of an allele for
proteolipid protein (PLP) causes the central nervous system myelinopathy Pelizaeus-
Merzbacher disease, and gain of an allele for PMP22 causes CMT disease type 1A.
Mouse models replicating the overexpression of PMP22 show a correlation between
the level of PMP22 expression and the degree of demyelination and reduction in
conduction velocity (Huxley et al., 1998). Contrived overexpression of the structural
myelin protein PO similarly disrupts myelination, in a dose-dependent manner.
Transgenic mice, overexpressing PO with a low and high copy number, showed a
dose-dependent arrest of nerve development, ranging from transient
hypomyelination, with mild overexpression, to inability of Schwann cells to
segregate axons, with the highest overexpression. This dose dependent problem was
reflected in their behavioural and neurophysiological phenotype (Wrabetz et ah,
2000). PO overexpression has not yet been found in human disease but the pathology
in transgenic mice resembles congenital hypomyelinating disease. These studies
suggest that caution is necessary in possible replacement gene therapy for CMT
patients where a mutation predicts underexpression of PO or PMP22, as precise
regulation of expression would be essential to avoid additional myelin disruption.
No models of overexpression of non-structural Schwann cell proteins have yet been
published. The importance of L-periaxin in its DRP2-dystroglycan complex in
stabilising the myelinating Schwann cell membrane is clear. Overexpression of L-
periaxin may disrupt this, but also may cause an alteration in signalling as excess L-
periaxin may be transported to the nucleus by virtue of the nuclear translocation
signal. In the future, it will be interesting to generate transgenic mice overexpressing
L-periaxin to reveal down-stream genes and proteins involved in myelinating
Schwann cell biology.
7.3.2. Transgenic mice overexpressing L-periaxin
In order to overexpress L-periaxin, mouse L-periaxin cDNA has already been linked
to 9kb of MBP promoter including Schwann cell enhancer 1 (SCE1) obtained from
Dr. A. Peterson's group in Montreal, Canada. This group had found that use of this
sequence without the SCE1 conferred a high level of reporter gene expression in
oligodendrocytes only, but addition of the SCE1 sequence also targeted expression to
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Schwann cells (Forghani et al., 2001). Periaxin expression in the central nervous
system has no obvious phenotype (Sherman and Brophy, 2000), probably as it is
confined to the nucleus in oligodendrocytes. The expression of L-periaxin in
oligodendrocytes can thus be used to check for expression of the transgene as well as
detecting PCR products corresponding to L-periaxin cDNA rather than genomic
DNA. We will determine the degree of overexpression of periaxin by doing
quantitative western blots. The construct is ready for injection but these mice are yet
to be made.
We might expect the overexpression of L-periaxin to disrupt the control of
myelination in these mice. Overexpression of L-periaxin may alter the localisation of
DRP2 and change the interaction between Schwann cell and basal lamina. Other
Schwann cell constituents involved in myelination may also be disrupted by this
transgene. MBP levels may be decreased, as regulatory proteins normally involved in
controlling MBP expression may be redirected to control Periaxin transgene
expression. Alternatively, MBP expression may be increased as the SCE1 element
may enhance expression even at a distance. Krox-20 (EGR2) acts as a transcription
factor regulating MBP, L-PERIAXIN, MPZ, CX32, MAG and PMP22. Therefore, by
changing the balance of genes to regulate by introducing the transgene, the
expression of the other proteins may alter which independently may lead to
disruption of normal myelination. Thus, we should gain information on whether the
correct stoichiometry of periaxin is necessary for the health and function of Schwann
cells and information on the interactions of periaxin and other Schwann cell proteins
involved in the pathogenesis of CMT disease.
7.3.3. Conditional Knock-outs
It is now possible to control the expression of genes in transgenic mice using a
conditional and inducible system. There are two arms to this system.
Firstly, gene expression can be confined to a specific tissue by employing a tissue-
specific promoter driving a Cre recombinase. The bacteriophage PI Cre recombinase
is a 38kD protein that recognises specific 34 base pair sequences called loxP sites
and catalyses site-specific recombination between two loxP sites (Sternberg and
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Hamilton, 1981). These two loxP sites are engineered within the gene of interest so
that when Cre recombinase is activated, the gene is inactivated. This was employed
to good effect in a paper disrupting the pi integrin gene in transgenic mice (Feltri et
al., 2002). Here, the Cre recombinase was driven by the MPZ promoter, so that it
was activated at E13.5-14.5 when P0 expression is turned on, inactivating the pi
integrin gene in Schwann cells and causing a severe neuropathy with impaired radial
sorting of axons.
Secondly, gene expression can be switched on and off using a tetracycline switch.
The system uses a modified version of the tetracycline repressor protein from
Escherichia coli fused to the transactivator region from VP 16 protein of herpes
simplex virus (called tTA) to control gene expression. The tTA binds to tet operator
sequences (tetO) and activates transcription of the gene of interest placed under the
control of tetO linked to a minimal CMV promoter (Gossen and Bujard, 1992).
However, when tTA is bound to tetracycline it loses this ability. The system can be
made tissue-specific by expressing the tTA protein under the control of a tissue-
specific promoter. This system was used by Perea et al., (Perea et al., 2001) who put
the tTA under the control of the PMP22 promoter, limiting its expression to Schwann
cells. PMP22 was overexpressed under the control of the tTA, causing
demyelination, but when the tetracycline was reintroduced, turning off
overexpression of the transgene, myelination normalised, showing that the Schwann
cells were poised to myelinate normally.
These systems can be combined to give an inducible system where a tetracycline-
dependent switch activates Cre recombinase expression and controls specific gene
expression in a tissue specific manner. This system has been used to produce
inducible knockouts in small intestine and colonic epithelium in mice (Saam and
Gordon, 1999). This used the reverse tetracycline regulated transactivator (rtTA)
under the control of an intestinal epithelium specific promoter. When rtTA binds
tetracycline, it acquires the ability to bind to tet operator sequences (tetO) and
activate transcription of Cre recombinase linked to a minimal CMV promoter. This
then allows recombination between loxP sites in a reporter gene (Figure 46). In this
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case the system was leaky, as background recombination in the absence of the
inducer was not zero (Saam and Gordon, 1999).
However, in spite of more complicated cloning and complex animal husbandry, these
systems will facilitate definition of gene function at different times throughout
development, in specific tissues, or under certain physiological or pathological
conditions.
We wished to produce an inducible and conditional periaxin knockout transgenic
mouse to further investigate the role of periaxin in Schwann cells, and to see whether
periaxin-null mice were able to recover normal myelination at different stages of
their development by reactivating periaxin expression. In preparation for these
experiments, embryonic stem cells carrying a 'floxed' Periaxin allele have been
generated.
7.3.4. The conditional periaxin construct
A construct was built to produce targeted mice with a floxed Periaxin gene. In the
presence of Cre recombinase, there is recombination between the loxP sites,
removing exon V of Periaxin, and changing the translation frame, leading to a
premature stop codon thirteen amino acids into the protein. It is highly likely that this
peptide will be unstable and not functional. Thus, a normal mouse can be converted
into a periaxin-null mouse in vivo.
The Centre for Genome Research in Edinburgh transfected this construct into
embryonic stem cells and have generated several clones of these cells with the
targeted floxed Periaxin gene construct. However, as yet, there has been no germ
line transmission.
When germ line transmission is achieved, we would like to cross these mice with
mice that are transgenic for a Schwann cell switch mechanism that will allow us to
turn on and off L-periaxin expression. An ideal switch mechanism would consist of
the tTA gene under the control of the PMP22 promoter, making tTA expression
specific to Schwann cells, with the TetO with a minimal CMV promoter driving
expression of Cre recombinase. Thus, we would be able to obtain Schwann cell
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specific expression of Cre recombinase that is controllable by the administration of
tetracycline (Figure 47).
Thus, there are several steps left to achieve before these mice will be generated.
However, once made, they will be invaluable at assessing the role of periaxin at
different stages of development by switching on and off periaxin expression at
different times. It would also be interesting to assess whether Schwann cells,
surrounding demyelinating nerves in mice with periaxin expression switched off, are
competent to regenerate normal nerves when it is switched back on. This has
implications for understanding the cell biology of myelin development and repair,
but also for the possible use of gene therapy in patients with demyelinating CMT
disease in the future.
7.4.FbI6
There is scope for further work examining the role of Fbl6 in the control of L-
periaxin levels and localisation, and myelination. We are generating a transgenic
mouse that contains a Flag-tagged form of Fbl6 lacking the F-box domain (26a
clone). Thus, the protein formed will theoretically be able to bind L-periaxin, but not
direct it to the SCF complex for ubiquitination and degradation. This may stabilise
the protein, leading to accumulation in the cell, and potentially causing a toxic gain
of function effect.
We are raising a further antibody to the new putative N-terminus of the Fbl6 protein
to help us further characterise the in vivo interaction of L-periaxin and Fbl6.
Transfection experiments show that full length Fbl6 is directed to nucleoli of cos-7
cells, but L-periaxin appears absent from these structures. The Fbl6 construct missing
the F-box domain (26a) is not targeted to these areas (Figure 43 and Figure 44). By
analogy to the E3 ubiquitin ligase Mdm2, whose target protein is the tumour
suppressor protein p53, it may be that overexpression of Fbl6 in the cell culture
system directs the protein to a nucleolar localisation. Thus, it would be interesting to
look at the localisation of endogenous Fbl6 in a variety of cell lines with the new
antibody against Fbl6.
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Proteins interacting with Fbl6 may help to explain its biology. There may be
interacting proteins which direct the protein to the nucleolus, which presumably
interact with the N-terminal part of the protein as 26a is not directed to nucleoli. As
Fbl6 appears to be sequestered in the nucleolus, away from the localisation of L-
periaxin, then there may well be other interacting proteins, such as pl4ARF with
Mdm2, which regulate formation of an Fbl6/L-periaxin complex. A yeast 2-hybrid
screen using the N-terminal part of Fbl6 would thus be potentially very interesting. A
similar screen using the leucine rich repeat domain would indicate other target
proteins of Fbl6 directed to the ubiquitin/proteasomal pathway.
My experiments have indicated the likelihood that Fbl6 degradation is also controlled
by the ubiquitin/proteasomal pathway, as Flag labelled Fbl6 is more stable in the
presence of a proteasomal inhibitor. This could be determined by
immunoprecipitation experiments using an anti-Flag antibody or the newly generated
Fbl6 antibody, and blotting with an ubiquitin antibody to detect ubiquitinated forms
of Fbl6. The addition of a proteasomal inhibitor to the culture system should increase
the amount of ubiquitinated Fbl6 and may increase Fbl6 polyubiquitination.
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FIGURE 45 - IMMUNOFLUORESCENCE OF HUMAN SKIN BIOPSY
a, b, c: Human nerve from skin biopsy labelled with anti-170 pep-1 periaxin
antibody (a), and neurofdament (b) with a merged picture (c). The periaxin antibody
labels myelinated nerve.
d, e, f: Human nerve from skin biopsy labelled with anti-170 pep-1 periaxin antibody




FIGURE 46 - THE TET ON AND OFF SYSTEMS
a: The TET - off system.
A tissue-specific promoter drives the expression of tTA which binds TETO sequence
and allows transcription of Cre recombinase. This catalyses the removal of DNA
sequence between loxP sites. In the presence of Tetracycline, tTA cannot bind to
TETO sequence and does not activate Cre recombinase expression.
b: The TET - on system.
A tissue-specific promoter drives the expression of rtTA which only binds TETO
sequence in the presence of tetracycline. This activates Cre recombinase expression


























FIGURE 47 - PROPOSED SCHEME FOR CONDITIONAL KNOCKOUT OF
L-PERIAXIN.
A Schwann cell specific promoter drives expression of rtTA in Schwann cells. In the
presence of tetracycline, this binds to the TETO sequence, and activates the
expression of Cre recombinase. This catalyses recombination between the loxP sites
(§ ) that flank exon V of the Periaxin gene inactivating the gene due to a frameshift
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